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Thyrotoxic periodic paralysis (TPP), first described 
in 1902, is characterized by episodes of hypokalaemic 
paralysis oc"Curring in some , thyrotoxic patients. It is 
said to be exceedingly rare among Caucasians but not 
uncommon in males of Asian races. The majority of attacks 
settle uneventfully with potassium supplementation. 
However ""life-threatening complications such as cardiac 
arrest and respiratory failure have been reported. The 
condition invariably resolves once euthyrbidism is 
achieved. The 'transient' nature of the illness and the 
paucity of cases make large scale study very difficult. 
Despite attracting a lot of attention from workers in the 
field, its pathogenesis remains largely unknown. The basic 
defect is not yet clear and it is not known why only some 
thyrotoxic patient develop TPP. 
An attack is precipitated by an acute transcellular 
shift of potassium ions from the extracellular compartment 
into the intracellular compartment against a high 
concentration gradient. The sodium pump is of central 
importance in this uphill transport of potassium ions. 
Sodium pump activity is known to be affected by thyroid 
status as well as stimulators such as insulin and 
catecholamines. 
Hypothesi's 
The hypothesis of this thesis is that thyrotoxic 
patients who have a high basal or stimulated sodium pump 
activity are more likely , to develop hypokalaemic periodic 
paralysis. 
Design of study 
Three main groups of subjects were studied in this 
thesis, healthy controls, TPP patients and uncomplicated 
thyrotoxic patients. For the in vitro study, platelets 
were used as a model. An assay for platelet Na-K ATPase 
was develpped and its effectiveness as an index of tissue 
hyperthyroidism was assessed. The basal platelet Na-K 
ATPase activity in the above three groups of subjects were 
measured and compared. For the in vivo 'study, changes in 
plasma rubidium concentration after an oral load of 
rubidium were measured. The clearance of rubidium reflects 
the in vivo activity of the Na-K ATPase~ An assay for 
rubidium was set up using a graphite furnace atomic 
absorption spectrophotometer. A validated 75 g oral 
glucose tolerance test was use~ to studY,the stimulated 
platelet Na-K )ATPase activity as well as serial changes in 
blood glucose and insulin. 
Main findings and conclusions 
1. Platelet Na-K ATPase is a good tissue marker of 
hyperthyroidism. At a cut-off value· of 190 J,lmol Pi/h/g 
protein, it gave a sensitivity of 93%, a specificity of 
90% and a sum of 183% which falls into the class of 'go~d' 
tests. 
2. TPP patients have a significantly higher basal platelet 
Na-K ATPase activity (in vitro sodium pump activity) than 
uncomplicated thyrotoxic - patients. This observation was 
confirmed by the rubidium loading test (in vivo sodium 
pump activity). Therefore a higher sodium pump activity is 
a feature of TPP patients. The increase in platelet Na-K 
ATPase activity resolves after anti-thyroid tre~tment. 
(Note: this study represents the first use of platelet Na-
K ATPase activity and of the rubidium loading test in the 
study of thyroid diseases.) 
3. Using , _~ validated OGTT protocol, ·TPP patients have a 
significantly higher stimulated platelet Na-K ATPase 
activity than uncomplicated thyrotoxic patients. Hyper-
insulinaemia is also a feature of TPP ' patients. These 
features resolve after anti-thyroid treatment. 
(Note: this is the first study to simultaneously measure 
the sodium pump activity and the insulin level (a 
stimulator of the sodium pump). 
4. There was no significant difference in plasma thyroid 
hormone concentrations between these two groups of 
thyrotoxic patients. i . e". The TPP patients were no more 
toxic than the uncomplicated thyrotoxic patients as far as 
thyroid hormone concentrations were concerned. 
5. Therefore TPP patients were unduly sensitive to the 
effect of an excess in thyroid hormones. This intrinsic 
sensitivity predisposes individuals to develop 
hypokalaemic periodic paralysis when they become 
thyrotoxic. This latent defect is unmasked by the excess 
in thyroid hormones. 
6. Further studies are required to elucidate the molecular 
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1.1 BRIEF HISTORY OF THYROID DISEASES. 
The word 'thyroid' derives from the Greek word for 
door, and originally meant a large stone placed against a 
, door to keep it shut (Knight, 1992). Andreas Vesalius 
(1514-1564) was probably the first person eo describe the 
thyroid gland (Langer, 1960). The name 'thyroid gland' was 
first used in 1646 by Thomas Wharton, the English 
physician _,.and anatomist who ascertained the anatomical 
site, size and weight of the thyroid (Langer, 1960; 
Knight, 1992). This began a series of discoveries which 
laid the cornerstone for the modern understanding of the 
thyroid gland and its diseases. 
However, descriptions of thyroid diseases have been 
well known since ancient times (Major, 1945; Sandison & 
Wells, 1967; Hetzel, 1989). It is not surprising that the 
first record of thyroid disease was a description of 
goitre. 
The Chinese term for goitre is tYing' which means a 
tassel hanging on the neck. One of the oldest references 
to goitre is attributed to the legendary Chinese emperor 
Shen-Nung (2838-2698 B.e.), who mentioned the use of 
seaweed as a remedy for goitre in his book Pen-T'sao Tsing 
(A Treatise on Herbs and Roots) (Langer, 1960; Hetzel, 
1989). Goitre was recorded also in the book Huang Ti Nei 
Ching (Internal Medicine of Huang Ti, the Chinese 
emperor)-, dating from the period of 2697-2597 B.C. However 
it could" not be certain whether emperors Shen-Nung and 
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Huang Ti actually made the descriptions because it was the 
usual practice to attribute credit to the reigning 
emperor. Neither was it possible to be certain about the 
date because it ' was likely that these books were written 
later, and the names of these famous and respected 
emperors were used to give a semi-sacred, "classical" 
stat~s (Croizier, 1973). Most likely repeated revisions 
were undertaken over the centuries but there is no 
consensus .,on the date when the present form appeared 
(Croizier, 1973; Lu & Needham, 1977; Wang, 1983). However 
it was certain that, goitre was well recorded in Shan Khai 
Tsing (A Treatise on Waters and Dry Lands), from the 
period 770-220 B.C. (Lang, 1960; Hetzel, 1989). 
Furthermore, there was record of endemic goitre as early 
as the 3rd century B.C. (Lee, 1941). 
Similar descriptions of goitre were made by other 
ancient civilizations such as India (4th Century B.C.), 
Egypt (30 B.C.- 50 A.D.) and Rome (1st Century B.C.) 
(Lang, 1960). It was also recorded in the Bible (Brim, 
1936). 
While most of these records were probably referring 
to endemic goitre and some of them might well be to 
cervical tuberculous lymphadenitis (Sandison & Wells, 
1967), there was indication that different types of goitre 
were well recognized in ancient China (Lee, 1941; Wei, 
1~83) . 
Long before the discovery of iodine and thyroxine, 
iodide-containing compounds and animal thyroid gland were 
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used in the treatment of thyroid diseases. In China, as 
early as the 3rd century, Ke-hung (281-361 , A.D.), the 
father of Chinese chemistry (Hsu & Peacher, 1977)" used an 
alcoholic preparation of Sargassum siliquastuum (a 
seaweed) to treat goitre (Lee, 1941; Langer, 1960). He 
seemed to know that the active ingredient was soluble in 
alcohol. Since then many kinds of marine products have 
been used in prescriptions (Chen, 1968). In the 12th 
century, Chang t'sung-cheng recommended the use of seaweed 
as a simple and efficient prophylaxis against goitre (Lee, 
1941). It is well documented that "organo-therapy" (i.e. 
the use of animal organs to treat diseases of 
corresponding organs in human) was widely practised in 
ancient China (Wei, 1984). The use of animal thyroid gland 
for goitre was first reported by Sun Ssu-mo (650 A.D.) 
(Medvei, 1993a). The operative treatment of goitre was 
recorded in the second century in China (Lee, 1941). 
Similar reports appeared in the Western literature at 
later dates (Schmidt, 1959). 
As early as 85 A. D., the physician Tsui Chih-thi 
seems to have distinguished between solid (malignant) neck 
swellings which could not be cured, and movable (benign) 
ones which were curable (Medvei, 1993b). It appears that 
different types of goitre were well recognised. A clear 
classification was reported in 610 'A.D. by Chao Yuen-fang 
in ,his "Chao's General Treatise on Aetiology and Symptoms 
of Diseases" (Lee, 1941). A part of it (page 31) is quoted 
'below (translated by Lee, 1941):-
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"There are three types of goitre: 1 bloody goitre 
treated by incision; 2. polypoid goitre treated by 
excision and 3. airy goitre treated by acupuncture. ----
In mountain areas the spring water which flows out from 
black soil causes the inhabitants to suffer from goitre. 
It is inadvisable for people to stay in such regions". 
The classification was expanded in later years to 
include five types, and assoc'iations between different 
types of goitre and different clinical syndromes such as 
simple goitre, thyroid cancer, thyrotoxicosis and acute 
thyroiditis were well recognized (Wei, 1983; Chau, 1988). 
It is' interesting to note that drinking water was 
also considered an aetiological factor as early as the 
first century AD by Hippocrates, the 'father of medicine' 
(Hetzel, 1989). 
It is not surprising that in the early years, goitre 
and different types of goitre were at the centre stage of 
medical attention. It was in the later years that the 
different syndromes of thyroid diseases were described. 
According to Fang (1989) who recently reviewed the 
history of thyroid diseases in Chinese, description of 
various features of the syndrome of thyrotoxicosis 
appeared in Chinese literature as early as the 7th century 
B. C •• Features included exophthalmos, goitre, 
irritability, emotional lability, nervousness and 
insomnia. Likewise, syndromes of both cretinism and 
myxoedema were described in ancient times although 
documentation was less clear. In the western world, the 
association of exophthalmos with goitre was recognised as 
early as 1136 by Al-Jurjani. However, in general, Parry 
has been credited with making the first discovery, in 1786 
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and it was published in 1825, three years after his death 
(Langer, 1960). It was later described by Graves in 1835. 
The first description of cretinism was made by Paracelsus 
in 1603 (Major, ' 1945; Mettler, 1947). The term myxoedema 
was first used by Ord in 1878 after the syndrome was first 
described by Gull 5 years earlier (Langer, 1960). 
It is remarkable that thyroid diseases have been 
known for almost thirty centuries. However it is only 
within the last one or two centuries that the scientific 
basis of our understanding of thyroid diseases has been 
established. 
This began with the discovery and isolation of iodine 
from seaweed by Courtois in 1812 (Schmidt, 1959). The 
connection of iodine with the thyroid gland , was not 
understood until 1889 when Gley demonstrated the presence 
of iodine in the gland (Knight, 1992). In 1907, Marine 
demonstrated that iodine was necessary for normal thyroid 
function (Nusynowitz, 1983). The breakthrough came in 1915 
when Kendall studied the 'active principle of the thyroid 
and isolated thyroxine which contained 60% iodine and had 
the full physiological activity of the gland (Kendall, 
1915). Since then much progress has been made in 
elucidating the pathology and the pathophysiology of 
thyroid diseases (Ureles, 1990) as well as in the 
development of therapeutic agents (Langer & Greer, 1977). 
It also opened the opportunity for modern laboratory 
investigation, resulting in the development and 
introduction of a large battery of thyroid function tests 
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(summarized in section 3.2.1). 
1.2 THYROTOXICOSIS ABD MUSCLE DISEASES. 
The association between thyroid disorders and musc~e 
diseases has long been recognised. Both Graves (1835) and 
Von Basedow (1840) recognized the presence of muscle 
weakness as a feature of Graves' disease (Engel, 1972; 
Kaminski &. Ruff, 1994). However, the significance of this 
observation initially did not attract much attention until 
the sixties (Kissel & Mendell, 1992). Since then a number 
of muscle disorders associated with thyrotoxicosis have 
been described. The majority of such disorders were due to 
thyrotoxic myopathy whereas thyroid-associated 
ophthalmopathy, myasthenia gravis and thyrotoxic periodic 
paralysis (TPP) occur much less frequently (Engel, 1972; 
Gilroy & Meyer, 1979; Ruff & Weissmann, 1988; DeLong & 
Adams, 1991). Differential diagnosis is usually not 
difficult. However, the · pathogenesis of these muscle 
disorders is fa~ from clear (DeLong & Adams, 1991; Kissel 
& Mendell, 1992).' 
Thyrotoxicosis of any cause can be associated with 
thyrotoxic myopathy and thyrotoxic periodic paralysis. 
Thyroid-associated ophthalmopathy and myasthenia gravis, 
however, are usually seen in the setting of Graves' 
disease, an auto immune disease (Kissel & Mendell, 1992). 
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1.2.1. Thyrotoxic myopathy. 
It is well documented that the severity of muscle 
weakness varies among thyrotoxic patients (Ramsay, 1966; 
Swash & Schwartz, 1988; Orgiazzi & Mornex, 1990; DeLong & 
Adams, 1991 ). Al though about 5 % of thyrotoxic patients 
will have muscle weakness as a dominant symptom at the 
time of clinical presentation, more than 75% of them have 
detectable ·,. muscle weakness on physical examination 
(Satoyoshi et al., 1963a; Puvanendran et al., 1979a; Swash 
& Schwartz, 1988). It is interesting to note that although 
thyrotoxicosis is more common in women, ·the myopathy is 
equally distributed between the sexes, suggesting greater 
susceptibility in men (Gilroy & Meyer, 1979; Kissel & 
Mendell, 1992). This association with the male sex, the 
same as for TPP, has not yet been satisfactorily 
explained. 
The occasional patient may develop bulbar weakness 
(Gaan, 1967; Kammer & Hamilton, 1974; Marks et al., 1980). 
However, it is now accepted that these patients probably 
were suffering from myasthenia gravis (Puvanendran et al. 
1979b) . 
The pathogenesis of thyrotoxic myopathy is not yet 
known although it is well documented that muscle 
metabolism is extensively affected by the excessive 
thyroid hormones (Kissel & Mendell, 1992; Kaminski & Ruff, 
1994). A number of disturbances are recognized and include 
acceleration of degradation of muscle protein (Rodier et 
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al., 1984), disruption of the anabolic effect of insulin 
on amino acid and protein metabolism (Kaciuba-Useilko & 
Brzezinska, 1979; Morrison et al., 1988) and glycogen 
depletion (Okajima & Ui, 1979). Serum creatine kinase 
activity, which 'can be extensively elevated in 
hypothyroidism (White & Walmsley, 1984), is usually normal 
(Docherty et al., 1984; Swash & Schwartz, 1988; Layzer, 
1990). However, rhabdomyolysis may occur in uncontrolled 
thyrotoxicosis and results in marked elevation of creatine 
kinase activity (Bennett & Huston, 1984). There may be 
electromyographic (EMG) abnormalities but the changes are 
. uninformative (DeLong & Adams, 1991 ). However, partial 
depolarization of muscle membrane is observed (Hofmann & 
Denys, 1972) despite an increase in sodium pump activity 
(Kjeldsen et al., 1984), which in theory could cause 
hyper-polarization in the membrane (Layzer, 1982). 
Histological changes are nonspecific and do not correlate 
with the degree of thyrotoxicosis (Gruener et al., 1975; 
Wiles et al., 1979; Engel, 1988). 
The mechanism for · these changes described ~bove 
remains unanswered. However there is no doubt that the 
myopathy is secondary to "the excess of thyroid hormones 
because it invariably resolves once euthyroidism is 
restored (Engel, 1988; Swash & Schwartz, 1988; DeLong & 
Adams , 1991). 
It is likely that the muscle weakness in thyrotoxic 
myopathy results from several different effects (Engel, 
1988). Experts have indicated that an increase in the 
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muscle sodium pump activity might be important in the 
pathogenesis of the myopathy (Engel, 1988; Swash & 
Schwartz, 1988). 
1.2.2. Exophthal~ic ophthalmoplegia (Gravels 
ophthalmopathy). 
According to Char (1991), the pathogenesis of this 
disease is,. not certain although the condition was 
described over 200 years ago and there are approximately 
1400 publications on ' this subject. There is controversy 
about its relationship with Graves' . disease. Some 
investig~tors believe that it is a distinct entity (Char, 
1991). However, it is widely held, that it is part of the 
syndrome of Graves' disease (Bahn et al., 1988"; Char, 
19~1). While its association with Graves' dis~ase may not 
be clear-cut, the sharing of a common antigen between the 
orbital fibroblasts and thyroid cells is likely to play a 
fundamental role in the development of sensitized T 
lymphocytes which accumulate ' in the orbital tissues in 
these patients and lead to the development of the disease 
(utiger, 1992). 
1.2.3. Myasthenia gravis. 
A number of auto immune disorders are observed in 
Graves' disease (Orgiazzi & Mornex, 1990). Myasthenia 
grqvis occurs in less than 0.1% of thyrotoxic patients, 
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but about ·5% of myasthenic patients have associated 
thyrotoxicosis (Layzer, 1990; DeLong & Adams,' 1991). In 
contrast to thyrotoxic myopathy, there is a preponderance 
of female pa~ients (Ali & Akavaram, 1980) . Its 
relationship with Graves' disease is not clear-cut. 
Hyperthyroidism has an adverse effect on the myasthenia 
( Engel , 1988 ) and correction of the hyperthyroidism is 
followed by improvement of the myasthenia in about two 
third of c~~es. However, the condition may deteriorate in 
some patients (Engel, 1972) especially among those who 
develop hypothyroidism (DeLong & Adams, 1991). The 
mechanism by which thyroid hormones affect the 
neuromuscular junction is not known. However, a decrease 
in the size of the miniature end-plate potential in 
hyperthyroid animals had been reported (Hofmann & Denys, 
1972) . 
1.2.4. Thyrotoxic periodic paralysis (TPP). 
1.2.4.1 Overview 
Although the syndrome of periodic paralysis was first 
described by Musgrave in" 1727 (Jackman & Jones, 1964; 
Tinker & Vannatta, 1987a), its association with 
thyrotoxicosis (syndrome of TPP) was not described until 
1902 by Rosenfield from Germany (Linder, 1955). 
The clinical features (Engel, 1961; Yeo & Q'Neill, 
1984; Yeung & Lam, 198'7), other than those of 
thyrotoxicosis, are not distinguishable from the more 
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well-known familial hypokalaemic periodic paralysis (FPP). 
Nei ther was it possible, apart from the paralysis, to 
distinguish clinically or biochemically thyrotoxic 
patients with and without paralysis. As a group, TPP 
patients are slightly younger but age does not help the 
differential diagnosis in individual patients. There is a 
preponderance of male patients and the attack of paralysis 
is associated with hypokalaemia. In , a mild attack, the 
plasma potassium may only be at the lower limit of normal 
and the attack may last only for an hour. The duration of 
a severe attack may be as long as 48 hours. A full 
recovery is expected although fatality and life 
threatening arrhythmias have been reported (Jackman & 
Jones, 1964; Fisher, 1982; Miller et al., 1989). The 
factors which provoke an attack of pa~alysis are similar 
to those of FPP. It usually occurs ' when the patient is 
resting after moderate or severe physical exercise or 
after taking a high carbohydrate meal. The severity of 
weakness which may be very variable, primarily involves 
the proximal muscles. Muscles of the head and neck are not 
involved and normal speech and swallowing functions are 
retained. 
Differential diagnosis, initially, may not be 
. 
straight-forward because TPP patients may exhibit few 
symptoms and signs to suggest an underlying thyrotoxicosis 
(Engel, 1961; Ramsay, 1974; Yeo & Q'Neill, 1984). However, 
there is no doubt about its association with 
thyrotoxicosis because, almost without exception, the 
condition will resolve once euthyroidism is achieved and 
it is not possible to induce further attack of paralysis 
unless the patient is rendered thyrotoxic again (Okihiro 
& Nordyke, 1966'; Layzer & Goldfield, 1974; Ober & 
Hennessy, 1981). 
The mild attacks could resolve spontaneously. 
However, oral . or intravenous potassium supplement is 
commonly instituted when the hypokalaemia is severe (Yeo 
& 0' Neill, ,.,1984). Treatment of TPP is· directed at the 
hyperthyroidism and propranolol is usually given in the 
first 4-6 weeks to prevent further attacks of paralysis 
until the reestablishment of the euthyroid state. Life-
threatening complications such as respiratory paralysis 
and arrhythmia are rare. Therefore prognosis is excellent 
(Yeo & O'Neill, 1984). 
However, the mechanism of paralysis and the 
pathogenesis of TPP remain undefined (Yeung & Lam, 1987; 
Riggs, 1989; Layzer, 1990). The consensus is that there is 
an underlying latent defect which is unmasked by the 
development of thyrotoxicosis. However, the nature of this 
defect or defects is still not known (Yeung & Lam, 1987; 
Riggs, 1989; Layzer, 1990)'-. 
1.2.4.2 Prevalence 
While thyrotoxicosis is relatively common, it is 
surprising that ·TPP was not documented earlier (Yeung & 
Lam, 1987). The first patient was reported in 1902. The 
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first Japanese TPP patient was reported in 1913 (Yeo & 
Q'Neill, 1984) and in 1941, the first Chinese TPP patient 
was reported from Peking (Su & Hsu, 1941). TPP patients 
have also been reported in many other racial groups (Yeo 
& Q'Neill 1984). 
TPP has not been studied as much as the other types 
of thyrotoxic muscle disorders probably because it occurs 
rarely in many parts of the world. It is exceedingly rare 
among Cauca-sians. For instance it could be so uncommon 
that "the first case of TPP" in UK had been published 
three times (Ali, 1975; Hay & McDougall, 1975; Papouchado, 
1980; Petch, 1980) and up till 1980, only six cases had 
been reported in UK (Hay, 1980). 
It is relatively more common in oriental populations 
(Engel, 1961; Yeung & Lam, 1987). Engel's 1961 survey of 
the world literature on TPP produced 228 cases, 90% of 
which were reported in Japan (Engel, 1961). Since then a 
similar survey has not been done but there is a consensus 
that TPP is relatively common among Asians. The prevalence 
of TPP among Chinese and Japanese thyrotoxic patients has 
been estimated to be between 2 and 6% (McFadzean & Yeung, 
1967; Hamada et al., 1982). 
One of the main difficulties in conducting any large 
study on TPP in a territory the size of Hong Kong, is the 
fact that it is still a relatively uncommon disease. For 
instance McFadzean & Yeung reported in 1967 a series of 25 
TPP patients (23 male and 2 female subjects), diagnosed 
over a period of five years at Queen Mary Hospital (the 
teaching hospital of the :Hong Kong University medical 
school). In an earlier survey of outpatients attending the 
same hospital, only one TPP patient was diagnosed in five 
years (1954-1958) out of 5.60 thyrotoxic patients (Choa, 
1960). 
The prevalence of TPP seems to be decreasing. This 
chronological change was first reported by Hama.da et al. 
( 1982) and reconfirmed again recently (Shizume et al., 
1992). The decrease was attributed to a change in dietary 
habit, from a traditional high carbohydrate diet to a more 
Western lower carbohydrate diet (Hamada et al., 1982; 
Shizume et al., 1992). 
Similar change in dietary habit has been occurring in 
Hong Kong (Lau et al., 1993) but study of the 
chronological change in prevalence has not been carried 
out. In a recent study on the genetics of TPP patients, 
conducted at the Prince of Wales Hospital (the teaching 
hospi tal of the Chinese uni versi ty of Hong Kong and 
serving a population of one million), only 31 TPP patients 
wer~ secured, suggesting that TPP is probably not as 
common as it used to be (Cavan DA et al., 1994). 
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1.3 PERIODIC PARALYSIS SYNDROMES IN THE CHINESE. 
There is a long list of causes of PP, both primary 
and secondary (Erigel, 1988; Lehmann-Horn et al.~ 1994). 
Most of them have been described in the Chinese. 
The focus has been on the association of TPP with the 
Chinese, among whom TPP is a relatively common disorder 
(summarized in section 1.2.4.2). There is a consensus that 
this assoc~ation is due to an iriherited defect which is 
more prevalent 
hypokalaemic PP 
among the Oriental races. Primary 
is uncommon in Hong Kong although it is 
more common than TPP in other parts of . China (section 
4.2.2). 
It is interesting ' to note that most of the primary 
hypokalaemic PP reported in the Chinese is sporadic rat~er 
than familial (Sham, 1983). Furthermore, primary 
hyperkalaemic PP rarely occurs. There is no published case 
in Hong Kong and the first case in China was reported 
about 10 years ago (Changet al., 1983). 
There are also · important differences in the secondary 
PP syndromes. Despi te the tr'adi tion of taking herbal 
medicine liquorice as a cause or a precipitating factor 
was not mentioned in all the major reported series of PP 
(Su & Hsu, 1941; Lau, 1957; Chen et al., 1965; Chin & Lau, 
1987; Mao et al., 1988). Recently we reported the first 
case of TPP precipitated by ingestion of liquorice in Hong 
Kong (Chan et al., 1992). 
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In contrast, barium poisoning was a very common cause 
of hypokalaemic pp in Szechwan province in China because 
of contamination of dietary salt by barium chloride 
(AlIen, 1943; Hung, 1943). Apparently the syndrome had 
been recognised in that part of China for several 
centuries (Lo, 1952). In Chinese, the syndrome was called 
"Pa-pin" which meant transient paralysis (Huang, 1943). 
. At one time gossypol, a male anti -fertili ty agent 
extracted f -rom the seed of cotton plant, was a common 
cause of hypokalaemic pp (Qian et al., 1980; Wang & Yeung, 
1985; Jin et al., 1989). 
There is evidence to suggest that the Chinese are 
more prone to develop hypokalaemic periodic paralysis. In 
1986, Ma et al. of Queen Mary Hospital, Hong Kong, 
published a series of 50 cases of Conn' s syndrome and 
reported that hypokalaemic pp was the presenting feature 
in 42% of the patients, occurring with equal frequency in 
the two sexes (Ma et al., 1986). It is not known why the 
hypokalaemia in these patients was more serious than those 
patients without paralysis . . Neither was it clear why 
Chinese patients with Conn's syndrome should have a lower 
plasma potassium concentration than other ethnic groups 
(private communication with Dr JTC Ma). However, a genetic 
difference in the sodium pump activity (i.e. higher 
activity in Chinese patients) might be important in the 
pathogenesis (Ma et al., 1986). Such an association was 
also reported from China in a series of 77 patients, in 
which the incidence of hypokalaemic pp was 31% (Koang et 
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al., 1979). It is interesting to note that the 
preponderance of the male sex among TPP patients does not 
occur here. In contrast, even though the patient described 
by Conn himself had attacks of hypokalaemic pp for seven 
years, a later report showed that this was not a common 
feature «6%) (Conn et al., 1964). 
Hypokalaemic pp due to Sjogren's syndrome was first 
reported in 1981 (Raskin et al., 1981). In 1989 three 
cases of hypokalaemic pp secondary to Sjogren's syndrome 
were reported by workers in Queen Mary Hospital, Hong Kong 
(Pun et al., 1989). These represented 3 of 26 cases of 
Sjogren's syndrome diagnosed in 10 years. "Another report 
of five similar cases from China also confirmed that 
hypokalaemic PP is a dominant feature of Sjogren's 
syndrome in the Chinese (Tung et al., 1983). In contrast, 
hypokalaemic PP complicating Sjogren's syndrome is rarely 
reported elsewhere (Venables, 1992). Ethnic variation in 
sodium pump activity might be ' important in the 
pathogenesis of the paralysis (Pun et al., 1989). In 
addition, the only patient with Sjogren's syndrome whom I 
personally diagnosed in Hong Kong, in 1989, also presented 
with hypokalaemic PP. 
It appears that the Chinese are more prone to 
developing hypokalaetnic PP ( private communication with 
Prof TP Hung, National Taiwan University). Whether this is 
related to an ethnic increase in sodium pump activity 
remains to be confirmed. 
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1.4 POTASSIUM HOMEOSTASIS IN TPP. 
Although a physiological role for thyroid hormone in 
the regulation of potassium distribution has not been 
delineated, thyroid dysfunctions are associated with 
disturbed potassium homeostasis (Perrone & Alexander, 
1994). TPP is a good example. 
While the clinical aspects of the pp syndromes have 
long been well characterized, our understanding of the 
pathophysiology, in general, has lagged behind. For 
instance, hypokalaemia during an attack of hypokalaemic pp 
was not described until 1934 (Tinker & Vannatta, 1987a). 
Most of the laboratory data on the homeostasis of 
potassium in hypokalaemic pp have been obtained from 
studies of patients with FPP. However, the consensus is 
th~t the mechanism is identical for FPP and TPP (Shizume 
et al., 1966a; Ruff & Gordon, 1986; Tinker & Vannatta, 
1987b; Engel, 1988; Ober, 1992). Although, the number of 
studies on TPP is small, 'all the important aspects of 
potassium homeostasis described in FPP have been 
-independently observed in TPP subjects. 
Hypokalaemia is the hallmark of TPP (Engel, 1961; 
McFadzean & Yeung, 1967; Yeo & O'Neill, 1984; Lerner & 
Wachtel, 1985; Ober, 1992), during both spontaneous and 
induced attacks of paralysis. Hypokalaemia invariably 
occurs during severe attacks of paralysis. The decline in 
plasma potassium concentration can be small and remains 
within the reference range if the paralysis is mild or 
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restricted. The decline is due to a transcellular shift of 
potassium from the extracellular compartment into the 
intracellular compartment. This was - demonstrated by 
Shizume et al. (1966a) who observed a constant positive 
arteriovenous difference for potassium in the leg during 
paralysis in TPP patients. 
Theoretically the potassium content in skeletal 
muscle should increase during paralysis but studies on the 
skeletal muscle potassium content have produced 
conflicting results. This may not be surprising since a 
demonstration of change in muscle potassium is difficult 
because the content o~ potassium in muscle - is high and a 
massive shift of the ion from the ECF is necessary to 
produce a detectable rise (Yeo & QINeill, 1984). Cheah 
(1974, MD thesis, cited by Yeo & QINeill, 1984) reported 
that the potassium content of the quadriceps muscle (mEq 
/kg fat-free dry solid, specimens obtained by biopsy) 
during paralysis was significantly increased in 7 of 10 
TPP subjects. Similar findings were not documented by the 
Shizume group earlier on (Shishiba et al., 1966). On the 
contrary, Satoyoshi et al., (1963) - reported a decrease 
during paralysis. However, entry of potassium into RBCs 
during paralysis has been demonstrated during paralysis 
(Feeley, 1981). 
There have been very few studies on the status of 
potassium homeostasis during attack-free intervals in TPP 
patients. Shizume et al., (1966b) studied the total 
exchangeable potassium (mEq /kg body weight) and reported 
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a significant decrease in thyrotoxic patients with (45.6 
vs 51.0) and without TPP (46.0 vs 51.0). However, when the 
exchangeable potassium result was expressed against lean 
body weight (mEq /kg lean body weight), the decrease in 
the TPP patients was not ' significantly different from 
controls (56.5 vs 61.1), whereas the decrease in 
uncomplicated thyrotoxic patients was significant (53.0 vs 
61.1). , 
Althougb a similar study has not been attempted on 
TPP patients by other workers in recent years, findings 
reported by the Shizume group in their three papers are 
widely cited by authorities ,in thyroid research (Ramsay, 
1974; Ruff & Gordon, 1986; Ruff, ·1989). However, 
interpretation of data with regard to body potassium might 
be difficult because of the limitations of the specific 
techniques used in these studies as well as the difficulty 
of determining normal values in patients who are 
frequently losing weight and may be in heart failure 
(Kleeman & Danovitch, 1986)~ 
Although a slight deficit in body potassium in TPP 
patients has been suggested, the hypokalaemia observed in 
a paralytic attack is not dbe to renal or extrarenal loss 
of potassium. During an attack the urine potassium 
concentration is decreased and there is no increase in 
potassium content in stool (Engel, 1961; McFadzean & 
Yeung, 1967). 
While exceptions have been reported (Norris et al., 
1971), correction of hypokalaemia, spontq.neously or by 
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potassium supplement, is associated with recovery of 
muscle power. The plasma potassium concentration is normal 
between attacks of paralysis. In general there is a 
correlation between the degree of hypokalaemia and the 
severity of muscle weakness (McFadzean & Yeung, 1967; Yeo 
& OlNeill, 1984; Ramsay, 1974; Kufs et al., 1989; Lawrence 
et al., 1990; Knochel, 1992;) . Typical ECG changes of 
hypokalaemia could be found during these attacks and 
dangerous arrhythmias cou~d develop requiring urgent 
potassium therapy (Secti6n 1.2.4.1). 
It is well recognized that factors which encourage 
transcellular shift of potassium can precipitate an attack 
of paralysis (Shizume et al., 1966a; McFadzean & Yeung, 
1967; Yeo & OlNeill, 1984; Ruff, 1989; Lawrence et al., 
1990; Ober, 1992). This has been explored in the past to 
induce attacks to confirm the diagnosis and for further 
investigation. Insulin infusion and carbohydrate intake 
can precipitate paralysis. Al though catecholamines are 
regar~ed as an important risk factor, their relationship 
with .pp is not clearcut. · For instance both Engel (1972) 
and Ali & Akavaram (1980) reported that infusion of a 
minute dose of adrenaline could not induce attack of 
paralysis among TPP patients. In contrast the same 
procedure could readily precipitate attack among FPP 
patients. These results seem to suggest FPP patients are 
more sensitive to adrenaline than TPP patients. It is 
interesting to note that adrenaline infusion was used in 
1897 by Goetsch to diagnose thyrotoxicosis, in which an 
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increase in blood pressure and pulse rate by at least "10 
points" was expected (Schmidt, 1959). 
There is an outflow of potassium ion from skeletal 
muscle during ex~rcise and an inflow at rest (Clausen & 
Everts, 1989; Stansbie & Begley, 1991; Young et al., 
1992). This might explain why paralytic attacks tend to 
occur while patients are resting several hours after heavy 
physical exertion. This might also be the reason why 
moderate exercise could attenuate the severity of 
paralysis and hasten the recovery of power (McFadzean & 
Yeung, 1967; Charness & Johns, 1978; Yeo & O'Neill, 1984; 
Kelly et al., 1989; Ober, 1992). A circadium rhythm of 
intercompartmental potassium fluxes has been recognised. 
There is a net uptake of potassium by the muscle tissue at 
night and this might explain the tendency for patients to 
develop paralysis at night (Zierler & Andres, 1957; 
Charness & Johns, 1978). 
In summary, there is ample evidence to suggest that 
hypokalaemia is secondary to · a transcellular shift of 
potass~um and that this process plays a central role in 
the development of paralysis in TPP patients. This further 
raises a number of issues which are important in the 
clarification of the pathogenesis of TPP:-
a. What is the driving force behind this 
transcellular shift of potassium and its relationship with 
the known I inci ting I factors? What is its relationship 
with the thyroid hormones? 
b. What is the mechanism of paralysis? What is the 
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link betweentranscellular , shift· of potassium and the 
development of muscle weakness? 
c. Why sbould it ,occur in some but not all thyrotoxic 
patients? 
Available information on these issues will be 
summarized in the following sections. 
1.5. CELLULAR POTASSIUM TRANSPORT. 
1.5.1. Role Qf the sodium pump. 
The intracellular potassium concentration is about 30 
times that of plasma. Therefore the transcellular shift of 
potassium described above occurs against a high 
concentration gradient and requires active transport, a 
process in which the sodium pump is known to play a 
central role (Skou, 1986; Guy ton , 1991a; De Weer, 1992). 
The sodium pump, first described by Skou in 1957, 
involves a membrane bound enzyme which hydrolyses ATP in 
the presence of Na, K and Mg ions (Skou, 1957). The enzyme 
is therefore commonly called Na-K ATPase. It can be found 
in nearly all animal cells and possesses a wide spectrum 
of physiologi~al functioris such as maintenance 6f 
transmembrane Na and K gradients, maintenance of membrane 
potential, regulation of intracellular Ca ion, and 
provision of electrochemical energy for the co-transport 
of sugars and amino acids (Lechene, 1988; Palmar, 1989; De 
Weer, 1992). It enables the body to adapt to various 
potassium excess an~ deficiency states. (Rosa et al., 
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199~). About 23% of the oxygen consumption in human 
subjects can be attributed to the sodium pump (Swaminathan 
et al., 1982). It is subject to regulation by a variety of 
hormones and will 'respond to changes in extra- and intra-
cellular electrolyte concentrations (Clausen, 1986; 
Rossier et al., 1987; Gick et al., ' 1988; Palmar, 1989). 
For instance, an increase in sodium influx will 
immediately stimulate the sodium pump activity to correct 
the imbalance until a new steady~state is reached. If the 
influx is sustained, it will respond by increased 
synthesis of new pumps. The changes will be resolved once 
the sodium influx returns to normal (Rossier et al., 1987; 
Lechene, 1988). Its physiological , importance can be best 
illustrated by its ability to maintain body potassium 
balance during exercise and potassium deficiency. 
A large amount of potassium is released from skeletal 
muscle during vigorous exercise and the potassium 
concentration in the interstitial fluid space may reach 
values up to 8 15 mmol/L (Clausen & Everts, 1989; 
Kjeldsen, 1994). This is brought under control by the 
sodium pump which has a tremendous reserve to adapt to the 
demand by rapidly and efficiently increasing the rate of 
potassium entry into muscle cells (Sejersted, 1988; 
Kjeldsen, 1994). 
In potassium deficiency states, there is a down-
regulation of skeletal muscle sodium pump concentration 
(Kjeldsen et al., 1984; Clausen & Everts, 1989; Kjeldsen, 
1994). In contrast, the decrease in cardiac muscle is much 
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less and there is no change in peripheral nerves and brain 
(Brown et al., 1986; Schmidt et al., 1992). There is also 
a preferential loss of potassium from the skeletal muscle, 
which normally contains 75% of body potassium, in an 
attempt to protect the potassium content of other more 
vital organs (Kjeldsen, 1994). 
It is therefore likely that hypokalaemic pp 
represents a disturbance in the control of sodium pump 
activity. P~~haps an excessively high and uncontrollled 
pump activity, 
both, may , be 
paralysis. 
at the basal state or on stimulation or 
responsible for the development of the 
1.5.2. Hormonal control of the sodium pump. 
It is well documented that sodium pump activity and 
number are increased in a variety of body tissues in 
thyrotoxic patients ( Gick et al ., 1988; Palmer, 1989 ; 
McNabb, 1992). The increase is reversible and resolves 
once patients are rendered euthyroid. 
Details of the cellular /molecular pathway of this 
process are not yet clear. There is a consensus that 
exposure to excessive thyroid hormones is characterized by 
a rapid increase in passive sodium influx and potassium 
efflux. This is followed by an increase in the synthesis 
of additional pump units (Haber & Loeb, 1986; Kjeldsen et 
al., 1986; Everts et al., 1988; Haber & Loeb, 1988). It is 
possible that the later response is due to a direct effect 
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of T3 at the nuclear receptor level, or is a result of the 
changes in passive ion fluxes affecting the expression of 
, 
the sodium pump gene through an unknown mechanism (Lingrel 
et al., 1990). 
In addition sodium pump activity can be stimulated by 
insulin and catecholamines (Yeo & O,'Neill, 1984; Clausen, 
1986; Gick et al., 1988; Rosa et al., 1992) , a 
characteristic correlating well with clinical and 
experimental "findings summarized in section 1.4. (Details 
on the effect of insulin and catecholamines will be 
discussed in chapter 6.) 
1.5.3 Molecular biology of the sodium pump 
It is beyond the scope of this thesis to give a 
detailed account on this rapidly developing subject. 
Aspects that may be important in the pathogenesis of TPP 
will be summarized (Haber & Loeb, 1988b; Yang-Feng et al., 
1988; Sweadner, 1989; Lingrel et al., 1990; Sweadner, 
1991; Jorgensen, 1992; McDonough et al., 1992). 
The Na-K ATPase consists of two subunits, the alpha-
subunit which probably is responsible for most of its 
physiological function, and the beta-subunit the role of 
which is not yet well defined~ The enzyme is heterogeneous 
because of a number of isoforms. Five alpha-subunit 
isoforms and three beta-subunit isoforms have been 
described. Each of them are independently represented by 
different genes. For instance, the alpha-1 subunit gene is 
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located on human chromosome ' lp, close to the centromere. 
The alpha-2 subunit gene is located on human chromosome 1q 
and alpha-3 subunit is · coded by a gene mapped to 
chromosome 13. 
Expression of alpha-1 is ubiquitous whereas alpha-2 
and alpha-3 are not found in every tissues. The relative 
amounts of these isoforms vary among tissues. The alpha-1 
isoform is believed to exercise a 'house-keeping' role 
such as maintenance of osmotic balance and cell-volume. 
The alpha-2 isoform is responsible for the tissue-specific 
function (Lingrel et al., 1990). 
Detailed comparisons between these isoforms have been 
hampered by the difficulty in obtaining pure extracts of 
these isoforms from tissues. Therefore estimates of 
relative quantities of isoforms depend on the analysis of 
the relative quantities of mRNAs. The correlation between 
the quantity of mRNA and the quantity of the isoform is 
not a close one. Most of data were obtained from animal 
studies and differences in expression between species are 
well recognized. 
It is generally accepted that different isoforms will 
confer differences in enzyme kinetics, mechanism of 
control and sensitivity to ouabain inhibition. The 
physiological significance of these characteristics is not 
yet defined. Neither is the pathological significance 
clarified. 
Based on studies in rat, the alpha-2 isoform is the 
dominant form in skeletal muscle. Alpha-2 isoform exhibits 
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a number of features which may be important in the 
pathogenesis of TPP. 
a. When rat was rendered thyrotoxic in experiments, 
there was selective increase in the expression of the 
alpha-2 isoform in the skeletal muscle. Changes in other 
alpha isoforms were very small (Haber & Loeb, 1988b) 
b. The affinity of isoform for sodium (a substrate of 
Na-K ATPase) varies among isoforms. Using the rat 
adipocyte model "it was found that, at the basal state, the 
alpha-2 was virtually inactive because of a low affinity 
for sodium ions. However, the affinity for sodium ions 
greatly improved after treatment with .insulin, reflected 
by an increase in enzyme activity. Assuming that a similar 
mechanism occurs in skeletal muscle, this represents a 
large reserve capacity of enzyme activity which will be 
manifested in conditions where insulin release is 
stimulated (Lingrel et al., 1990; Sweadner, 1991). 
c. The sensi ti vi ty to inhibi tion by cardiac 
glycosides varies between isoforms. Alpha-2 isoform is 
more sensi ti ve to ouabain inhibition than other alpha 
isoforms. The significance of this finding is not certain 
yet (Sweadner, 1989; Lingrel et al., 1990; Jorgensen, 
1992). However, there have been reports on the existence 
of . endogenous ' digoxin-like substances (DLS). 
Theoretically, fluctuations in DLS levels may affect the 
activity of these isoforms. 
d. The expression of alpha isoforms is affected by 
potassium balance (McDonough et al., 1992). In potassium-
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deficent rats, selected decrease in alpha-2 activity has 
peen reported. However, there is no data on acute change 
in potassium balance. 
Interpretation of the significance of these findings 
in the pathogenesis of TPP is difficult. It is not yet 
certain how far these findings can be extrapolated to 
humans. The impact of thyrotoxicosis on the expression of 
these isoforms is not clear. The difference between TPP 
patients and -, uncomplicated thyrotoxic patients in these 
characteristics of the Na-K ATPase has not yet been 
studied. Theoretically differences in the expression of 
Na-K ATPase· resulting in differences in the enzyme 
activity and response to stimulator or inhibitor may be 
the reasons why TPP develops in some but not all 
thyrotoxic patients. 
1.5.4 Ha-X-Cl transporter. 
In recent years, another potassium transporter, the 
Na-K-CI ~ransporter, has been described but little is 
known about its characteristics in thyroid diseases or its 
role in the pathophysiology cif the periodic paralysis 
syndromes. 
It was first documented in 1974 (Wiley & Cooper, 
1974) that there was an ability to cotransport potassium 
with sodium and chloride ions, in a ratio of 1:1:2, across 
cell membranes simultaneously with no net movement of 
electrical charge. The Na-K-Cl transporter depends on the 
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electrochemical force provided by the large difference in 
extra- and intracellar sodium concentrations (142 vs 10 
mmol/L) established by the sodium pump (Chipperfield, 
1986; Palmer, 1989; Haas, 1994). 
In contrast to the sodium pump, the Na-K-Cl 
transporter is not sensitive to ouabain but easily 
inhibited by loop diuretics such as frusemide and 
bumetanide. Therefore the activity of this transporter is, 
in general / determined as the "ouabain-resistant, 
fruseinide-sensi ti ve" rubidium (86Rb) uptake (Frelin et al. , 
1986). 
It is not known whether the Na-K-Cl tra'nsport has any 
role in the pathophysiology of thyroid diseases. In animal 
(mouse) experiments, hyperthyroidism has not been shown to 
affect the ouabain-resistant potassium transport in 
skeletal muscle (Clausen, 1986). In humans, its activity 
decreases in RBCs (Arumanayagam et al., 1990) but remains 
unchanged in lymphocytes (Oh et al., 1990) in 
uncomplicated thyrotoxic s~bjects. 
It was recently reported that in the lymphocytes of 
TPP patients, the sodium pump activity (measured by 
ouabain sensitive rubidium influx) is no different from 
uncomplicated thyrotoxic patients despite an increase in 
sodium pump numbers. However the ouabain-resistant 
rubidi urn inf I ux was increased ( Oh et al ., 1990 ). The 
significance of this interesting finding is uncertain 
because it is not sure whether such findings in blood 
cells reflect what actually happens at the skeletal muscle 
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(Kjeldsen, 1994). 
Moreover, it was recently documented that in skeletal 
muscle the Na-K-CI transporter does not seem to possess 
the ability to tr-ansport potassium ions although it was 
possible to demonstrate an active transport of rubidium 
ion using standard methodology for the measurement of Na-
K-CI transporter activity (Dorup & Clausen, 1994). The Na-
K-CI transporter in skeletal muscle might have lost its 
ability to transport potassium ion, an ability which is 
present in the myoblast stage (Panet et al., 1987). 
Insulin does not stimulate Na-K-CI transporter 
.. 
activity in skeletal muscle (Weil et al. ', 1991; Weil-
Maslansky, 1994) al~hough previous studies have reported 
such- a stimulating action using "non-classical" target 
cells, such as RBCs and fibroblasts (Geck & Heinz, 1986; 
Panet & Atlan, 1990). The Na-K-Cl transporter activity in 
lymphocytes is inhibited by beta-adrenergic agonist 
(Feldman, 1992) and similar findings from studies on RBCs, 
endothelial cells and smooth muscle cells have also been 
reported . (Feldm~n, 1992). Therefore it is unlikely that 
the Na-K-Cl transporter has any significant role in the 
pathogenesis of TPP. 
1.5.5 Summary. 
In summary, the sodium pump is the driving ~orce 
behind -the transcellular shift of potassium ions. Its 
enhanced activity in thyrotoxicosis and its ability to 
respond to insulin and catecholamine stimulation could 
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account for the clinical characteristics described above. 
Numerous authorities in the study of thyroid diseases have 
proposed that the sodium pump plays a central role in the 
pathogenesis of TPP (Clausen, 1986; Kjeldsen et al., 1986; 
Yeung & Lam, 1987; Clausen & Everts, 1989; Kaminski & 
Ruff, 1994; Kjeldsen, 1994) although neither definite 
laboratory evidence nor detailed explanation has been 
provided (DeLong & Adams, 1991). 
Perhaps '- ' a genetic difference in the sodium pump may 
account for the ethnic difference in the incidence of TPP 
as well as the development of TPP only in certain selected 
group of thyrotoxic patients. 
It . is a definite possibility that hypokalaemic 
periodic paralysis tends to develop among those thyrotoxic 
subjects who have the highest basal sodium pump activity. 
One fundamental difference between FPP and TPP is 
that the basal sodium pump activity in FPP is known to be 
not increased (Samaha, 1969; Ruff, 1989; Lehmann-Horn et 
al., 1994). This does not exclude the possibility that the 
stimulated-activity cou~d be increased. On the otper hand, 
an exceptionally high stimulated-activity of the sodium 
pump might be another factor which predisposes certain 
thyrotoxic patients to develop TPP. Excessive levels of 
stimulators like insulin or catecholamines might also have 
a role to play in the pathogenesis. 
1.6 MECHANISM OF PARALYSIS. 
TPP is . characterized by muscular inexcitability in 
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response to direct electrical stimulation in attacks of 
paralysis (Puvanendran et al., 1977; Yeo & Q'Neill, 1984; 
Kelly et al., 1989; Ruff, 1989). 
The normal resting skeletal muscle membrane potential 
(Em) is largely determined by the diffusion potentials 
(Ediff ) of K q.nd Na ions. The contribution by the 
electrogenic potential (EeLect)' generated by the sodium 
pump, is small. Therefore the Em is closed to the Ediff 
(Yeo & Q'Neill, 1984; Guy ton , 1991b) which can be 
calculated according to the modified Nernst equation (i.e. 
the Goldman-Hodgkin-Huxley equation) listed below:-
RT 
F 
When the internal sodium concentration is low, it can 





In K + aNa 
o 0 
Alpha value, which stands for the Na-K permeability 
ratio, is approximately equal to 0.01, resulting in an Em 
of -90 mV. 
A decrease in extracellular potassium concentration, 
according to the above equation, should lead to an 
increase in Em (i. e. · hyperpolarization). This has been 
confirmed in animals (dog) and humans studies (Knochel, 
1989; Knochel, 1992). Theoretically, an enhanced ~odium 
pump activity may increase its contribution to the resting 
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Em. Therefore it is expected that the Em in TPP patients 
should be higher than normal and the paralysis probably is 
the result of a hyperpolarization block. 
However, in human as well as animal (rat) 
experiments, the Em was found to be lower than normal in 
all . thyrotoxic subjects (Gruener . et al., ~975; Clausen, 
1986) . . Based on the Goldman-Hodgkin-Huxley equation, this 
could happen if there has been an increase in the alpha 
value; either an increase in P~ or an decrease in PK, or 
a combination of both (Yeo & Q'Neill, 1984; Lehmann-Horn 
et al., 1994). Similar changes in Em and alpha value were 
observed in FPP where the membrane defect ' is life-long 
(Hofmann & Smith, 1970; Rudel & Ricker, 1985; Ruff & 
Gordon, 1986). 
An acute t .ranscellular shift in potassium ions is 
expected to aggravate the situation. Instead of giving 
rise to an increase in Em, it precipitates further 
depolarization. Neither PNa nor PK are static. PNa would 
increase and PK decrease (ie increase in the alpha value) 
if there ,is a large decrease in extracellular potassium 
concentration (Rudel et al., 1984; Rudel & Ricker, 1985; 
Lehmann-Horn et al., 1994).. It is generally accepted that 
such a low Em will lead to inactivation of the Na or K 
channels resulting in the loss of excitability (Kaminski 
& Ruff, 1994; Lehmann-Horn et al., 1994), manifested 
clinically as paralysis. 
However, there is no consensus on which ion channel 
is involved in the pathogenesis (Ruff et al., 1988; Kelly 
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et al., 1989; Grafe et al.~ 1990; Schipperheyn et al., 
1992; Lehmann-Horn et al., 1994). 
without exception, studies on ion channels have 
focused on FPP pati~nts. A si~ilar study on TPP patients 
has not been carried out although it is generally believed 
that the two conditions have similar membrane defects, and 
that the primary cause is different (Ruff, 1989; Lehmann-
Horn et al., 1994). However, this should be confirmed by 
an independent study. While there might be a decrease in 
PK in FPP, there i~ probably an increase in PK in TPP since 
increased passive potassium efflux secondary to the effect 
of thyroid hormone is well documented. There might be 
major differences between the two conditions because it 
was suggested that even for TPP, the pathophysiology of 
TPP might be different in different racial groups (Marx et . 
al., 1989). 
Since Em is decreased in all thyrotoxic subjects, why 
should TPP occur only in some but not all subjects? A 
study which compares the Em between · the two thyrotoxic 
groups (same racial group) may provide the answer. 
It has been reported that the- decrease in' Em in 
thyrotoxic subjects is about 10-20 mV (Clausen, 1986). 
However, in a single report in which the Em was measured 
in a TPP patient (Hofmann & Smith, 1970), the decrease in 
I 
Em was 31 and 55 mV before and during an attack of 
paralysis. The magnitude was even greater than that of an 
FPP patient who had an decrease in Em of 16 -and 29 mV 
before and during paralysis. Therefore, based on this 
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isolated report, . ; , TPP patlents probably have a greater 
degree of depolarization than the uncomplicated thyrotoxic 
patients secondary to a greater change in the alpha value. 
1.7. AETIOLOGY OF TPP. 
1.7.1 Genetic predisposition. 
It is generally accepted that TPP patients have an 
underlying genetic defect which is unmasked by 
thyrotoxicosis (Shishiba et al., 1980; Hamada et al., 
1982; Leung, 1985; Yeung & Lam, 1987; Kufs et al., 1989). 
Reports of familial TPP cases (Okinaka et ai., 1957; 
Brown, 1960; Engel, 1961; McFadzean & Yeung, 1969) support 
the possibility of a genetic basis. 
It is well documented that Graves' disease is 
associated with certain Human Leucocyte Antigens (HLA) in 
various populations (Fisher, 1990; Schimke, 1992). 
Furthermore, studies have demonstrated an association 
-between certain HLA antigens and the onset of the illness 
(Nakao et al., 1978'; Hawkins et al., 1985; Chan et al., 
1986) as well as the relapse rate following the withdrawal 
of treatment (Irvine et al., 1977). Therefore there is a 
distinct possibility that certain HLA antigens exist which 
will predict the development of TPP among thyrotoxic 
patients. Indeed, similar studies carried out in Hong 
Kong, Singapore and Japan have documented an association 
between HLA antigens and the development of TPP (Yeo et 
al ., 1978; Hawkins et al., 1985 ; Tamai et al., 1987 ) . 
However, in general, the associations ' are not strong 
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enough to enable the establishment of any particu~ar HLA 
antigens as a genetic ma'rker of TPP patients. 
All these studies were conducted before the era of 
molecular biology'. As summarized in section 1. 5 . 3, much 
progress on the molecular biology .of the Na-K ATPase has 
been made. However, the molecular defects of TPP have not 
been studied. There has not been any published information 
on the genetic difference, at the molecular level, between 
TPP and other--',· thyrotoxic patients. The mechanism for the 
un~asking of the latent defect by excessive thy~oid 
hormone is not yet known. 
1.7.2 possible membrane defect. 
As outlined in section 1.6, thyroid hormone affects 
the . membrane cation permeability resulting in 
depolarization (decrease in Em). Available but limited 
data so far suggest that TPP patients probably have a 
'greater' membrane defect which leads to a greater alpha 
value resulting in a lower Em. However, there has not been 
any study which compares the skeletal muscle membrane 
cation permeability or the electrophysiological 
characteristics of the ion channels between these two 
groups of thyrotoxic patients. The relationship between 
the suspected membrane defect and the ·sodium pump is also 
not known. In FPP patients, sodium pump activity is not 
disturbed despite a change in membrane permeability. 
Therefore, there could be separate defects affecting the 
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sodium pump as well as the muscle membrane in TPP 
patients. 
1.7.3 The central role of the sodium pump in the 
pathogenesis of TPP. 
As outlined in section 1.6, it is the current 
consensus that a further and acute decrease in E'm, 
precipitated by an acute transcellular shift of potassium, 
will lead to paralysis possibly secondary to an 
inactivation of ionic channels. The driving force behind 
the acute ' etranscellular shift of potassium is an active 
sodium pump (section 1.5). 
Al though it is not yet proven, it is logical to 
deduce that thyrotoxic patients who have an exceptionally 
high basal or stimulated sodium pump activity are more 
likely to develop attacks of paralysis. As ~ result of an 
increase in .thyroid hormones, sodium pump activity in a 
large variety of body tissues is increased. Therefore a 
higher thap usual sodium pump activity probably reflects 
an undue sensitivity to the effect of thyroid hormone. 
Various inciti~g factors will precipitate an attack 
of paralysis through the stimulation of the sodium pump 
activity. Recovery of muscle power occurs after the 
inciting factors have been resolved. Restoration of basal 
sodium pump activity will facilitate a correction of the 
hypokalaemia. There will also be improvement in the alpha 
value, and re-establishment of a higher Em and 
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reactivation of the ionic channels. 
1.7.4 Environmental factor • 
. , 
There is probably an environmental factor in the 
pathogenesis of TPP. The prevalence of TPP is reported to 
have decreased over the years. The decrease is attributed 
to a change in dietary habit, fr'om a tradit~onal high 
carbohydrate -"diet to a more Western lower carbohydrate 
diet (Hamada et al., 1982; Shizume et al., 1992). 
1.7.5 Summary 
It is not yet certain what is the underlying defect. 
It could be multiple, involving the muscle membrane, the 
sodium pump and stimulators of the sodium pump (Yeo et 
al., 1988). The mechanism at the cellular level is far 
from clear. 
There is no doubt that the sodium pump plays a 
central role iri the pathogenesis of TPP. An exceptional 
increase in sodium pump activity, due to undue sensitivity 
to the effect of excess in thyroid hormones, may be the 
reason why TPP develops in some but not all thyrotoxic 
patients. However, such a difference in sodium pump 
activity between these two groups of th~rotoxic patients 
has not yet been demonstrated. 
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1.8. AIMS OF THE THESIS 
As indicated in section 1.5.5, numerous authorities 
have proposed that the sodium pump plays a central role in 
the pathogenesis of TPP. However, neither definite 
laboratory evidence nor detailed explanation has been 
provided. The key question is why TPP develops in some but 
not all thyrotoxic patients. 
The hYP'othesis of this thesis is that thyrotoxic 
patients who have a high basal or stimulated sodium pump 
activity are more likely to develop hypokalaemic periodic 
paralysis. 
The ultimate objective of this thesis is to provide 
laboratory evidence to support this hypothesis. However, 
it is very difficult to perform research on this subject. 
The analytical and clinical problems involved are 
summarized in section 4.2.2. 
In this thesis, three groups of subjects will be 
studied: healthy controls, TPP patients and uncomplicated 
thyrotoxic patients before and . after anti -thyroid 
' . r " 
treatment. 
The aims of this thesis are summarized as b~low:-
1. To conduct a pilot study to assess the feasibility 
of using . a simple but indirect model (in vitro decline in 
plasma potassium concentration), to study the sodium pump 
activity in healthy controls, TPP patients and 
uncomplicated thyrotoxic patients. 
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2. To establish an enzymatic assay for platelet Na-K 
ATPase activity . 
. 3. To study its correlation with thyroid hormones in 
healthy controls as well as in thyrotoxic patients. 
4. To study its performance as a tissue marker of 
hyperthyroidism. i.e. its ability to differentiate between 
euthyroidism and hyperthyroidism. To study the difference 
between healthy controls and treated thyrotoxic patients. 
5. To study its relationship with age and sex, since 
both factors have aetiological significance. 
6 . To examine the difference between the sexes in 
terms of thyroid hormones results and platelet Na-K ATPase 
ac~ivity in control subjects and thyrotoxic patients 
before and after treatment. 
7~ To study the thyroid hormone results between TPP 
patients and uncomplicated thyrotoxic patients. To confirm 
that the TPP group is no more toxic than the other 
thyrotoxic group as far as plasma thyroid hormone 
concentrations are concerned. 
8. To study and compare the basal · platelet Na-K ' 
ATPase activity between the two groups of thyrotoxic 
patients befo~e and. after anti-thyroid treatment. To 
compare the results in TPP patients before and after anti-
thyroid treatment. 
9. To correlate the platelet Na-K ~TPase results (in 
vitro sodium pump activity) with that of the rubidium 




10. To validate the "standard oral glucose tolerance 
test" protocol and to derive an improved protocol. 
11. To study and compare the stimulated platelet Na-K 
ATPase activity in the three groups of subjects by 
measuring the activity before and after a standard glucose 
load, according to the improved OGTT protocol. 
12. To study simultaneously the profile of plasma 
insulin (a stimulator of ' sodium pump) and the platelet Na-
K ATPase activity in the three groups of subjects. 
13. .To study the relationship between glucose 
intolerance and plasma insulin profile in the three groups 
of subjects. 
14. To study the effect of propranolol on the 
stimulated insulin secretion. i.e. to ~tudy the effect of 
an inhibitor on the secretion of a sodium pump stimulator. 
15. To identify strategies for future studies. 
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· Chapter 2 
A PILOT STUDY ON THE PATHOPHYSIOLOGY OF TPP 
44 
2.1 AIM 
To assess the 





feasibility of using a simple but 
vitro decline in plasma potassium 
study the sodium putqp activity in 
TPP patients and uncomplicated 
2.2.1 The measurement of Na-K ATPase/ sodium pump 
activity. 
As outlined in Chapter 1, the sodium pump may play a 
central role in the pathogenesis of TPP. A high basal or 
stimulated sodium pump activity may result in an acute 
transcellular shift of potassium which precipitates an 
attack of paralysis. Differences in the characteristics of 
sodium pump function may be the reason why TPP develops in 
certain thyrotoxic subjects and not in others. Therefore 
it will be meaningful to compare the sodium pump activity 
between these two sub-groups of thyrotoxic patients. 
The methods in current use for studying the sodium 
pump include:-
a. Measurement of the increase in the intracellular 
sodium concentration of RBCs after incubation whole blood 
with ouabain (Cumberbatch & Morgan, 1978). 
RBC sodium pump activity ,is inhibited in the presence 
of excess ouabain. The efflux of Na will be inhibited. The 
intracellular concentration of sodium (Nai) will increase. 
The rate of rise in Nai reflects the ouabain sensitive 
efflux rate of Na. The efflux rate constant can be 
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calculated by dividing the efflux rate by the original Nai. 
I 
This method is attractive because radioactive labels are 
not involved and sample preparation is not required. 
However, the ouabain sensitive Na efflux normally accounts 
for about 75-85% of the total Na. efflux (Sachs & Welt, 
1967) . . Therefore results for the efflux rate constant 
obtained by this method are in general lower than those of 
other methods. In addition, the relationship between Nai 
and the ouabain sensitive efflux is linear only over a 
limited range of Nai. 
b. Direct measurement of the cellular enzymatic 
activity (Baron & Khan, 1985). 
Na-K ATPase ac~ivity is measured by monitoring the 
rate of hydrolysis of ATP. It commonly involves the 
measurement of the rate of generation of inorganic 
phosphate with and without the presence of ouabain. Sample 
pretreatment with detergent is normally required. However, 
radioactive labels are not involved and it is possible to 
automate spme of the analytical steps. 
c. Determination of cellular ion transport, such as 
potassium influx, rubidium influx or sodium efflux, using 
radioactive isotopes (Akera, 1984). 
Measurement of sodium efflux involves incubation of 
isolated intact cells in an isotonic solu~ion containing 
a known amount of radioactive sodium (22Na ). After a 
loading period of three hours the cells · are washed and 
placed in another isotonic solution. The rate of release 
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of 22Na from the cells with and without the presence of 
ouabain are measured. 
Measurement of potassium uptake involves the use of 
radioactive potassiu~ (~K) or rubidium (~Rb). Rubidium is 
preferred because of its longer ~alf-life. Intact cells 
are incubated in isotonic solution containing the 
radioactive label with and without the presence of 
ouabain. The amount of cellular label is subsequently 
determined. :-,. . 
All these methods are well established. Radioactive 
rubidium uptake is the preferred method. However, it 
involves the use of radioactivity and it would be 
difficult to use these methods to study TPP patients who 
present infrequently. (problem with logistics will be 
discussed in chapter 4). 
d. Assessment of the number of pump sites on cell 
membrane using radioactive ouabain binding (Akera, 1984). 
It involves incubation of intact cells with a known 
amount Of radioactive ouabain and increasing 
concentrations of unlabelled . ouabain for a defined period. 
The cells are then washed .and the bound radioactivity is 
eluted and determined by using a liquid scintillation 
counter. Scatchard analysis is done to determine the 
number of binding sites and the dissociation constant. 
e. Oral rubidium loading tes~ (Boon et al.,· 1984). 
This is an ' in vivo assay of the sodium pump activity. 
It involves measurement of plasma rubidium concentrations 
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after oral rubidium loading~ Rubidium is taken up into 
cells mainly through the action of the sodium pump. 
Therefore the clearance of rubidium reflects the in vivo 
sodium pump act,ivit'y. The plasma rubidium, concentration is 
determined by atomic absorption. This in vivo test is 
attractive because it avoids the possible artifacts that 
may be introduced in ,the in vitro assays. However, it 
requires fasting the patient for five hours and cannot be 
readily repeated. 
In summary, there is no perfect assay for the sodium 
pump activity. The methods described above are in general 
quite labour intensive. Some of them require the use of 
radioactive isotopes. In addition the sample preparation 
step may int~oduce serious analytical errors (Poston et 
al., 1982; Main et al., 1989; Siebers et al., 1989). 
A simple non-radioactive method which involves 
minimal sample preparation would be ideal for this 
project. 
2.2.2 In vitro decline in plasma potassium concentration 
In blood specimens, the plasma potassium 
concentration changes in a biphasic mode if stored in 
vitro. There is an initial decrease in the first 8 - 10 
hours because of the continuous cellular uptake of 
potassium via the sodium pump (mainly by RBCs) , su~tained 
. 
by energy generated by glycolysis (Danowski, 1941; 
Houtsmuller, 1959; Kalsheker & Jones, 1984). The decrease 
is relatively steep in the first three hours and slows 
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down considerably after five :hours. The rate of decFease 
reflects sodium pump activity (Kalsheker & Hales, 1985). 
Therefore the rate of in vitro decrease in plasma 
potassium concentration could potentially be used as an 
indirect index of sodium pump activity. 
In a recent report, the decrease in potassium 
concentration (in vitro) was greater (0.33 vs 0.13 mmol/L, 
after 2 hours) when insulin (0.67 nmol /Kg body weight) 
had been given intravenously before blood sample 
collection (Kalsheker & Hales, 1985). The peaked plasma 
insulin level was about 1500 mIU/L. The results indicated 
that insulin stimulates potassium uptake by the RBCs. 
Therefore it might be possible to study the insulin-
stimulated sodium pump activity by means of a similar 
protocol. Such a method is attractive because it is 
simple, non-radioactive and ' involves minimal sample 
handling. 
2.2.3 Catecholamines 
Although catecholamines are known stimulators of the 
sodium pump, production of catecholamines tends to 
decrease in thyrotoxic subjects (Christensen, 1973; 
Stoffer ,et al., 1973). , Whether there is any increase in 
catecholamine production in TPP subjects is not known. 
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2.3 SUBJECTS & METHODS. 
A 75 g oral glucose tolerance test was carried out on 
10 healthy subjects. Venous blood was taken at 0, 30, 60, 
90 and 120 min. One aliquot of blood was separated 
immediately and plasm~ stored for potassium, glucose and 
insulin measurement. Another aliquot of the blood samples 
was kept at room temperature for three hours (22°C), then 
the plasma was separated for potassium measurement. 
A 75 g oral glucose tolerance test was also carried 
out on two TPP patients (after full · recovery of 
hypokalaemia and paralysis), four thyrotoxic male patients 
and four healthy male subjects. Venous blood was taken at 
0, 60 and 12.0 min. Duplicate aliquots of blood taken at 
these times were incubated at 37°C for 0, 1, 2, 3, 4 and 
5 hours after which the plasma concentration of potassium 
and glucose were measured. 
Haematocrit was determined on the time 0 samples. 
Two 24 hours urine collections for catecholamines 
were obtained from the two TPP patients. 
Plasma potassium was determined by flame photometry 
with the IL-943 flame photometer (Instrumentation 
Laboratory ~nc., Lexington, MA, USA), which has a between-
batch CV of 1.5%. Plasma glucose concentration was 
determined by a glucose oxidase method using the 'Encore' 
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· centrifugal analyzer (Baker Instruments Co, Allentown, 
USA). Plasma insulin was measured using a radioimmunoassay 
kit (Pharmacia Diagnostics AB, Sweden). - Urine 
catecholamines were determined bya HPLC method. 
2.4 RESULTS 
After incubation at room temperature for three hours, 
there was a " mean decrease of 0 . 2 mmol/L in the plasma 
potassium concentration in the time 0 samples. Blood 
samples collected at other times demonstrated a similar 
degree of change despite an increase in endogenous insulin 
(Fig. 2.1 and 2.2). The peak plasma insulin concentration 
was 75 mIU/L. Insulin, at physiological concentration, did 
not have a demonstrable effect on the in vitro decrease in 
plasma potassium concentration. 
Differences between the two groups of thyrotoxic 
patients and healthy control are summarized in Table 2.1. 
and 2. 2 . Only the changes after five hours are shown. 
Haematocrit results were similar between the three groups 
of subjects. 
There was much overlap in the 
results between the three groups of 
definite pattern could be detected in 
post-glucose load samples. 
plasma potassium 
subjects and no 
the basal or the 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































glucose load were higher in the thyrotoxic groups and more 
so among the TPP patients. This is suggestive of impaired 
glucose tolerance. 
The decrease in plasma glucose was dramatic. This is 
expected since samples were not preserved by anti-
glycolytics. 
Insulin'" resul ts are summarized in Table 2. 3. There is 
overlap between the three groups of subjects. It may have 
been possible to demonstrate a difference if sample 
numbers had been larger. 
The 24 hours urine adrenaline and noradrenaline 
results were well within the reference ranges for the two 
TPP patients (~able 2.4). 
2.5 DISCUSSION 
Results of the first part of the experiment confirm 
the reported phenomenon of in vitro decrease in plasma 
potassium concentration. However the decrease was small, 
0.2 mmol/L in three ' hours. The expected exaggerated 
decrease in the presence of insulin was not seen. 
However, others were able to demonstrate an increase 
in RBCs sodium pump activity in the presence -of insulin 
using other more demanding methodology (Davis et al., 
1985; Baldini et al., 1986). 
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Table 2.4. 24h urine catecholamines excretion in two 
TPP patients (nmoll day) 



















Perhaps there may have been a demonstrable effect if 
a pharmacological dose of insulin has been used in this 
study. Nevertheless, such a procedure should not be used 
in thyrotoxic patients because of the danger of 
precipitating hypokalaemic paraly~is. 
The changes in the plasma potassium concentration in 
the basal (ie time 0 samples) and the post-dose samples do 
not allow diff,erentiation between thyrotoxic subjects with 
or without TPP. The simple procedure described in this 
study is not sensitive enough to distinguish one group 
from the other. 
The glucose results demonstrate the importance of 
sample handling. Unless adequate anti-glycolytic measures 
are ensured, misleading results can occur. 
There was no increase in catecholamine production in 
the two TPP patients. However, this does not exclude the 
possibility that they may be more sensitive to the effect 
of catecholamines. 
2.6 CONCLUSION 
Results show that this simple indirect measurement of 
sodium pump activity cannot be used for further study. The 
change in plasma potassium concentration was small. It was 
not possible to differentiate the two sub-groups of 
thyrotoxic patients. 




. PLATELET NA-K ATPASE AS A 
TISSUE MARKER OF HYPERTHYROIDISM 
- 59 -
3.1 AIM 
Aims No. 2-6 of section 1.8:-
2. To establish an enzymatic assay for platelet Na-K 
ATPase activity. 
3. To study its correlation with thyroid hormones in 
healthy controls as well as in thyrotoxic patients. 
4. To study its performance as a tissue marker of 
hyperthyroidism. i.e. its ability to' differentiate between 
euthyroidism "and hyperthyroidism. To study the difference 
between healthy controls and treated thyrotoxic patients. 
5. To study its relationship. with age and sex, since 
both factors have aetiological significance~ 
6 . To examine the difference between the sexes in 
terms of thyroid hormones results and platelet Na-K ATPase 
activity in control subjects and thyrotoxic patients 
before and after treatment. 
3.2 BACKGROUND 
3.2.1. Thyroid function tests (TFTs). 
Disorders of the thyroid gland are the most common 
endocrine diseases in clinical practice. While thyroid 
diseases have been clearly ' described since ancient times 
(Lee, 1941; Major 1945) laboratory investigations did not 
appear until late in the last century (Liewendahl 1990; 
Medvei 1993a). Biological assays were used in the early 
years. with the introduction of modern technology these 
were largely replaced by better tests such as total and 
free T4 assay, total and free T3 assay and the sensitive 
TSH assay (Van Herle, 1990; Sherman & Ladenson, 1994) . . 
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Measurement of protein bound iodine was introduced in the 
1930s and remained popular until the era of immunoassay 
(Liewendahl 1990). The technique of radioimmunoassay (RIA) 
was first described in 1959 (Berson & Yalow, 1959). RIAs 
for T4 andT3 were not available until . the beginning of 
the 70s because of the problems involved in raising 
polyclonal antibodies to small haptens (Liewendahl, 1990). 
However, a radioimmunological technique was actually 
described in" 1960 for measurement of T4 using a labour 
intensive competitive saturation analysis method (Ekins, 
1960), which therefore never was introduced for routine 
use. 
Over the years, better an~ more sensitive tests have 
been introduced. Modern tests are characterized by more 
specific antibodies, shorter incubation times, simple 
separation steps, nonradioactive labels and improved 
analytical performance. They can also be automated (White, 
1987; Kricka, 1993). It is now within the reach of ' most 
laboratories to provide services for a large battery of 
TFTs such as sTSH, total and free T4 and T3. 
However, it is well documented that each TFT has its 
own limitations (Liewendahi, 1992; Mak et al., 1992). In 
particular they do not provide a reliable index of tissue 
hyperthyroidism (Trzepacz et al.~ 1989). 
3.2.2 TFTs vs tissue markers as an index of 
hyperthyroidism. 
Theoretically hyperthyroidism should be assessed by 
measurement of tissue responses ' rather than by serum 
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thyroid hormones concentrations, which are several steps 
removed from the site of thyroid hormone action (Refetoff, 
1989). Therefore it is not surprising that there is poor 
correlation between clinical assessment of disease 
activity and serum levels of thyroid hormones (Braverman 
& Utiger, 1991). 
Manifestations of hyperthyroidism are characterized 
by a wide range of symptoms and signs which cover every 
system of the body, many of these features being quite 
typical (Orgiazzi & Mornex, 1990; McDougall, 1991). It was 
a common practice in the diagnosis of thyrotoxicosis to 
use a diagnostic index based on a scoring system for the 
common symptoms and signs (Crooks et al., 1959; Crooks et 
al., 1960). 
However it is well documented that the presentation 
of individual patients can be very heterogeneous. Atypical 
presentation is not uncommon. TFTs results may be markedly 
abnormal when the patient is only marginally symptomatic. 
Also TFTs results can be only modestly elevated when the 
patient exhibits typical symptoms (Vagenakis & Braverman, 
1976; Larsen, 1982; Bors-t et al., 1983). Differences in 
tissue sensitivity to thyroid hormones are considered an 
important contributing factor (Spaulding & Lippes, 1985). 
Most of the tissue markers previously described are 
not suitable for routine clinical practice. Most of them 
are non-specific and demonstrate much overlap between 
diseased and control subjects and. they require labour-
intensive methodology (Kaplan, 1985; Ladenson, 1985). 
Recently described markers like Red Cell Zinc (Swaminathan 
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et al., 1976; Chan et al.-, 1991) and Neutrophil Alkaline 
Phosphatase (Barsono et al., 1989; Cheung, 1995) represent 
considerable improvement in these respects. Therefore 
while conventional TFTs have played a dominant role in 
routine clinical practice, selective tissue markers of 
thyroid status could be of value in selected cases 
(Refetoff, 1989; Sherman & Ladenson, 1994). 
3.2.3 Sodium'--pump activity as a tissue marker and TPP. 
Sodium pump activity in human subjects is known to be 
affected in hyperthyroidism. Activity is increased in 
muscle (Kjeldsen et al., 1984) and leucocytes (Arnott et 
al., 1982; Khan & Baron, 1987) but decreased in 
erythrocytes (Khan & Baron, 1987; Arumanayagam et al., 
1990). However, the number of subjects studied was small 
and there was also considerable overlap between patients 
and controls. Therefore, based on existing data, there is 
little value in using sodium pump activity as a tissue 
marker of hyperthyroidism in routine clinical practice. 
However , it remains a distinct possibility that a 
better tissue marker may be able to distinguish control 
and thyrotoxic subjects. Likewise such an effective tissue 
marker may be able to distinguish thyrotoxic subjects with 
and without TPP, an area in which conventional TFTs have 
not been able to provide an answer (McFadzean & Young, 
1967; Yeo & O'Neill, 1984). 
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3.2.4 Choice of tissue for sodium pump study. 
The ideal tissue in which to study TPP is skeletal 
muscle. However, muscle biopsy is invasive and platelets 
provide a . readily accessible alternative. Furthermore, 
there are striking similarities between the energy 
metabolism of the platelet and skeletal muscle (Karpatkin 
& Langer, 1968; Karpatkin et al., 1970). In addition, more 
recently the'!' platelet was proven to possess the sodium 
pump and to behave .like nuclear cells. (Turaihi et al., 
1989). Therefore platelets could be an attractive model 
for the study of the sodium pump because collection and 
preparation of platelets can be accomplished easily 
(Turaihi et al., 1989). 
In contrast, the use of RBCs and lymphocytes are not 
satisfactory. As indicated in the section immediately 
above, the sodium pump activity is affected in 
hyperthyroidism and RBCs behave differentlY r Instead of an 
increase, the sodium pump activity in RBCs decreases. 
Therefore it is uncertain to what extent RBC-based results 
could be extrapolated to other body tissues like skeletal 
muscle. The use of lymphocytes requires difficult sample 
separation steps which may lead to serious errors (section 
2.2). There is also evidence to suggest that lymphocyte 
may behave very differently from skeletal muscle (section 
1.5.4). 
64 
3.2.5 Rationale behind the aim of study 
The enzymatic expression of the sodium pump is the 
membrane bound Na-K ATPase (EC 3.6.1.3). The aim of this 
project is to establish a method for the measurement of 
platelet Na-K ATPase and to validate its effectiveness as 
a tissue marker of hyperthyroidism. i.e. its ability to 
discriminate thyrotoxic patients from healthy controls. If 
it has poor discriminating power, it is doubtful that it 
will be able' to discriminate TPP patients from other 
thyrotoxic patients. 
In particular, its correlation with thyroid hormones, 
sex and age are important because these parameters may 
have significance in the pathogenesis of TPP. 
a. Sex:-
It is not known why TPP occurs predominantly in male 
thyrotoxic subjects (Engel, 1961; McFadzean & Young, 1967; 
Yeo et al., 1988). One study had reported that it did not 
occur in females. Ip a 12 year survey of more than 20000 
female thyrotoxic patients, not a single case of TPP was 
diagnosed (~amada et al., 1982). 
Based largely on animal- studies, it has been reported 
that sodium pump activity is greater in the male (Fraser 
& Arieff, 1989; Papadakis et al., 1990) and that female 
sex hormones appear to inhibit the pump while male sex 
hormones stimulate it (del Castillo et al., 1987; Guerra, 
1987). Results from human studies, using erythrocytes as 
the model, did not produce conclusive results (Woods et 
al • , 1981; Laska et al ., 1985 ; Smith et al ., 1986 ) . 
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Apparently, there has not been a similar study using other 
hum~n tissue. 
Therefore it is important to examine, using .the 
platelet as a model, whether the sodium pump activity is 
greater in male than female sUbjects with and without 
thy~otoxicosis. If the sodium pump is more active in male 
subjects, this may contribute to the development of TPP. 
b. Age:-
The role of age in the pathogenesis of TPP is not 
clearly defined. In a 12 year survey involving 25262 
thyrotoxic patients (male = 4961), Hamadaet al. (1982) 
identified 503 TPP patients (no female subjects) and 
reported that their age distribution showed a shift to 
younger ages when' compared with that of uncomplicated 
thyrotoxic patients. In a smaller series involving 25 TPP 
and 1341 uncomplicated thyrotoxic patients, there was a 
slight but non-significant shift in . the same direction 
(McFadzean & Young, 1967). 
The relationship between sodium pump activity and age 
is not clear. Na-K ATPase activity in renal tissue (rat) 
was reported to decrease with increasing age (Beauchene et 
al., 1965; Gambert et al., 1981). Furthermore the 
magnitude of the increase in the enzyme activity resulting 
from thyrotoxicosis, was significantly less with each 
increase in the age of the experimental animals (Gambert 
et al., 1981). 
Human erythrocytes were studied and Gambert & Duthie 
(1983) demonstrated a significant decrease in Na-K ATPase 
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activity with age. However Simat et al. (1984) reported 
there was a weak correlation in females but no correlation 
in males. Recently Bozzo et al. (1990) studied human 
lymphocytes and found a decrease in Na-K ATPase activity 
among elderly subjects (age>60) with no significant 
difference between young (age<40) and middle-aged subjects 
(age 41-60). Furthermore, significant changes with age 
were not seen in a small study when biopsies of human 
vastus lateralis muscle from 20 subjects, age 25-80, were 
studied (Norgaard et al., 1984). Therefore the effect of 
age, if any, on human Na-K ATPase activity has not yet 
been defined. However similar changes among thyrotoxic 
subjects have not been studied. 
It is therefore important to examine such 
relationship between platelet Na-K ATPase activity and age 
in subjects with and without thyrotoxicosis. If an age-
related change can be- demonstrated, it might explain why 
TPP tends to develop in the younger age group. 
c. Thyroid hormones:-
Although the association between thyroid hormone 
concentrations and the severity of 
shown to be weak ( section 3 . 2 . 2 ) , 
thyrotoxicosis was 
this has not been 
examined again in recent years. It is important to study ' 
the relationship between an improved tissue marker (ie 
platelet Na-K ATPase) and thyroid hormone concentrations 
determined by modern methodologies. It is meaningful to 
examine the distribution of enzyme activity at each level 
of thyroid hormones concentration. 
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3.3 SUBJECTS & METHODS. 
3.3.1 Chemicals 
All chemicals were of analytical grade and purchased 
from Sigma Chemical Co, ( St . L.ouis, Minnesota, USA), 
unless otherwise stated. 
3.3.2 Subjects 
3 groups' of subjects were studied. 
a. Control group: 34 healthy individuals, none of 
them having any known illness or were taking any 
medication. 
b. Euthyroid group: 34 treated thyrotoxic patients, 
attending the thyroid clinic, who had been treated for 
hyperthyroidism with antithyroid drugs and at the time of 
the study were clinically and biochemically euthyroid. 
c . Thyrotoxic group: 89 thyrotoxic patients, 
attending the thyroid clinic who had clinical and 
biochemical evidence of hyperthyroidism at the time of the 
study. 
Characteristics of the ' subjects are summarized in 
Table 3.1 
In all subjects venous blood samples were taken in 
the morning, at least 3-4 h after the last meal or after 
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an overnight fast, into trisodium ci trate (9mL of blood to 
ImL of citrate) and heparinised tubes. Citrated blood was 
used for l?latelet studies and plasma from heparinised 
blood was used for the measurement of thyroid hormones and 
TSH. 
3.3.3 Plasma thyroid hormones analysis 
Plasma TSH was measured by an immunochemiluminometric 
assay (Ciba Corning, USA) with a detection limit of 0.02 
mU/Le Plasma FT3 and FT4 were determined by commercial 
immunoassay kits ('Amerlex-M', Amersham Co, USA for FT3 
and 'Gammacoat' two-step assay, Baxter, MA,USA for FT4). 
The analytical CVs (%) of methods were 6.4, 4.8 and 7.5 
for TSH, FT3 " and FT4 respectively. 
69 
Table 3.1 Characteristics of subject groups 
Male Female Age (Range) 
Control 15 19 38 (21 - 89) 
Euthyroid 7 27 34 (18 - 66) 
Thyrotoxic 35 53 34 (15 - 69) 
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3.3.4 Determination of platelet Ra-K ATPase activity. 
· 3.3.4.1 Principle 
The sodium pump is an intrinsic component of the 
plasma membrane. In order to determine the Na-K ATPase 
activity of a body tissue, it is a common practice to 
treat the tissue sample with detergent to extract the 
sodium pump and prevent resealing of membrane with 
formation of -vesicles (Jorgensen & Skou 1971; Charalambous 
& Mir, 1982). Therefore platelets were lyzed in this case 
by saponin. Na-K ATPase activity was measured with a 
method based on the rate of release of · phosphate by 
hydrolysis of ATP in the presence and absence af ouabain 
as described by Baron and Khan (1985). The phosphate (Pi) 
released was determined by an automated method based on 
that described by Daly and Ertinghausen (1972). The 
protein content of the platelet sample was determined by 
Lowry's method (Lowry et al., 1951). Na-K ATPase activity 
was expressed in ~mol pi /hr /g protein. The procedures · 
are summarized in Fig 3.1. 
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Platelet Na-K ATPase Assay 
5 - 10 ml Blood in Citrate 
~ 
Centrifuge at 160 x g for 15 min 
~ 
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3.3.4.2 Preparation of platelets 
Platelet-rich plasma was prepared as described by 
Turaihi et al. (1989). The citrated blood was centrifuged 
at 160 x g for 15 min at room temperature. Contamination 
of the plasma with erythrocytes and leucocytes was 
minimal, accounting for <0.5% of the platelet count. The 
platelet-rich plasma was centrifuged and the platelet 
pellet washed twice with ice cold magnesium chloride to 
remove any trapped plasma. The platelet pellet was stored 
at -70°C and the Na-K ATPase activity measured within 24 
hours. 
3.3.4.3 Preparation of platelet lysate 
Lysing solution: 
Saponin 0.1% (w/v) 
EDTA 2 mmol/L 
Imidazole 50 mmoL/L PH 7.6 
The platelets were resuspended in a fixed volume of 
distilled water and lysed by freezing and thawing followed 
by the addition of an equal volume of saponin solution 
. . 
(final concentration 0.05% .w/v). 
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3.3.4.4 ~easurement of Na-K ATPase activity 
Buffer 1: 
NaCI 200 mmol/L 
KCI 30 mmol/L 
MgCl2 14 mmol/L 
EDTA 2 mmol/L 
Tris-HCI 100 mmol/L PH 7.2 
(stored at room temperature) 
Buffer 2: 
Same as buffer 1 but containing ouabain (2mmol/L). 
(stored at room temperature) 
• 
Trichloroacetic acid (10% w/v): 
10 g TCA in 100 mL distilled water. 
(stored at room temperature) 
Incubation medium A: ATP 10mmol/L 
This solution was freshly prepared by dissolving 
0.011 g of ATP in 2 mL of buffer 1 prior to use. 
Incubation medium B: ATP 10mmol/L 
This solution was freshly prepared by dissolving 
0.011 g of ATP in 2 mL of buffer 2 prior to use. 
Procedure: 
A set of four tubes was used for a platelet 
sample, one pair of A tubes containing 0.1 mL incubation 
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medium A in each tube and the other pair of B tubes 
containing incubation medium B in each tube. An aliquot of 
platelet lysate (0.1 mL) was then added to each tube. All 
tubes were incubated for 60 min at 37°C in a shaking water 
bath. Therefore the reaction mixture contained, in mmol/L, 
Na 100, K 15, ATP 5, Mg 7, EDTA 1 and Tris-HCI 50, with 
ouabain present at 1 mmol/L in B tubes, according to the 
protocol of Baron and Khan (1985). The reaction was 
stopped by the addition of 0.1 mL 10% TCA to each tube. 
The tubes were then centrifuged and the phosphate content 
of the supernatant measured. The Na-K ATPase activity was 
calculated from the difference in the pi content of tubes 
A and tubes B. 'In a separate step, protein content of the 
platelet lysate was determined. 
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3.3~4.5. Measurement of pi 
The measurement of pi is based on the reaction of 
. 
molybdate with phosphate to form a heteropolyacid complex 
which can be · read at 340 nm .(Daly & Ertingshausen, 
1972). 
Reagent 1: 1.1 mmol/L ammonium molybdate in sulphuric 
acid solution (450mmol/L) . 
. ;:' 
Reagent 2: Tween 80 in methanol, 1:1 by volume. 
Working reagent: 26 parts of reagent 1 and one part 
of reagent 2, prepared fresh before use. 
Phosphate standards: 646 J,lmol/L and 1292 J,lmol/L, 
purchased from New England Reagent Laboratory. 
The measurement was automated by using a centrifugal 
analyzer (Cobas Bio, Roche Company, Basle, Switzerland). 
10 J,lL of sample was mixed with 300 J,lL ,of working reagent 
and reacted for 6 minutes· at 30 0 C. The parameters for the 
pi measurement are shown in Fig 3.2. 
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(1 ) Units J-lmol/L 
(2 ) Calculation factor 0 
(3 ) Standard 1 cone 646 
(4 ) Standard 2 cone 1292 
(5 ) Standard 3 cone 0 
( 6 ) Limit 2000 
( 7 ) Temperature [deg.oC] 30 
(8 ) Type of analysis ' 5 
( 9 ) Wavelength [nm] 340 
(10) Sample ' volume [J-lL] 10 
(11) Diluent volume [J-lL] 24 
(12) Reagent volume [J-lL] 300 
(13) Incubation time [sec] 0 
(14) Start reagent volume [J-lL] 0 
(15) Time 'of first reading [sec] 0.5 
(16) Time interval [sec] 360 
(17) Number of readings 2 
(18) Blanking mode 1 
(19) Printout mode 1 
Fig. 3.2 Parameters for the measurement of pi in the 
Cobas sio centrifugal analyzer. 
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3.3.4.6 Measurement of protein 
Protein was measured by Lowry's method (1951). 
LOwry A reagent: 
1. 2% Na2C03 (anhydrous) in 0.1 N NaOH solution. 
2. 2% NaK tartrate solution. 
3. ",1% CuS04 solution . . 
Lowry A reagent was prepared fresh by mixing 96 
parts of solution 1 and two 'parts of solution 2, 
followed by two parts of solution 3. 
Lowry B reagent: 
Freshly prepared by diluting stock Folin and 
Ciocal teau 's phenol reagent with distilled water 
( 1 : 1 ) . 
Protein standards: 
Bovine serum albumin (BSA) standards were 
prepared by diluting a stock standard with 
saponin solution to give a set of BSA standards 
at 125, 250 and 500 mg/L. The final saponin 
concentration of these standards was 0.05%. i. e. 
the same as that of the platelet lysate. 
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Principle: 
Protein reacts with copper in alkaline solution. 
The copper-protein complex reduces phospho-
tungstic phosphomolybdic acid to a blue product 
which has a maximum absorbance at 750 nm. 
Interference by saponin in the protein 
measurement is corrected by having both the 
samples and standards contain an identical 
concentration of saponin (Wang & Smith, 1975; 
Cheung, 1995). 
Procedure: 
50 ~L of sample or standard ~as diluted with 50 
~L of 0.1 N NaOH, followed by 1 mL Lowry A 
solution and kept at room temperature for 10 
minutes. o. 1 mL of Lowry B solution was then 
added and kept at room temperature for another 
30 minutes. Sample and standards were then read 
at 750 nm against reagent blank using the 
"Response" Spectrophotometer (Gilford Instrument 
Lab Inc., Ohio, USA). 
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3.4 STATISTICS & DATA HARDLING 
Results of TFTs and Na-K ATPase activity (mean and 
SD) were compared by the Mann-Whitney U test and a p value 
<0.05 was considered significant. Correlation between 
variables were performed by using linear regression 
analysis. Performance of Na-K ATPase as a diagnostic test 
was calculated according to standard protocols (Galen & 
Gambino, 1975-; Knapp & Miller, 1992). 
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3.5 RESULTS 
3.5.1 Development of the Platelet Ha-K ATPase assay. 
3.5.1.1 Introduction 
As outlined in section 3 . 3 . 4. 1, the Na-K ATPase 
activity was determined according to Baron & Khan IS 
protocol (1985), in which the conditions for measuring 
Na-K ATPase have been optimized. Therefore emphasis has 
been placed on the use of saponin. 
3.5.1.2 Effect of saponin concentration on the Ha-K ATPase 
activity. 
Identical platelet aliquots were treated with 
increasing concentrations of saponin solution from 0 to 
0.1% to study the optimal concentration required for the 
activation of the sodium pump. The effect of saponin 
concentration on the enzyme activity is shown in Fig. 3.3. 
It was demonstrated 
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Fig 3.3 Effect of saponin concentration on 
platelet Na-K ATPase activity 
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3.5.1.3 Linearity of the Na-K ATPase assay • . 
To demonstrate that · there is a linear relationship 
between the amount of enzyme (protein) and the production 
of phosphate, the protein content ~'n the incubation medium 
was varied by serial dilutions of a platelet sample. It 
was linear up to a level of 1400 mg/L (Fig 3.4). 
Therefore the protein concentration in all platelet 
lysate samples studied was determined and diluted by 
lysing solution if the protein concentration exceed 1400 
mg/L. 
3.5.1.4 Imprecision of the Na-K ATPase assay. 
This was determined by duplicate analysis of 20 
platelet samples according to the protocol described by 
White & Fraser (1984). The analytical CV for phosphate 
generation was 4.8% (Table '3: 2). The analytical CV for 
protein determination was 4.3%, resul ting in a total 
































Protein concentration (mull) 
Fig 3.4 Effect of varying protein concentration on 
production of Pi 
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Table 3.2 Analytical CV of pi generation 
Reading 1 Reading 2 d (difference) 
34.8 35.4 0.6 
56.7 62.3 5.5 
21.0 17.6 3.4 
26.2 24.7 1.5 
55.6 55.0 0.6 
79.7 80.8 1.1 
64.5 · 60.3 4.2 
83.0 77.5 5.5 
60.1 53 '.2 6.9 
66.0 71l.6 8.6 
35.5 34.2 0.7 
23.9 24.1 0.2 
59.8 51.6 8.2 
25.1 28.1 3.0 
56.2 55.7 0.5 
88.7 94.2 5.5 
145.4 138.5 6.9 
155.5 144.9 10.6 
163.7 167.0 4.3 
199.0 185.6 4.4 
Mean = 75.0 , 
so x SO = [sum of dxd] /2n = 13.02 
SO = 3".61 
























3.5.1.5 Linearity of the pi assay 
The measurement of phosphate was linear up to a 
concentration of 1300 ~mol/L as shown in Fig. 3.5. 
Therefore all samples with phosphate concentration 
exceeding the linearity range were diluted and the 
measurement repeated. 
3.5.1.6 Linearity of the protein assay 
The measurement of protein was linear up to a 
concentration of 500 mg/L as shown in Fig. 3.6. Therefore 
all samples with protein concentration exceeding the 
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Fig 3.6 Linearity of the protein assay 
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3.5.2 Thyroid function tests. 
Results of the thyroid hormone assays of all three 
patient groups are summarized in Table 3.3 and Fig. 3.7. • 
All thyrotoxic subjects had typical thyroid hormone 
profiles. They had increased FT4 and FT3, whereas the TSH 
levels, determined by ' a sensitive TSH assay, were 
suppressed. Results were significantly different from the 
corresponding results of the other two groups (P<O.OOl). 
Profiles of the control g~oup confirmed that all 
control subjects were biochemically euthyroid. 
Although thyroid hormones of the "Euthyroid" group 
were within reference ranges and their TSH levels were not 
suppressed, their FT4 and FT3 were higher than that of the 
control group and the TSH resul ts were slightly lower. 
These patients were previously thyrotoxic. 
There . was no significant difference between sexes 


























































































































































































































































































































































































































































































































































































3.5.3 Platelet Ha-K ATPase activity. 
Results of the platelet Na-K ATPase activity for all 
patient groups are summarized in Table 3.4 and Fig. 3.7 
and 3.8. 
The enzyme activity of the thyrotoxic group was 
almost twice that of the euthyroid and control groups. The 
euthyroid group had a slightly higher enzyme activity in 
relation to the control group. Fig. 3.8 shows that there 
was good separation between control and thyrotoxic groups. 
The overlap was minimal. 
There is no significant difference between the sexes 















































































































































































































































































































































































































E 500 -~ 
2, . .. 
400 -~ . ~ · ... ~ · 
· 
. 
. > 300 --
.. .. 
. - .... .' ...... ..., 
.... 
u ., ...... 
c 200 -- . .. . 




Q) . . \ ... . .. . , . 
en . . . ' . , .. . ". ... , . 
c 100 -- . . e ••• I • . . '. :.-a.. ' ... .. 
~ 0 I I I I I I 
CONTROL EUTHYROID THYROTOXIC 
Fig 3.8 Platelet Na-K ATPase activity in subjects 
with different thyroid status. 
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3.5.4 Correlation between thyroid hormones concentrations 
and platelet Ra-K ATPase activity. 
There was a good correlation between platelet ATPase 
activity, FT3 (Fig 3.9; r=0.706 and p<O.OOl) and FT4 (Fig. 
3.10; r=0.696 and p<O.OOl). At any level of FT4 or FT3, 
ATPase activity could be quite variable reflecting 
variable tissue response to the same level of thyroid 
hormones. Moreover, there tended to be a greater spread of 
results at higher FT4/FT3 concentrations. 
There were five thyrotoxic patients (3 males and 2 
females) who had distinctly high platelet Na-K ATPase 
activity. As a group, their FT3 and FT4 were on the high 
side. They did not have TPP. Whether they represent a 
different sub-group iS ' not certain. 
3 • 5 • 5 ' Correlation between age and platelet Ha-K ATPase 
activity. 
There was a poor correlation between these two 
parameters (Fig 3.11; r=0.080 and p=0.32). ATPase activity 
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Figure 3.11 Correlation between platelet NaK ATPase activity & age. 
A: Control & Euthyroid B: Thyrotoxic 
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3.5.6 Performance of platelet ATPase as an indicator of 
hyperthyroidism. 
The performance of this test, was evaluated by the 
plotting of a Receiver Operator Characteristic (ROC) Curve 
(Fig 3.12). The point nearest to the left "apex" 
represents the highest sum of sensitivity and specificity 
(in %) of the 'test and should be chosen as the cut-off of 
a diagnostic test. For platelet Na-K ATPase, the 
sensitivity is 93% and the specificityis 90% at a cut-off 
of 190 J..lmol Pi/h/g protein (Table 3.5). with a sum of 
183%, it is classified as a good test (Gambino, 1991). 
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Table 3.5 Sensitivity and Specificity of Platelet Na-K-ATPase 
for Hyperthyroidism 
ATPase Cutoff Value Sensitivity (0/0) Specificity (0/0) Sum 
400 10 100 110 
246 61 100 161 
220 77 97 174 
200 86 90 176 
190 93 90 183 
180 ~5 85 180 
168 100 72 172 
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Fig 3.12 Receiver operator characteristic curve of platelet 
Na-K-ATPase as a diagnostic test for hyperthyroidism 
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, 3. 6 DISCUSSION 
While thyrotoxicosis is known to affect the 
haemopoietic $ystem, clinically recognizable haematologic 
abnormalities are not a prominent feature (Ansell, 1991; 
Desforges, 1995). The focus has . been on the changes in 
erythropoiesis and disturbances in the platelet count 
(Panzer, 1990; Ansell, 1991)' with the clinical 
biochemistry of platelets not receiving as much attention. 
However recently platelets were proven to possess the 
sodium pump (Turaihi et al., 1989) and there has been 
attempt to use the platelet sodium pump as a model to 
study the pathogenesis of diabetes mellitus (Bergstrom et 
al., 1989). 
This project represents the first study of platelet 
sodium pump in thyroid diseases. Healthy volunteers, 
euthyroid subjects and thyrotoxic patients were found to 
have platelet Na-K ATPase activities (median) of 125, 147 
an~ 271 umol Pi/h/g protein respectively (Table 3.4). 
While there is a lack of published dat~ for comparison, 
our results were comparable to leucocyte Na-K ATPase 
a ,ctivity published by Khan & Baron (1987) who used a 
similar technique and reported a result (median) of 179 
umol ~i/h/g protein for healthy controls (n=15) and' 218 
umol Pi/h/g protein for thyrotoxic subjects (n=ll). 
Thyrotoxicosis is characterized by changes in tissue 
sodium pump number and activity (Loeb, 1986; Gick et al., 
1988) although the responses are not uniform over 
different body tissues (Lin & Akera, 1978). It has been 
demonstrated in both animal and human experiments that the 
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sodium pump number and activity in most tissues increase 
in thyrotoxicosis (Arnott et al., 1982; Kjeldsen, 1984; 
Khan & Baron, 1987; Gick et al., 1988; Oh et al., 1990) . 
. However, there is no detectable change in brain tissue 
(Lin & Akera, 1978). As for erythrocytes, a decrease has 
been repeatedly documented (Cole & Waddell, 1976; Rubython 
et al., 1983; Dasmahapatra et al., 1985; Khan & Baron, 
1987; Arumanayagam et al., 1990). 
Theorebically it is possible to explore these 
differences because a significant difference has been 
demonstrated between the thyrotoxic and control groups in 
thes~ studies. However, without exception, there was a 
large overlap between the results of the two groups of 
subjects and the number of subjects studied was small. 
Therefore the potential value of such a tissue marker of 
hyperthyroidism in routine clinical practice is severely 
restricted. 
In contrast, the potential usefulness of platelet Na-
K ATPase as a tissue marker - of hyp-erthyroidism has been 
clearly demonstrated in this study. The result (median) 
for the thyrotoxic group was 2.2 times that of the control 
group (Fig 3.7 & Table 3.4). Such a large difference is 
not matched by any previous study utilizing erythrocytes, 
lymphocytes or mixed leucocytes for the determination of 
Na-K ATPase activity. The overlap . between the two groups 
was very small (Fig 3.8) and resulted in a respectable 
R.O.C. Curve (Fig 3.12). At a cut-off value of 190 umol 
Pi/h/g protein (Table 3.5), it gave a sensitivity of 93%, 
a specificity of 90% and a sum of 183% which fell into the 
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class of 'good' tests (Gambino, 1991). The number of 
subjects studied in this project (Table 3.1) was also 
larger than all the previous reports. 
The determination of platelet Na-K ATPase activity 
(Fig 3.1) required only a small . blood samp~e volume and 
the sample preparation was not demanding. Both the protein 
and phosphate measurements could be automated and it may 
be possible to simplify the procedure further by 
introducing ··coupled enzyme reaction (Li et al., 1994). The 
analytical imprecision was acceptable (Table 3.2) and the 
linearity range was adequate (Fig 3.4, Fig 3.5 & Fig 3.6). 
There was a good correlation between platelet Na-K 
ATPase activity and Free T3 (Fig 3.9) and Free T4 (Fig 
3.10). However, it is interesting to note that at anyone 
level of Free T3 or Free T4 the ATPase activity was not 
the same and the variation was greater at higher Free T4 
and Free T3 levels. Hence, whether the subjects were 
'control', 'euthyroid' or 'thyrotoxic', individuals could 
have different ATPase activities even though their TFTs 
were comparable. This possibly reflects different tissue 
sensitivities among individual subjects to the same levels 
of circulating thyroid hormones. Such individual variation 
might explain why the presenting symptoms and signs of 
thyrotoxicosis, as discussed in section 3.2.2., could be 
so variable. It is not certain whether the five thyrotoxic 
patients who have much higher platelet Na-K ATPase 
activities represent a different sub-group. 
Platelet Na-K ATPase activities and FT3 and FT4 
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concentrations in the euthyroid group (i.e. treated 
thyrotoxic patients without non-suppressible STSH results) 
_were slightly higher than those of healthy controls. The 
differ~nce was just statistically significant for platelet 
Na-K ATPase activity. 
The results also demonstrate that once euthyroidism 
is achieved after anti-thyroid therapy the platelet Na-K 
ATPase activity in thyrotoxic patients will fall to levels 
comparable _to those found in control subjects. 
As outlined in section 3.2.5a., it is meaningful to 
examine the effect of gender, if any, on the platelet Na-K 
ATPase · acti vi ty . However, no significa-nt difference 
between the two sexes could be demonstrated. P value was 
greater than 0.5 for ATPase, Free T4, Free T3 and STSH in 
all three groups of subjects. 
Likewise, no significant correlation between age and 
ATPase could be demonstrated in all three group of 
subjects (Fig 3. 11). In particular, in the thyrotoxic 
group, there is no evidence that the ATPase activity is 
significantly higher among younger subjects. 
On the other hand, the Na-K ATPase activity is 
determined genetically (Beautler et al., 1983; -DeLuise & 
Flier, 1985) and differences .between racial groups have 
been reported (Woods et al., 1981; Beautler et al., 1983; 
Lasker et al., 1985). It is not certain whether this 
genetic difference contributes to the pathogenesis of TPP 
which occurs almost exclusively in Asian subjects (Okinaka 
et al., 1957; Engel, 1972; Yeung & Lam, 1987). However, 
there is a paucity of data on Na-K ATPase activity among 
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Asian subjects. , Furthermore similar studies comparing 
thyrotoxic subjects of different racial groups have never 
been done. It is not known whether the Na-K ATPase 
activity of Asian thyrotoxic subjects is higher than that 
of other racial groups with comparable levels of 
circulating thyroid hormones. 
Recently, a local study demonstrated no difference in 
erythrocyte -Na-K ATPase activity between European males 
(n=10), non-Chinese Asian males (n=ll) and Chinese males 
(n=12) (Arumanayagam et al., 1987). Whether platelet 
ATPase activity, a better tissue marker, will be able to 
demonstrate a significant difference between different 
racial groups with and without ' hyperthyroidism requires 
further study. 
In summary, platelet Na-K ATPase was found to be a 
good tissue marker of hyperthyroidism. The overlap between 
control and thyrotoxic subjects was small. It could be a 
potential 'routine' thyroid function test. Furthermore it 
may be possible to explore its discriminating value to 
study the pathogenesis of TPP. 
106 
Chapter 4 
BASAL NA-K ATPASE ACTIVITY IN THYROTOXIC SUBJECTS 
WITH AND WITHOUT HYPOKALAEMIC PERIODIC PARALYSIS 
- 107 -
4.1 AIM 
Aims No. 7-9 of section 1.8:-
7. To study the thyroid hormone results between TPP 
patients and uncomplicated .thyrotoxic patients. To confirm 
that the TPP group is no more toxic than the other 
thyrotoxic group as far as plasma ·thyroid hormone 
concentrations are concerned. 
8. To study 
ATPase activity 
patients before 
and compare the basal platelet Na-K 
between the two groups of thyrotoxic 
and after anti-thyroid treatment. To 
compare the results in TPP patients before and after anti-
thyroid treatment. 
9. To correlate the platelet Na-K ATPase results (in 
vitro sodium pump activity) with that of the rubidium 
loading test (in vivo sodium pump activity). 
4.2 INTRODUCTION 
4.2.1 Background 
Much of our present understanding of the pathogenesis 
of TPP is based on studies conducted mainly in familial 
hypokalaemic periodic paralysis (FPP) patients. However, 
there is so much similarity in the clinical features, 
disturbances in potassium homeostasis, inciting factors 
responsible for the development of attacks of paralysis 
and changes in Em that experts in the field put them 
together in their discussion on the pathogenesis of 
hypokalaemic periodic paralysis syndromes. On the other 
hand, it is generally accepted that TPP and FPP, while 
similar, are two different diseases. One fundamental 
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difference between the two pp syndromes is the sodium pump 
'activity. Sodium pump activity in TPP is higher than in 
controls but a similar difference is not detectable in FPP 
(section 1.7.2). However; the significance of this 
important difference has not been discussed in the 
literature. 
Therefore it is not clear to what extent the two 
diseases are related (Ruff, 1989; Griggs, 1991; Kaminski 
& Ruff, 1994; Lehmann-Horn et al., 1994). How far data 
derived from the study of FPP could be projected to TPP is 
not yet defined. Furthermore , it has been suggested 
recently that the pathomechanism might be different in tne 
rare Caucasian cases and the rather more common oriental 
cases of TPP (Marx et al., 1989). The significance of this 
observation requires further study. 
4.2.2 Difficulties and limitations in TPP study. 
As outlined in section 1.2.4.2, TPP is not a very 
common disease even among Asian countries. It is 
exceedingly rare elsewhere. Therefore it is very difficult 
to identify a large number of patients. 
In addition, appropriate patient selection is 
important in any study on TPP. There could be a 
substantial difference even among populations of the same 
racial group. For instance, based on the analysis of the 
human leucocyte antigens, the Southern Chinese have a 
different genetic make-up compared to that o,f the Northern 
Chinese (Hawkins, 1987). This is reflected by the 
difference in the pattern of periodic paralysis syndromes 
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among different Chinese popuiations. 
Based on the admission records of the Prince of Wales 
Hospital for the last ten years, not a single case of FPP, 
hyperkalaemic periodic paralysis or female TPP has been 
admitted although sporadic .cases of idiopathic 
hypokalaemic periodic paralysis occur infrequently (One 
female thyrotoxic patient was seen as an outpatient in 
1988 and gave a typical history of paralytic attack but 
the diagno,sis' of TPP was never confirmed). · In Hong Kong, 
TPP accounts for the great majority of hypokalaemic 
periodic paralysis cases. In contrast, TPP is relatively 
rare compared to other periodic paralysis syndrome among 
Chinese in other parts of China; eg two out of a series of 
11 periodic paralysis patients reported from Peking (Su & 
Hsu, 1941), three out of 28 from Taiwan (Chen et al., 
1965) and three out of 64 from Wunan (central China) 
(Cheng, 1983). 
The timing of studies on TPP patients is important. 
There is a consensus that these patients have a latent 
defect which does not manifest itself until the 
development of thyrotoxicosis (Yeo & O'Neill, 1984; Yeung 
& Lam, 1987). It is not yet possible to distinguish 
euthyroid TPP subj ects from normal controls. However, 
there are exceptions. A number of TPP subjects could 
continue to develop periodic paralysis after ~estoration 
of euthyroidism (Satoyoshi et al., 1963b; Coates et al., 
1987; DeLong & Adams, 1991) although these could be 
examples of coexistence of two separate diseases (Kufs et 
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al., 1989; DeLong & Adams, · 1991). Furthermore it is 
possible to precipitate TPP if susceptible individuals 
were given oral thyroxine (Okihiro & Nordyke, 1966; Layzer 
& Goldfield, 1974; Ober & Hennessy, 1981). Apart from a 
single exception, pp is not . known to occur among 
hypothyroid subjects (Kinoshita et al., 1990). 
Therefore TPP patients should be studied before 
commencement of antithyroid drugs or beta-blockers which 
are known to ' limit the development of TPP attacks (Conway 
et al., 1974; Yeung & ~se, 
However, this will limit 
1974; Shayne & Hart, 1994). 
the choice of analytical 
techniques. As outlined in section 2. 2 . 1c i radioactive 
isotopes could be used to study the sodium pump activity 
but it normally takes one week, in Hong Kong, to secure a 
supply of radioactive labels from overseas. These labels 
have relatively short half-lives. Unless a constant supply 
of such labels could be ensured (i.e. with repeated orders 
at 3 weeks intervals), it would not be possible to s 'tudy 
TPP patients who present irregularly and infrequently. I 
attempted to do this initially but gave up later because 
of the cost. 
Previous studies on sodium pump activity in thyroid 
diseases invariably involved the · use of RBCs or white 
cells. These in vitro results 'should be interpreted with 
care (Kjeldsen, 1994) because blood cells may behave 
differently from skeletal muscle (section 3.2.4) . 
Against such a background of difficul ty and 
limitation, it is not surprising that there is a lack of 
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studies focusing on the pathogenesis of TPP. 
4.3 SUBJECTS AND METHODS 
4.3.1 Platelet Ha-K ATPase 
The platelet Na-K ATPase activity was studied in 12 
untreated patients with TPP ('TPP') and six treated TPP 
patients (' EuTPP' ). Male subjects of the three groups 
described in section 3.3.2 were included, i.e. 15 ~ealthy 
volunteers {'Control'), 35 untreated thyrotoxic patients 
('Thyrotoxic') and seven treated thyrotoxic ('Euthyroid') 
patients (Table 4.1). 
None of the TPP or EuTPP patients had a positive 
family history . . 
The TPP patients who were admitted to hospital with 
paralysis were studied within 48 hours of admission after 
correction of hypokalaemia and muscle weakness but before 
starting treatment with beta-blockers or antithyroid 
drugs. The EuTPP patients were clinically and 
biochemically euthyroid at the time of study. 
As outlined in section 3 . 3 .2, blood samples were 
collected in the morning, at least 3-4 hours after the 
last meal, or after an overnight fast. Measurement of TFTs 
and platelet Na-K ATPase activity were done as described 
in sections 3.3.3 and 3.3.4. 
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Table 4.1 Characteristics of subject groups (all male) 
Subject group Number Mean Age (Range) 
Control 15 35 (22 - 56) 
Euthyrd'id 7 41 (23 . - 66) 
Thyrotoxic 35 38 (17 - 65) 
TPP 12 33 (20 - 49) 
EuTPP 6 35 (23 - 43) 
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.4.3.2 Rubidium loading test 
In vivo sodium pump activity was measured in six 
healthy subjects (three men and three women aged 26-43 
years), eight untreated thyrotoxic subjects (two men and 
six women aged 17-51 years), and seven untreated TPP 
subjects (all men, aged 22-40). 
In vivo sodium pump activity was assessed by 
measuring tIle changes. in plasma rubidium concentration 
after an oral dose of rubidium chloride (8mg/kg body 
weight) (Boon et al. , 1984). Venous blood samples were 
taken before, and one and five hours after loading. The 
blood samples were centrifuged and the plasma was 
separated and stored at -20°C until analysis. 
The plasma rubidium concentration was measured in a 
graphite furnace atomic absorption spectrophotometer 
(model AA-1475, Varian Techtron, Mulgrave, Australia) by 
the standard addition method (Hallis et al., .1985). 
The setting of the atomic absorption spectro-
photometer (AAS) and the programme for the graphite tube 
atomizer (GTA) are shown in Table 4.2. 
The plasma sample was diluted with distilled water 
(one in 20), and the peak absorbance measured. In 
identical samples different amounts of aqueous standards 
of rubidium chloride were added and peak absorption 
measured again. The peak absorption was plotted against 
the concentration of the added standard and the 
concentration of the rubidium in the plasma determined 
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from the intercept on the x-axis. The imprecision 
(coefficient of variation) of the method at a mean plasma 
rubidium concentration of 5.5 ~mol/L was 5.3%. All samples 
in the study were analyzed in one batch. 
4.4 STATISTICS & DATA HANDLING 
Results (mean and 95% confidence interval) were 
compared by the Mann-Whitney U test and a p value <0.05 
was considered significant. 
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AAS 
Table 4.2 Setting and program oC AAS and GTA 
Cor detennination oC Rubidium 
Wavelength 




Background correction lamp On 
Reading absorbance, peak height mode 
GT A Furnace operating parameters 
Step Temperature Time Gas Gas Read 
No. DegreeOC Sec. Flow Type Command 
1 150 10 3.0 Normal 
2 150 50 3.0 Normal 
3 700 25 3.0 Normal 
4 700 15 3.0 Normal 
5 700 1.0 0.0 Normal 
6 1800 0.6 0.0 Normal * 
7 1800 1.0 0.0 Normal * 
8 1800 1.0 3.0 Normal 
9 2700 1.0 3.0 Normal 
10 2700 3.0 3.0 Normal 
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4.5 RESULTS 
4.5.1 Platelet Na-K ATPase activity 
Details of the 12 TPP patients are shown in Table 
4.3. Hypokalaemia was documented in most patients. Patient 
9 was admitted nine hours after the onset of paralysis and 
muscle power had improved by 30-40%. Patient 11 was 
admitted three hours after onset of paralysis and muscle 
power had improved by 40%. Patient 12 was admitted with 
TPP before ~nd developed a relapse of thyrotoxicosis but 
without paralysis at the time of study. 
There was no correlation between platelet Na-K ATPase 
activity and plasma potassium concentration on admission 
(Fig 4.1). 
The overall picture of platelet Na-K ATPase activity 
in all groups is displayed in Fig 4.2. Results of 
corresponding female groups are included in the display to 
facilitate ~omparison and discussion. As recorded in 
Chapter 3, there is no significant difference between the 
sexes in each of the Control, Euthyroid and Thyrotoxic 
groups. 
However there is overlap between the Thyrotoxic and 
the TPP groups. Some of the female Thyrotoxic subjects had 
elevated platelet Na-K ATPase activity comparable to that 
of the TPP subjects although not a single case of female 
TPP was documented in this study or in the past 10 years 
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Fig 4.1 Correlation between Platelet Na-K ATPase activity 
and plasma potassium concentration on admission 
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Fig 4.2 Platelet Na-K ATPase activity in subjects 
with different thyroid status. 
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All numerical results are summarized in Table 4.'4 and 
expressed in mean and 95% confidence levels. The mean and 
the median are similar for TFTs results (details not 
shown). However, for the platelet Na-K ATPase activities, 
both the mean and the median are shown since the median 
may be a better measure of 'average' for a skewed sample 
(Campbell & Gardner, 1989; Campbell 1989). 
Results of statistical analyses are summarized in 
Table 4.5. 
4.5.1a. Thyrotoxic vs TPP 
Plasma concentrations of FT3 and FT4 were raised and 
STSH concentrations were suppressed in all untreated 
thyrotoxic subjects with and without paralysis. 
TPP patients, as a group, were younger than 
Thyrotoxic patients as a whole although the difference was 
not significant. There was no significant difference in 
thyroid hormones concentrations between the two groups. 
However, the TPP group had a significantly higher platelet 
Na-K ATPa~e activity (~mol Pi/h/g protein) (mean: 522 vs 
299; median: 374 vs 253; p=O.0024). 
FT3 was only mildly increased in a few TPP subjects. 
Therefore the tissue response to excessive thyroid 
hormones was greater in the TPP group. However, there was 












































































































































































































































































































































































































































































































































































































































Correlations between platelet Na-K ATPase activity 
and FT3 are shown in Fig 4.3 (A and B). There was a good 
correlation in the Thyrotoxic group (R = 0.580, p<O.OOl) 
and, as indicated in section 3.5.4, there was a greater 
spread of results towards higher FT3 levels, reflecting 
greater variability . in individual tissue sensitivities 
towards comparable circulating thyroid hormone 
concentrations. 
There was no correlation, however, between platelet 
Na-K ATPase activity and FT3 in the TPP group although, as 
a group, the mean (and median) platelet Na-K ATPase 
activity was 75% higher than the Thyrotoxic group. The 
enzyme activity could be relatively ·very high while the 
FT3 level was moderately elevated. TPP occurred in patient 
. 
10 who had the lowest enzYme activity at 195 ~mol Pi/h/g 
protein, moderately above the upper limit of the control 
groups. He worked as a taxi driver (12 hours shift) and 
took a lot of soft drinks and a carbohydrate meal. He also 
had exercise a few hours before the onset of paralysis. 
Patient 11 had the next lowest enzyme activity at 256 ~mol 
Pi/hi g protein. He worked in a candy factory and took a 
carbohydrate meal before bed-time and woke up with 
paralysis. 
4.S.1b. ~hyrotoxic vs Euthyroid and TPP vs EuTPP 
The platelet Na-K ATPase activity (~mol Pi/h/g 
protein) of the Thyrotoxic group was markedly higher than 
that in the Euthyroid group (mean: 299 vs 132; median: 253 
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Fig 4.3 Correlation between platelet Na-K ATPase activity and FT3 
A: Thyrotoxic; B: TPP 
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elevated in the TPP group (mean: 522 vs 132; median 374 vs 
131; p<O.OOOl). The increases reflect tissue 
hyperthyroidism as discussed in section 3.6. 
4.S.1c. Control vs Euthyroid and ,EuTPP 
There was little or no difference in platelet Na-K 
ATPase activity between the groups. The increases in 
activity in the Thyrotoxic group and the TPP group 
described in' section 4.5.1b resolved after treatment. 
There was no difference in FT4 although FT3 was lower 
in the control group. 
Alth'ough the platelet Na-K ATPase activity (J..Lmol 
Pi/h/g protein) of the TPP group was higher than that of 
the Thyrotoxic group before treatment, there was no 
significant difference after treatment (mean: 132 vs 163; 
median: 131 vs 148; p>O.05). 
It was not possible to distinguish Euthyroid and 
EuTPP groups by means of , circulating thyroid hormone 
concentrations or platelet Na-K ATPase activity which has 
been shown to be a good tissue marker of hyperthyr9idism. 
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4.5.2 Rubidium loading test 
Results for the three groups of patients are 
summarized in Fig 4.4. The mean (95% confidence interval) 
plasma rubidium concentration at five hours in thyrotoxic 
subjects (7.0 (6.6-7.5) ~mol/l) was significantl~ low~r 
than that in healthy subjects (10.2 (9.5-10.9) ~mol/l, 
p<O.OOl). In TPP subjects the five-hour concentration (6.0 
(5.7-6.3) ~mol/l) was significantly lower than that in the 
thyrotoxic group (p<O.Ol). The plasma rubidium 
concentration at one hour also showed a similar picture 
(17.0 (14.9-19.2), 11.4 (10.9-11.9), 10.4 (9.7-11.2) 
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4.6 DISCUSSION 
4.6.1 Clinical marker of TPP 
As outlined in Chapter 1 the mechanism of weakness 
and the pathogenesis of TPP remain undefined (Yeung & Lam, 
1987; Riggs, 1989; Layzer, 1990) . . In particular, it is not 
known why TPP should occur in certain thyrotoxic subjects. 
Detailed analyses of clinical features and conventional 
TFT results have not been able to distinguish one group 
from the other (McFadzean & Yeung, 1967; Hamada et al., 
1982; Yeo & O'Neill, 1984). 
In the largest series of thyrotoxic patients 
reported, Hamada et al. (1982) identified 503 male TPP 
patients among 25262 thyrotoxic patients (including 4961 
male patients) over a period of 12 years. There was no 
female TPP patient. None of the variables examined was 
able to distinguish the two groups of thyrotoxic patients 
al though there was a shift to younger ages among TPP 
patients. These variables included thyroid hormone 
concentrations, age of onset, duration and severity of 
other thyrotoxic symptoms, size 
exophthalmos and anti-t.hYroid 
of goitre, degree of 
autoantibodies. Other 
smaller studies and reviews confirmed that neither 
clinical features nor TFT results could distinguish the 
two groups of patients (Engel, 1961; MCF~dzean & Yeung, 
1967; Yeo & O'Neill, 1984). In this study TPP subjects as 
a group were younger than Thyrotoxic subjects although the 
difference was not significant (mean : 33 vs 38 years, 
p>0.05). Apart from the episodes of paralysis, it was not 
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possible to differentiate these two groups of patients in 
this project,. Furthermore, some of the TPP patients had 
I silent I thyrotoxicosis. Apart from the paralysis they 
exhibited minimal or a total absence of symptoms · 
suggestive of hyperthyroidism. The episode of paralysis 
was the presenting symptom of their underlying 
thyrotoxicosis. This interesting characteristic is a 
recognized feature of the TPP syndrome (Engel, 1961; 
Bienert & We~Ver, 1963; ' Ramsay, 1974; Yeo' & OlNeill, 1984; 
Tinka & Vanatta, 1987b). 
4.6.2 RBC /lymphocyte sodium pump activity. 
In view of the fact that the sodium pump is known to 
play a central role in the transcellular shift of 
potassium and that thyrotoxicosis is known to affect its 
activity (section 3.2.3; decreasing it in RBCs but 
increasing in most tissues), there have been attempts to 
compare the sodium pump activity between different groups 
of patients and to study whether it can be used as a 
marker of TPP. The first study was carried out by 
Yeung & Au (1978), using RBC as a model, and their results 
are summarized in Table 4.6A. They demonstrated a decrease 
in RBC ouabain-sensitive ATPase activity (~mol Pi/h/g Hb) 
among thyrotoxic subjects (8.9 vs 11.8). However, a 
similar decrease was not seen among TPP subjects. Instead, 
the enzyme activity in TPP subjects was higher than that 
of controls (17.2 vs 11.8) but the difference was not 
statistically significant. The difference between the TPP 
and thyrotoxic groups was significant (p<0.05). 
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A : Yeung & Au (1978) 
Mean fasting ouabain-sensitive ATPase activity 





. Thyrotoxic vs TPP 
B : Lam, Yeung, Benson & Wang (1989) 
Subjects 
Control (n = 69) 
Thyrotoxic (n = 30) 
TPP (n= 13) 





















Table 4.6 RBC sodium pump :summary of reported findines 
• 
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However, slightly different results were reported by 
the same group later using different laboratory techniques 
. (Lam, Yeung, Benson & Wang, 1989) and their results are 
summarized in Table 4. 6B. The TPP group demonstrated a 
decrease in ouabain binding sites ·(0.268 vs 0.333 pmol/109 
cells) and ouabain-sensitive sodium efflux rate constant 
(0.215 vs 0.254). A similar but larger decrease was seen 
among the thyrotoxic group with the changes in ouabain 
binding sites significantly different from the TPP group 
(0.234 vs 0.268 pmol/109 cells, p<0.05). However, a 
significant difference in sodium efflux rate constant was 
not demonstrated (0.215 vs 0.195). 
A similar study was also carried out by Yeo & Q'Neill 
in 1984. They studied one TPP patient and demonstrated a 
decrease in ouabain binding sites (0.253 pmol/109 cells; 
ref range: 0.512 0.912). Sodium pump activity was 
measured by the radioactive rubidium uptake test. The TPP 
patient had a higher pump activity (nmol K uptake/h/109 
cells) (112; ref range: 53 - 94). In addition, seven 
.thyrotoxic subjects were studied. The ouabain binding 
sites were reduced (data not shown) but _sodium pump 
activity was normal. 
It is interesting to note . that Yeo & Q'Neill 
considered the RBC a -poor model for this kind of study and 
concluded that it is unlikely that RBCs act similarly to 
muscle cells. 
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Howe~er, one finding in ' common in all these studies 
on RBCs is that the sodium pump activity in TPP subjects 
is higher than that of thyrotoxic subjects. On the other 
hand, there is a lack of consistency in the other 
findings. Furthermore, differences. between the sexes were 
not studied and the numbers in the control and the 
thyrotoxic groups were small. 
There are only two reports, both from Singapore, 
which used the lymphocyte as the model to study the sodium 
pump in these groups of patients. The reported results are 
summarized in Table 4.7. Interpretation of the findings is 
difficult because the sodium pump activity was initially 
reported to be more active in TPP patients (Yeo et al., 
1988) but the difference was not confirmed in a later 
report (Oh et al., 1990). 
In recent years, in addition to the sodium pump, 
another membrane potassium transporter (Na-K-Cl 
transporter) has been identified. Its presence in RBC and 
lymphocyte has been confirmed (Chipperfield, 1986; 
Grinstein & Dixon, 1989; Haas, 1994). However, it was 
recently documented that the Na-K-Cl transporter in mature 
skeletal muscle cells does not possess the ability to 
transport potassium ions (Dorup & Clausen, 1994). It has 
been documented that irreversible reduction in potassium 
transport accompanies terminal differentiation of human 
myoblasts to myotubes (Panet et al., 1987). Perhaps the 
Na-K-CI transpor,t system is modified during . this 
maturation process (section 1.5.4). 
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A : Yeo, Lee & Cheah (1988) " 
Control (n=30) 
Thyrotoxic (n=9) 
TPP (n = 17) '.,. 
Thyrotoxic vs TPP 
Ouabain binding 





B : Oh, Taylor, Yeo & Lee (1990) 
Control (n = 26) 57.0 
Thyrotoxic (n = 11) 66.1 
TPP (n=18) 69.6 
Thyrotoxic vs TPP NS 
Rubidium-86 
. uptake 









Table 4.7 Lymphocyte sodium pump : summ'ary of reported findini!s 
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Therefore in summary, it is difficult to interpret 
results which are derived from studies on RBC and 
lymphocyte, and to relate the findings to what actually 
happens at the skeletal muscle in TPP subjects. 
Furthermore, none of these models h~s gone through the 
same degree of validation as described in the last 
chapter. The numbers of controls and thyrotoxic subjects 
studied were small and differences between the sexes ·were 
. not examined ·~' 
4.6.3 Platelet Na-K ATPase activity. 
The platelet was chosen for this study because, as 
outlined in section 3 . 2 . 4, it was recently proven to 
possess the sodium pump and to behave like nucleated 
cells. There are striking similarities between the energy 
metabolism of the platelet and skeletal muscle (reviewed 
by Bithell, 1993). The correlation between platelet Na-K 
ATPase activity. and thyroid hormone levels and the 
differentiation between the control and thyrotoxic groups 
are better than with other tissue markers that have been 
studied. The relationships with age and sex and the 
effects of anti-thyroid treatment have also been defined 
(Chapter 3)~ 
This is the first study of TPP using platelets as the 
model and the results have helped elucidate the 
pathogenesis of TPP. 
Results show that Na-K ATPase activity in platelets 
is increased in thyrotoxic subjects with and without 
periodic paralysis. The similarity between the changes in 
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platelets and nucleated cells such as leucocytes (Khan & 
Baron, 1987; Oh et al., 1990) and muscle cells (Kjeldsen 
et al., 1984) in hyperthyroidism suggests that platelet 
Na-K ATPase activity reflects that occurring in other 
tissues. 
The enzyme activity of the TPP group, despite 
overlapping, was significantly higher than that of the 
Thyrotoxic group (p= 0.0024) although there was no 
difference in the circulating thyroid hormone 
concentrations. 
To verify that platelet Na-K ATPase activity measured 
in vitro reflects the sodium pump activity in vivo, the in 
vivo sodium pump activity was measured. Rubidium is 
transported . into cells by the sodium pump and the 
transport characteristics of rubidium and potassium are 
similar (Bernstein & Israel, 1970). The disappearance of 
rubidium from extracellular fluid therefore depends 
largely on the sodium pump activity, and the plasma 
concentration of rubidium is inversely related to the 
sodium pump activity. Skeletal muscle is the largest 
single tissue in the body. Thus it is likely that the 
plasma rubidium concentration mirrors skeletal muscle 
sodium pump activity. The lower plasma concentration of 
rubidium at one and five hours after an oral load in 
untreated thyrotoxic subjects shows that the sodium pump 
activity is increased, and this confirms results from in 
vitro studies in mtlscle and leucocytes (Kjeldsen et al., 
1984; Khan & Baron, 1987). In untreated subjects with TPP, 
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the plasma rubidium concentration · was lower, thus the 
activity of the sodium pump is higher than that of 
thyrotoxic subjects without paralysis. This supports the 
data of platelets. 
The observed difference in plasma rubidium 
concentration between groups could also be due to reduced 
absorption of rubidium or enhanced clearance by the 
kidney. However, renal clearance of rubidium is slow and 
the half-life is between 20 and 50 days (Fieve et al., 
1971). Thus it is unlikely that the observed differences 
are due to renal clearance. Rubidium is handled like 
potassium and it is unlikely that reduced absorption would 
have contributed to the observed changes. These results 
therefore indicate that higher Na-K ATPase activity is a 
feature of TPP and that this enhanced acti vi ty may be 
responsible for the hypokalaemia observed in these 
patients. 
The correlation between platelet Na-K ATPase activity 
and plasma potassium concentration on admission was poor 
(Fig 4.3). This is not surprising because patients were 
admitted in different stages of recovery. eg Patients 9 
and 11 were admitted when muscle power was already 30 -
40% recovered. 
In EuTPP subjects, the platelet Na-K ATPase activity 
was similar to that found in the control and euthyroid 
groups, showing that the sodium pump activity returns to 
normal with treatment. Thus the higher platelet Na-K 
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ATPase activity in TPP patients is likely to be due to 
increased sensitivity to thyroid hormones and this is 
demonstrable only in the presence of hyperthyroidism. 
unlike . the thyrotoxic group, the correlation between 
the platelet Na-K ATPase activity and thyroid hormone 
concentrations in the TPP group was poor (Fig 4.3). Enzyme 
activity could be relatively high when TFT results were 
marginally elevated, suggesting that even among these TPP 
patients some are more sensitive to thyroid hormones than 
others. 
The sensitivity of TPP patients to the effects of 
circulating hormones also explains why attacks of 
paralysis occur in patients with moderately increased 
resul ts, eg patient 5 and 12 (Table 4.3). Perhaps the 
skeletal muscle in some of these patients was so sensitive 
to the effect of excess thyroid hormones that attacks of 
paralysis occurred with little or no other symptoms (i.e. 
'silent' thyrotoxicosi~). 
It is interesting to· note that patient 12, who was 
admitted with TPP in the past, did not develop paralysis 
at the time . of study, w~ereas patients 10 and 11 had 
paralytic attacks when their enzyme activities were not 
very high (lowest in the TPP group). Both patients 10 and 
11 had definite risk factors in their histories such as 
being a taxi driver, high carbohydrate intake, and heavy 
. exercise followed by · a period of rest /sleep (McFadzean & 
Yeung, 1967; Hamada et al., 1982; Yeo & Q'Neill 1984). 
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Perhaps even though the basal ' enzyme activity was not very . 
high in some of these patients the activity may increase 
on stimulation leading to the development of hypokalaemia 
and paralysis.. The presence of risk factors supports this 
possibility and this issue will . be examined again in 
Chapter 6. For patient 12, it seems that the threshold to 
develop TPP had changed. This could be due to 
environmental factors, and a c~ange in glucose tolerance 
(Chapter 6) . -,. 
Platelet Na-K ATPase activity could be quite high in 
some thyrotoxic subjects without the development of 
paralysis. Perhaps this small group of thyrotbxic subjects 
represents those who will develop paralysis if they are 
exposed to the same risk factors encountered by patients 
10 and 11. 
It has been reported that it is possible to induce 
attacks of paralysis in all untreated TPP subjects using 
a combination of a high carbohydrate intake and insulin 
injection (McFadzean & Yeung, 1967; Yeung & Tse, 1974) 
although some patients (perhaps those where the sodium 
pump activity is not very high) require additional 
stimulation in the form of taking flurohydrocortisone for 
several days (McFadzean & Yeung, 1967). This means that 
the sensitivity to induction among TPP subjects varies. 
However, once rendered euthyroid, it was not possible to 
induce paralysis. 
In contrast, it was not possible to induce paralysis 
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in uncomplicated thyrotoxic patients by us"ing a 
combination of a high carbohydrate intake and insulin 
infusion. However ( with the addition of fluro-
hydrocortisone, some thyrotoxic subjects would develop 
paralysis (McFadzean & Yeung, 1967"). 
Hence it is possible to induce paralysis in all TPP 
subjects although some may require more powerful stimuli. 
A very powerful stimulus is required to induce paralysis 
in other thyrotoxic subjects and even the majority of 
these patients will not develop paralysis. There is a 
spectrum of susceptibility to developing paralysis among 
thyrotoxic subjects. This variation in susceptibility may 
be due to variation in sodium pump activity. 
However it is not known why TPP rarely occur among 
female thyrotoxic subjects although the platelet Na-K 
ATPase activity in some of them could be quite high. This 
is most intriguing, because as shown in sections 3.5.2 and 
3.5.3, a sexual difference in TFTs or platelet Na-K ATPase 
activity could not be demonstrated in the control, 
euthyroid and thyrotoxic " groups. In contrast to familial 
hypokalaemic periodic paralysis where the majority of 
patients present before the age of 16 and almost 
invariably by the third decade (Talbot, 1941; Riggs, 
1988), TPP does not occur before the age of 14 (Hamada et 
al., 1982). The occurrence of TPP might be related to the 
sexual maturity of the male (Hamada et al., 1982). The"re 
is as yet no satisfactory answer to explain this 
preponderance of male TPP subjects. The potential effect 
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of sex steroids on sodium pump activity was summarized in 
section 3.2.5. 
As outlined in section 1.2.4.2, the incidence of TPP 
has declined in Japan. It was 8.6% among male and 0.4% 
among female thyrotoxic subjects. in 1957. In 1991, it 
decreased to 4.3% among male and 0.04% among female 
thyrotoxic subjects (Shizume et al., 1992) ·. It is not 
known why there should have been such a dramatic ten-fold 
decrease among female thyrotoxic subjects. 
In summary, this study has demonstrated that a higher 
platelet Na-K ATPase activity is a feature of TPP patients 
and that this enhanced activity may be responsible for the 
I 
hypokalaemic paralytic attacks seen in these patients. 
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Chapter 5 
VALIDATION OF THE ORAL GLUCOSE TOLERANCE TEST 
- 142 -
5.1 AIM 
Aim No. 10 of seqtion 1.8:-
8. To validate the "standard oral glucose tolerance 
test" protocol and derive an impro.ved protocol. 
5.2 BACKGROUND 
5.2.1 Need for a validated protocol for OGTT. 
One of the main aim of this project was to use the 
oral glucose tolerance test (OGTT) to study the stimulated 
activity , of the platelet Na-K ATPase activity and its 
relationship with insulin. Insulin is a stimulator of 
sodium pump activity and it can precipitate a decrease in 
Em of the skeletal muscle (section 6.2.2). Therefore, in 
addition to a difference in the basal platelet Na-K ATPase 
activity, a difference in the stimulated platelet Na-K 
ATPase activity and the plasma insulin levels may be the 
reasons why TPP develops in some but not all thyrotoxic 
patients. 
This could be confirmed by studying and comparing the 
responses to a standard oral glucose load in TPP patients, 
uncomplicated thyrotoxic patients and healthy controls. It 
is well documented that very often an attack of paralysis 
is preceded by an oral intake of carbohydrate. Therefore 
an oral GTT is preferred over the intra-venous GTT because 
it reflects the clinical situation more closely. , 
The qualtty of OGTT results will be compromised if it 
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is not properly performed (Home, 1988; ~een, 1992). 
Therefore strict criteria have been issued for 'proper 
patient preparation and how the test should be conducted 
and supervised (NDDG, 1979; WHO, 1985). The importance of 
following these strict guidelines has been repeatedly 
emphasized (Fajans, 1990; Davidson, 1991). However, this 
is not universally realized. Tremendous variability in how 
a "standard OGTT" is conducted in different laboratories 
has been rep'orted (Wiener i 1987). Perhaps this might 
explain partly why data on glucose tolerance in thyrotoxic 
subjects have been so difficult to interpret (section 
6.2.4). 
As shall be shown later, improper sample handling for 
glucose measurement may introduce serious error. This is 
one important area of the OGTT which has not been 
validated. 
5.2.2 Effectiveness of sodium fluoride as a preservative 
of glucose in blood sample. 
The glucose concentration in unpreserved blood 
samples decreases rapidly at room temperature, largely 
because of gly.colysis (Overfield et al., 1972; Dietzer & 
Smith, 1980; Alberti, 1988). Various procedures can be 
used to preserve glucose in blood, but each has its own 
shortcomings (Dietzler & Smith, 1980; Sidebottom et al., 
1982). Nevertheless, the usual practice is to use chemical 
preservatives such as sodium fluoride (NaF) or sodium 
iodoacetate. The al ternati ve is to process the blood 
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sample immediately after collection but this is not 
practical and some delay in separation of plasma for 
glucose measurement is usually unavoidable. 
NaF, the most widely used (Pileggi & Szustkiewicz, 
1974), is reportedly the best available preservative for 
glucose in blood (Young & Bermes, 1986). Nonetheless, 
opinions about its effectiveness differ. Some report that 
in blood samples treated with various amounts of fluoride, 
glucose concentrations remain stable at room temperature 
for up to 10 days (Major, 1923; Sander, 1923; Denis & 
Beven, 1924; Roe et al., 1927); others report continued 
declines in blood glucose concentrations despite the 
presence of fluoride (Bueding & Goldfarb, 1942; Lin et 
al., 1976; Nakashima et al., 1987). These discrepancies 
may have resulted from the poor methods of glucose 
analysis used in the earlier studies (Bueding & Goldfarb, 
1942; Kantor & Wilkerson, 1957). 
others have questioned the need for antiglycolytics 
for routine glucose analysis (Sazamaet al., 1979). For 
example, heparinized plasma gives identical values to 
fluoride-treated plasma if the heparinized plasma is 
separated from cells within 30 to 60 min (Passey et al., 
1982; Sidebottom et al., 1982). 
More recently, Sanders & Deadman (1985), · using a 
reasonably precise glucose analyzer, reported that NaF was 
able to preserve gl ucose in whole blood for 48 hours. 
145 
.Their findings were promptly disputed (Francis et al., 
1985) . 
On the other hand, others have claimeq that the 
apparent decline in blood glucose .as reflected by plasma 
glucose levels is an artifact (Davis & Williams, 1984). 
They reported that the whole blood glucose concentration 
remained unchanged, the decline in plasma glucose being 
due to a trartscellular shift of glucose from the plasma 
into the RBCs. 
It is important that the mechanism for the decline in 
plasma glucose concentration in blood samples and the . 
effectiveness of NaF as a preservative of blood glucose 
are well defined. Otherwise the reliability of glucose 
results will be compromised. It will be difficult to 
compare results of different studies or results between 
patients in the same study if a unified and validated OGTT 
protocol is not followed. 
5.2.3 Effect of delay in s "ample handling. 
There has been a . lack of published data to 
demonstrate the clinical significance of this pre-
analytical error. Theoretically delay in separation of 
plasma ' for glucose measurement could over-diagnose 
hypoglycaemia and under-diagnose hyperglycaemia (De Pasqua 
et al., 1984). It could possibly lead to error in the 
interpretation of OGTT results and misclassification of 
patients with respect to their glucose tolerance. 
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5.2.4 Ideal concentration of RaF. 
Despite the widespread use of NaF, there is as yet no 
consensus concerning the ideal concentration of NaF. 
Recommended concentrations of NaF include 2 (Young & 
Bermes, 1986), 2.5 (Caraway & Watts" 1986), 4.3 (Passey et 
al., 1982), 6 (NDDG, 1979; WHO, 1985) and 10 (Pileggi & 
Szustkiewicz, 1974) g/L blood. However, the scientific 
basis for these different recommended concentrations is 
not known. For instance, it is not clear why both the NDDG 
and the WHO recommended the use of NaF at 6 g/L blood 
(private communication with Prof KGMM Alberti, member of 
the WHO Study Group on Diabetes' Mellitus). However, 
excessive NaF should be avoided because it may induce 
haemolysis (Alper, 1974). On the other hand, none of the 
fluoride specimen bottles available in the market has NaF 
greater than 3 g/L blood. If the effectiveness of NaF is 
concentration-dependent, the use of different NaF 
concentrations will yield different results. It appears 
neither the users nor the manufacturers of specimen 
bottles are following the NDDG /WHO recommendation. 
It might be possibl.e to define an optimal NaF 
concentration which will minimize the degree of error. ' 
There are no published data on this subject. 
5.2.5 D-mannose as a preservative of blood glucose. 
D-mannose is the latest preservative proposed and is 
reported to act more quickly and more effectively than NaF 
(Nakashima et al., 1987; Faulkner, 1988; Liss, 1989). It 
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has the added advantage that blood sample treated with D-
mannose can be used for electrolyte determinations. 
However, theoretically, D-mannose should not be used 
as a gl ucose preservat.j.. ve. . Gl ucose and D-mannose are 
transported across the RBC membrane by the same 
transporter. There could be a hetero-exchange between 
intracellular glucose and extracellular D-mannose (Miller, 
1964; Eilam & Stein, 1972) resulting in an artificially 
increased plasma glucose concentration. Moreover, D-
mannose is known to interfere with some enzymatic glucose 
methods (Burrin & Price, 1985; Ho et al., 1991). It is 
also doubtful whether samples treated with an anti-
glycolytic agent should be used for electrolytes. 
Theoretically it will lead to an increase in the measured 
plasma potassium concentration because bf a decrease in 
sodium ' pump activity as a result of deficient supply of 
ATP. While a better gl ucose preservative would be most 
welcome further evaluation is required before D-mannose 
can be used in clinical practice. 
5.2.6 Rationale behind the aim of study. 
The significance and the nature of this pre-
analytical error in glucose measurement should be 
clarified. It is important to validate this part of the 
OGTT protocol and to derive a protocol that will minimize 
the magnitude of this error. otherwise, it will continue 
to be difficult to compare results between studies. 
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5.3 SUBJECTS AND METHODS 
5.3.1 Effectiveness of RaF. 
Blood was sampled from diabetic and non-diabetic 
subjects into 1 mL screw-capped tubes (Sarstedt Ltd,. 
Leicester, UK) containing either NaF (1 - 2 g /L blood) or 
heparin. In all samples, glucose concentrations were 
determined by a glucose oxidase method, in a YSI Model 
23AM glucose analyzer (Yellow Springs Instrument Co., 
Yellow Springs, OH). This analyzer can measure plasma and 
whole blood glucose without sample pretreatment. Within-
batch and between-batch CVs were <1%. All the analyses 
were performed by one operator. 
Venous blood from 19 adults · was dispensed into 
fluoride-containing tubes. Concentrations of glucose in 
whole blood were measured immediately and after ,1, 2, 4, 
24, 48, and 72 hours. The specimens were thoroughly mixed 
by inversion immediately before each measurement. 
Blood samples from another 10 adults were each 
aliquoted into seven fluoride tubes. One aliquot from each 
subject was centrifuged immediately and the others 1, 2, 
4, 24,48, and 72 hours later. Immediately after 
centrifugation plasma was removed for measurement of 
glucose concentration. 
In order to study the changes in glucose 
concentration more closely in the first hours and to 
compare the changes with and without NaF, blood samples 
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were obtained from 16 adults ' and aliquoted into pairs of 
tubes, one tube containing heparin and the other NaF. 
Whole blood glucose was determined immediately, then at 
15-min intervals for 2 hours, and then after a further 2 
hours and 20 hours. Blood samples . from another 10 adults 
were each aliquoted into nine pairs of tubes, one set 
containing heparin and the other set NaF. One pair of 
tubes was centrifuged immediately and successive pairs at 
15-min intervals over the next 2 hours before measurement 
of glucose in the plasma. 
All the specimens were kept at room temperature . 
during these studies. 
5.3.2 Effect of delay in sample handling. 
The effect of delay in sample handling on the 
interpretation of OGTT results was examined. One hundred 
consecutive 75 g OGTTs were studied. Blood samples were 
collected in commercial fluoride tubes (NaF: 1-2 g/L 
blood. Sarstedt Ltd, Leicester, UK). An aliquot from each 
blood sample was centrifuged immediately at the bed-side 
and the plasma separated for glucose analysis. A second 
aliquot was sent to the laboratory as a 'routine' sample. 
The routine practice is to send all specimens (0, 1 and 2 
hours) in one batch to the laboratory. In our experience, 
it may take up ' to 4 hours for a specimen to reach the 
laboratory. 
Plasma glucose concentration was measured by a 
glucose oxidase method using the 'Encore' centrifugal 
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analyzer· . (Baker Instruments Co., Allentown, USA) with a 
between-batch CV not exceeding 3.7%. 
Thus for each patient two sets of OGTT results were 
obtained; OGTT result A from sample·s processed immediately 
and OGTT result B from samples measured routinely. These 
were then classified according to the WHO (1985) and the 
American NDDG (1979) criteria into normal, diabetes 
mellitus, impaired glucose tolerance and non-diagnostic. 
5.3.3. Ideal concentration of RaF. 
Heparinized venous blood was taken from six adults 
and dispensed into a set of screw-capped tubes containing 
NaF at concentrations of 0, 1, 2, 6 and 12 g/L blood. 
These fluoride tubes were specially prepared. The 
specimens were kept at room temperature and glucose 
concentrations were measured immediately, then at 15 min 
intervals for 2 hours for each tube. Whole blood glucose 
concentration was measured by a glucose oxidase method in 
a YSI Model 23AM glucose analyzer · (Yellow Springs 
Instrument Co., OH). The specimens were thoroughly mixed 
by inversion immediately before each measurement. 
5.3.4 Evaluation of D-mannose as a preservative of blood 
glucose. 
To study the effectiveness of D-mannose as a 
preservative of blood glucose, heparinized blood samples 
from 16 adults were obtained and each sample was aliquoted 
into seven sets of tubes containing no other preservative 
151 
(P); D-mannose, 3 g/L (M); NaF, 6 g/L (F); or a mixture of 
NaF (6 g/L) and D-mannose (3 g/L) - (C). The contents of 
each tube were gently mixed. One set was centrifuged 
immediately and the remaining sets were left at room 
temperature and centrifuged after ,2, 4, 6, 8, 12, and 24 
hours. The plasma was collected and stored for glucose 
analysis. 
To study the short-term effect of D-mannose" 
heparinized blood samples from 17 adults were obtained and 
each sample was aliquoted into seven pairs of F and M 
tubes. One pair was centrifuged immediately (within 2 min) 
and the remaining pairs were centrifuged after storage at 
room temperature for 15, 30, 45, 60, 90 and 120 min. The 
plasma was separated and stored for glucose analysis. 
The effect of D-mannose on the plasma sodium and 
potassium concentrations was studied in heparinized 
samples obtained from 31 adults. Blood samples were 
aliquoted into seven pairs of P and M tubes. After gently 
mixing the samples, one pair was centrifuged immediately 
and the remaining pairs after storage at room temperature 
for 2, 4, - 6, 8, 12, and - 24 hours. The plasma was stored 
for potassium and sodium analysis. 
Plasma glucose concentration was determined by a 
hexokinase method with the Dimension clinical chemistry 
system (Du Pont Co., Wilmington, DE). The between-batch CV 
was 1.2%. D-mannose at 3 g/L in blood does not interfere 
with the assay of gl ucose by this method (Ho et 'al., 
1991). 
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Plasma potassium and sodium concentrations were 
determined by flame photometry with the IL-943 flame 
photometer (Instrumentation Laboratory Inc., Lexington, 
MA), which has a between-batch CV of 1.5%. All specimens 
from an individual subject were · analyzed in the same 
batch. 
5.4 RESULTS AND DISCUSSION 
5.4.1 Effectiveness of NaF. 
The stability of blood glucose in fluoride-containing 
tubes at room temperature for three days is shown in Table 
5.1. The concentration of glucose declined with time, the 
main decrease occurring during the first hour. Thereafter 
the rate of decrease was slower, and after 4 hours the 
blood gl ucose concentration was stable. The pattern is 
similar to that reported by Sidebottom et al. (1982) and 
Nakashima et al. (1987), although these authors examined 
the changes only during the first few hours. Results show 
that, despite the initial drop of about 0.5 mmol/L, NaF 
can maintain blood glucose concentrations for up to three 
days. 
If the decline in plasma glucose concentration were 
merely due to ' transcellular shift of glucose from plasma 
into RBCs (Davis & Williams 1984), the whole blood glucose 
results should remain unchanged with time. However the 
data show that the decrease is a result of continuous 












































































































































































































































































The changes in blood glucose concentration with and 
without NaF are shown and compared in Table 5.2. The 
pattern for whole blood was similar to that of plasma. 
During the first hour, the decre.ase of glucose in the 
fluoride-containing tubes paralleled that of the heparin 
containing tubes. After 1 hour the rate of decrease in the 
heparin-treated samples was much greater than in the 
fluoride-treated tubes. 
Results therefore suggest that NaF is slow but 
effective in preserving blood glucose, having· no effect in 
the first hour but slowing glycolysis considerably by the 
second hour, and more or less completely inhibiting it by 
the fourth hour. It is effective in preserving blood 
glucose for at least three days; however, for specimens 


















































































































































































































































































































































































































































































































s. 4,. 2 Effect of delay in sample handling. 
The effect of delay in separating plasma for glucose 
measurement on the interpretation of OGTT results is shown 
in Table 5.3. Ninety-three patients had concordant 
classifications irrespective of whether OGTT results ' A or 
B were used. In these 93 patients the mean (+/- SEM) 
difference in glucose concentration between the two sets 
of results were O. 7 (+ /-0.03), 0.6 (+/-0.05), 0.5 (+ /-
0.06) mmol/L at 0, 1 and 2 hours respectively. 
Seven patients by the NDDG criteria and four patients 
by the WHO criteria had discordant classification between 
resul ts A and B. The mean difference in blood glucose 
concentration in these seven patients were 0.8 (+/-0.06), 
0.9 (+/-0.14) and 0.9 (+/-0.'17) mmol/L at 0, 1 and 2 
hours, respectively. 
Results show that delay in processing blood specimens 
for glucose determination in normal practice may lead to 
misclassification in up to 7% of OGTTs. In this series, no 
patient with diabetes mellitus was misclassified as 
impaired glucose tolerance. However, since completing the 
study, two such patients have been discovered. 
Therefore marginal OGTT results should be interpreted 
with caution. Delay~d separation is one cause of the lack 
of reproducibility of OGTTs and this is of particular 
importance in the contert of epidemiological studies where 













































































































































































































































































































































5.4.3 Ideal concentration of RaF. 
Results of the changes in blood glucose concentration 
with time at different NaF concentrations are shown in 
Table 5.4. The '1 giL' fluoride tube was the commercial 
fluoride tube used in the previous experiments. Results 
show that NaF at such a low concentration is slow in 
action and results differ · little from tubes without 
fluoride in the first 30 - 60 min. 
Higher NaF concentration is associated with an 
earlier action and a smaller decrease in glucose 
concentration. The measured glucose value thus depend on 
the concentration of NaF in the specimen and the delay 
between taking the blood specimen and analysis or 
separation. These sources of variation may significantly 
affect the interpretation of results as demonstrated . in 
the section immediately above. It may be particularly 
important in newborn babies in whom the rate of glycolysis 
in erythrocytes is much higher (Baens & Oh, 1961; Meites 
& Saniel-Banrey, 1979) as well as in some adults who are 
"strong glycolysersll (Meites & Saniel-Banrey, 1979). 
The use of NaF at a concentration of 1 g/L blood 
·should be discouraged since -it is slow in action and has 
no demonstrable effect in the first hour or so. At high 
concentration, however, NaF causes haemolysis (Alper, 
1974). Therefore the use of 6 g/L blood, as recommended by 
the NDDG and the WHO seems an appropriate compromise. 
However, a search of catalogues showed that none of the 
fluoride-tubes available in the market has NaF greater 





































































































































































































































































































5. 4. 4 D-mannose as a preserva'tive of glucose in blood. 
Changes in plasma glucose concentration in the various 
types of tubes are summarized in Table 5.5. The glucose 
concentration in the unpreserved samples (P tubes) 
decreased rapidly, the rate of decrease in blood glucose 
being about 0.3 mmol/L per hour during the first 12 hours. 
Blood glucose concentration in the F tubes decreased by 
about 0.4 mmol/L during the first 2 hours, after which the 
rate of decl'ine was negligible, confirming previous 
results (section 5.3.1). The blood glucose concentration 
in D-mannose-containing tubes (M and C) at time zero was 
about 0.3 mmol/L higher than that in P or F tubes. In the 
M tubes the plasma glucose concentration decreased 
. continuously with time; the rate of decrease was 0.25 
mmol/L per hour for the first 2 hours and 0.05 mmol/L per 
hour thereafter. In. the presence of NaF and D-mannose 
(tube C), the blood glucose concentration decreased by 
0.11 mmol/L per hour during the first two hours; 
thereafter, there was very little decrease for 24 hours. 
Changes in glucose concentration in M and F tubes 
. 
during the first 2 hours are ' shown in Table 5.6. The rate 
of decrease in glucose concentration in the F tubes was 
greatest during the first 15 min. In the M tubes the 
glucose conceritration at time zero was 0.3 mmol/L greater 
than the corresponding F tubes and this increased further 
(to 0.6 mmol/L higher) at 15 min. There was a gradual 
decrease in the blood glucose concentration after the 





































































































































































































































































































































































































































































































































































































































































































































































Changes in the plasma potassium " and sodium 
concentrations in P and M tubes are summarized in Table 
5.7. In the P tubes, the plasma potassium decreased slowly 
with time, being 0.23 mmol/L lower at 12 hours than at 
time zero. It then increased by 0.2 mmol/L over the next 
12 hours. In contrast, the plasma potassium concentration 
increased progressively in the M tubes, some samples being 
visibly haemolyzed tow~rds the end of the experiment. By 
12 hours the plasma potassium concentration was 0.6 mmol/L 
higher than at time zero. The changes in plasma sodium 
concentration were relatively small; however, results in 
the P tubes were consistently highe~ than those in the M 
tubes. 
Results show that D-mannose, on its own, cannot be 
used as a preservative because the blood glucose 
concentration decreased continuously with time in the M 
tubes. The mech~nism accounting for the incomplete action 
is not clear. D-mannose is metabolized to fructose 6-
phosphate (Schwartz, 1982) so that the concentration of D-
mannose in the tubes decreases progressively. The lower 
concentration of D-mannose may not be adequate to prevent 
glycolysis( Nakashima et al., 1987). 
At time zero, the gl ucose concentration in the 0-
mannose containing tubes (M and C) were about 0.3 mmol/L 
higher than in the P and F tubes (Table 5.5 and 5.6). This 
is not likely to be due to interference with the glucose 
assay by D-mannose because, as we have shown (Ho et al., 
1991) at 3 g/L that D-mannose does not interfere with" the 
glucose as~ay used in this experiment. The higher glucose 
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concentration in the D-mannos~ containing tubes is likely 
to be due to rapid exchange of intracellular glucose for 
extracellular D-mannose across the RBC membrane. Glucose 
and D-mannose are transported across the RBC membrane by 
the same transporter, and the hetero-exchange between 
intracellular glucose and external D-mannose is very rapid 
(Miller, 1968; Eilam & Stein, 1972). The apparent increase 
'during the first 15 min of storage in an M tube (Table 
5.6) is probably also due to this transcellular exchange. 
Therefore the use of D-mannose will introduce error into 
plasma glucose determination. 
In the C tubes, the glucose concentration was 
relatively stable (Table 5.5), althougp the concentration 
was higher than in p tubes at time zero. Theoretically 
whole blood glucose result will not be affected by this 
hetero-exchange of gl ucose and D-mannose. Therefore a 
combination of NaF and D-mannose may be the best 
preservative for estimation of whole blood glucose. 
The plasma potassium concentration in heparinized 
blood samples decreased probably because of the entry of 
pot~ssium ions into the RBCs (Kalsheker & Jones, 1984). On 
the other hand, the plasma potassium increased in blood 
samples containing D-mannose. This increase was small 
(0.11 mmol/L) in the first two hours and was probably due 
• 
to the leakage of potassium as a result of inhibition of 
glycolysis. However, the increase was considerable 
thereafter. Therefore the use of D-mannose will lead to 
'pseudo-hyperkalaemia'. The small change in plasma sodium 
























































































































































































































































































































































































Results confirm that blood samples for glucose 
determination must be preserved unless they can be 
processed immediately after collection. NaF is effective 
but slow in action at low concentration. It is more 
effective at higher concentrations. The use of NaF at 1 
g/L blood or less should be discouraged. D-mannose cannot 
be used as a ~~eservative. 
Improper sample handling is one important source of 
pre-analytical error in the determination of 'blood 
glucose . 
. 
For the purpose of this project, all blood glucose 
specimens were collected in commercial fluoride tubes 
which contain NaF at 3 g/L blood. Instead of sending blood 
specimens individually, all specimens (0, 1 and 2 hours) 










Aim No. 11-14 of section 1.8:-
11~ To study and compare the stimulated platelet Na-K 
ATPase activity in healthy controls, thyrotoxic patients 
with and without paralysis by measuring the activity 
before and after a standard glucose load, according to the 
improved OGTT protocol. 
12. To study simultaneously the profile of plasma 
insulin (a stimulator of sodium pump) and the platelet Na-
K ATPase activity in the three groups of subjects. 
13. To study the rela~ionship between glucose 
intolera'nce and plasma insulin profile in the three groups 
of subjects. 
14. To study the effect of propranolol on the 
stimulated insulin secretion. i.e. to study the effect of 
an inhibitor on the secretion of a sodium pump stimulator. 
6.2 BACKGROUND 
6.2.1 Insulin, hypokalaemia and sodium pump. 
The effect of insulin on potassium homeostasis was 
first recognized in 1923, just two years after it was 
isolated and purified by Banting & Best (Rosa et al., 
1992). Since then, insulin has been shown to stimulate 
cellular uptake of potassium ions in body tissues 
including skeletal and cardiac muscle, kidney, hepatocytes 
and adipocytes (Gick et al., 1988; Rosa et al., 1992). 
This 'hypokalaemic' effect is independent of its 





glucose arid at such a low plasma insulin . concentration 
that a change in cellular uptake of glucose is not 
demonstrable (Zieler, 1960; Zieler & Rabinowitz, 1964; 
Williams & Epstein, 1989). 
It is now known that insulin exerts its hypokalaemi? 
effect through the sodium pump because the effect can be 
blocked by ouabain (Gick et al., 1988; Knochel, 1992; Rosa 
et al., 1992; ,-'Schipperheyn et al." 1992; Kjeldsen, 1994). 
The effect on the sodium pump is direct and dose-related 
(Bia & DeFronzo, 1981). However the mechanism is not yet , 
clear. It may be tissue-specific (Clausen, 1986; Gick et 
al., 1988). In skeletal muscle, it probably involves a 
change in the sodium pump affinity for sodium ion (Lytton, 
1985), but it is not ,certain whether it will also involve 
recruitment of latent pumps or an increased supply of new 
pumps (Erlij & Grinstein, 1976; Clausen & Hansen, 1977; 
Turaihi et al., 1988). , The response in sodium pump 
activity to stimulation by insulin is rapid. For instance, 
it is possible to demonstrate an average increase of 25 -
50% in leucocyte sodium pump activity one to two hours 
after an oral glucose load (Ng & Hockaday, 1987; Turaihi 
et al., 1988). 
6 _ 2.2 Insulin and skeletal muscie membrane potential (Em). 
As might have been expected, an increase in sodium 
pump activity will normally lead to an increase in Em 
(hyperpolarization) because of a greater contribution of 
Eelect (section 1.6). This has been confirmed. Insulin was 
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found to increase Em in . normal human intercostal fibres 
(Hofmann et al., 1983) and animal muscle fibres (rat, 
mouse and frog) (Flatman & Clausen, 1979; Moore & 
Rabovsky, 1979; Zemkova et al., 1982). The change in Em is 
detectable within seconds and can be induced by' insulin at 
physiological concentration (Clausen, 1986). 
Paradoxically, instead of hyperpolarization, insulin 
will induce depolarization (decrease in Em) if there is an 
underlying severe potassium depletion (Clausen, 1986; 
Knochel, 1989). (Note: as outlined in section 1.6, there 
is a slight increase in Em in the early stage of potassium 
depletion.) Similar depolarization also occurs if the 
extracellular potassium concentration is severely 
decreased (Moore, 1983). The details of the mechanism of 
the depolarization are not certain. However, an increase 
in PNa and a decrease in PK" resulting in a change in the 
alpha value, have been suggested (Layzer, 1982; Moore, 
1983; Clausen, 1986, Le'hmann-Horn et al . .' 1994). 
There are few published data on the effect of insulin 
on Em in thyrotoxicosis. As outline-d in section 1.6, 
. thyrotoxicosis is characterized by a decrease in Em as a 
result of an increase in the alpha value, the PNa/PK ratio. 
In the only report on a TPP patient, Em was found to be 
even lower and the decrease was aggravated by the presence 
of insulin (Hofmann & Smith, 1970). However, a similar 
study on the effect of insulin on Em in uncomplicated 
thyrotoxic patients was not conducted. It is not known to 
what extent insulin will aggravate the decrease in Em in 
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this group of patients. 
6.2.3 Potential role of insulin in the pathophysiology of 
TPP. 
The association between carbohydrate intake and TPP 
is well recognized. According to McFadzean & Yeung (1967), 
Shinosaki first reported in 1926 the association between 
carbohydrate intake and the development of paralysis. 
Since then this association has been well confirmed 
(McFadzean & Yeung, 1967; Hamada et al . , 1982) . 
Presumably, the paralysis is precipitated by an increase 
in insulin secretion in response to an increase in blood 
glucose. This causal relationship is supported by the fact 
that the administration of insulin can induce an attack of 
paralysis in TPP patients (McFadzean & Yeung, 1967;'Yeung 
& Tse, 1974; Yeo & Q'Neill, 1984). Furthermor~, there have 
been case reports of spontaneous attacks of TPP associated 
with hyperinsulinaemia (Shishiba et al., 1972; Hay & 
McDougall, 1975; Kusakabe et al., 1975; Hamada et al., 
1983). In the presence of high insulin concentrations, a 
sodium pump stimulator, it is likely that there will be an 
increase in the sodium pump activity. 
As summarized in section 1.6., an attack of 
paralysis is precipitated by the sodium pump-driven 
transcellular shift of potassium ions. Insulin plays a 
central role because of its ability to stimulate ' the 
sodium pump and to depolarize the muscle membrane of TPP 
patients. This will lead to inactivation of Na . or K 
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channels resulting in the loss of excitability, manifested 
clinically as paralysis. 
6.2.4 Hyperinsulinaemia and thyrotoxicosis. 
A high insulin level is an important inciting factor 
in the development of hypokalaemic periodic paralysis. 
However, is hyperinsulinaemia a feature of thyrotoxicosis? 
While it -has been well recognized that thyrotoxicosis 
is associated with glucose intolerance, the detailed 
mechanism is not yet clear and experimental findings have 
been controversial (Kozak & Cooppan, 1985; - Shen & 
Davidson, 1985; Jap et al., 1989; Raboudi et al., 1989; 
Ganda, 1990; O'Meara et al., 1993). For instance, the 
insulin response to oral glucose loading has been reported 
normal (Ikejiri et al., 1978; Ikeda et al., 1990), -
increased (Kabadi & Eisenstein, 1980; Shen & Davidson, 
1985) or decreased (Woeber et al. , 1966). The 
discrepancies could be due - to differences in patient 
selection, design of experiment, analytical procedures and 
a great variation in what is considered a normal response 
(Wiener, 1987; Pestell et al~, 1990; Lee et al., 1991). 
On the other hand, apart from a single report (Yeung & 
Tse, 1974), hyperinsulinaemia has consistently been a 
feature of TPP patients (section 6.1.3). 
6.2.5 TPP vs uncomplicated thyrotoxic patients. 
Is there any difference in plasma insulin 
concentrations between these two groups of thyrotoxic 
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patients? Insulin stimulates sodium pump activity and the 
effect is dose-related. Therefore it is reasonable to 
deduce that thyrotoxic patients who have hyper-
insulinaemia are more likely to develop paralysis. This 
may be one of the reason why TPP d~velop in some but not 
all thyrotoxic subjects. 
As a group, TPP patients demonstrate a greater 
glucose and insulin response to a carbohydrate load than 
uncomplicated thyrotoxic patients (Ide et al. ,. 1977; Yeo 
et al., 1988; Lee et al., 1991). However, sodium pump 
activity was not measured in all these studies on insulin 
secretion in TPP patients. It is insufficient to study the 
stimulator alone without simultaneously documenting the 
response (Ruff & Gordon, 1987). Therefore, an aetiological 
relationship between hyperinsulina~mia and increase in 
sodium pump activity in TPP patients has not been 
convincingly proven. 
In addition to the absolute level of the insulin 
concentration, an increase in affinity for insulin binding 
may also be important. Hofmann et al. (1983) demonstrated 
that the skeletal muscle of FPP patient has a higher 
affinity f~r insulin binding. Whether the skeletal muscle 
of TPP patients will have q similar increase in affinity 
for insulin binding is not yet known. 
As shown in chapter 4, a high basal sodium pump 









A high stimulated sodium pump 'activity is probably equally 
important. Thos.e thyrotoxic patients who have a higher 
basal or stimulated sodium pump activity due to 
hyperinsulinaemia are more likely to develop hypokalaemic 
periodic paralysis. 
6.2.6. Catecholamines and insulin secretion. 
Although many of the symptoms and signs of 
thyrotoxicosis indicate an excess of sympathoadrenal 
activity (Silva & Landsberg, 1991), thyrotoxicosis is not 
associated with an excess in the production of adrenaline 
or noradrenaline (Christensen, 1973; Stoffer et al., 
1973). Likewise, excessive production of catecholamines in 
TPP patients has never been reported. The two TPP patients 
studied in chapter 2 had normal 24 hour urine 
catecholamines results. On the qther hand, an increase in 
tissue beta-receptors has been reported (Clausen, 1986; 
Silva & Lanqsberg, 1991). Perhaps this explains the 
enhanced sympathomimetic manifestations of thyrotoxicosis 
(Yeo & O'Neill, 1984). 
Catecholamines are stimulators of the sodium pump, 
and at one time adrenaline infusion was used to 
precipitate attacks of hypokalaemic periodic paralysis 
among TPP patients (Engel, 1961). However, failure to 
induce paralysis have been reported (Engel, 1972; Ali & 
Akavaram, 1980). ~eserpine, which induces a depletion of 
stored amines in adrenergic nerve terminals, had no 




al., 1969). In contrast, TPP 'patients could be protected 
from the development of paralysis by taking a moderate 
dose of propranolol, a non-selective beta-blocker (Conway 
et al., .1974,· Yeung & Tse , 1974). The role of 
catecholamines in the pathophysiolqgy of TPP is therefore 
not clear. 
While the overall 24 hour production of 
catecholamines, may not increase, perhaps some of the 
attacks of TPP occur as a result of a sudden increase in 
catecholamine secretion. Perhaps propranolol acts by 
blocking the effect of these episodes. 
On the other hand, the secretion of insulin is 
affected by catecholamines. Insulin secretion is 
stimulated by beta-agonist and inhibited by alpha-agonist 
and release of endogenous catecholamines inhibits insulin 
secretion because of the predominantly alpha effect 
(Bowman & Rand, 1980; Maki et al., 1990). As expected, 
insulin secretion induced by beta-agonist can be blocked 
by propranolol. It was shown that intravenous propranolol 
could inhibit intravenous ' glucose-stimulated insulin 
release (Cerasi et al., 1972; Wajchenberg et al., 1978; 
Ahren & Lundquist, 1981; weiner, 1985; Laceyet al., 
1993). The clinical significance of this finding was well 
recognized because of the possibility that glucose 
intolerance may occur in patients on long term beta-
blockers (Day, 1975; Brass, 1984; Dornhorst et al., 1985). 






demonstrated suppressed insulin secretion and decreased 
glucose tolerance in response to an oral glucose load in 
diabetic patients receiving propranolol 80 mg twice daily. 
However, similar findings were not seen in a group of 
hypertensive patients on propranolo~ 40-160 mg three times 
daily (Day et al., 1979). 
A similar study has been done in TPP patients but the 
results were -, not conclusive (Yeung & Tse, 1974). 
Propranolol decreased the insulin secretion during an 
episode of induced paralysis in one patient but no obvious 
effect was detected in another patient. As shall be 
discussed later, hyperinsulinaemia is a feature of TPP. It 
is not yet clear whether propranolol renders its 
protecti ve effect by inhibiting the gl ucose-stimulated 
insulin release in TPP patients. 
6.3 SUBJECTS AND METHODS 
Twenty-four healthy controls (8M and 16F, 21-56 
years), 17 uncomplicated thyrotoxic patients (7M and 10F, 
18-45 years), 15 TPP patients before treatment (all M, 22-
39 years) and 4 TPP patients after anti-thyroid treatment 
(treated TPP) (all male, 24-32 years) were studied. All 15 
TPP patients were studied after they had recovered from 
the acute paralytic episode but before treatment with 
anti-thyroid drugs. All TPP patients had been admitted 
with paralysis and had hypokalaemia. They were given 
potassium supplements and recovered from the paralysis 
spontaneously. In all patients thyrotoxicosis was 
177 
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confirmed biochemically with " suppressed TSH and clearly 
elevated FT3 and FT4. None of the healthy controls were on 
any medication or known to have diabetes or thyroid 
disease. 
In ' all patients and healthy subjects, a 75 g oral 
glucose tolerance test was performed according to the 
protocol described in the last chapter. Blood samples were 
taken into fluoride, heparin and citrate tubes for 
measurement of glucose, potassium and insulin and platelet 
Na-K ATPase acti vi ty respectively at 0, 1 and 2 hours. 
Four TPP patients were put on propranolol '40 mg three 
times daily. OGTT was repeated two weeks later. 
Plasma glucose was measured by a ·· glucose oxidase 
method (Beckman, California, USA). Insulin was measured by 
a radioimmunoassay using a commercial kit from Pharmacia 
(Sweden). (Note: this insulin kit had been evaluated 
previously and found to have minimal cross-reactivity with 
proinsulin. Proinsulin may increase in thyrotoxicosis and 
therefore affect interpretation of insulin results 
(Raboudi et al., 1989». Platelet Na-K ATPase activity was 
measured as described in chapter 3. Plasma concentration 
of TSH was measured by an immunochemiluminometric assay 
(Ciba Corning, USA) with a detection limit of 0.02 mU/Le 
Plasma free thyroid hormone concentration wa~ determined 
by commercial kits (Amerslex-M, Amersham, USA for FT3 and 








6.4 STATISTICS & DATA HANDLING 
Differences between basal values between groups were 
compared by the Mann-Whitney U-test. Results before and 
after treatment with propranolo.l were compared by 
Student I s paired t test. A p-value less than 0.05 was 
considered significant. 
Area under the curve (AUC) was calculated by the 
trapezoid method. Changes in plasma glucose, insulin and 
platelet Na-K ATPase activity during OGTT were compared by 
two-factor analysis of variance (ANOVA) for repeated 
measurements using a commercial software package. 








Table 6.1 shows the age and plasma concentrations of 
FT3 and potassium in the different groups of patients. 
Plasma potassium concentration in TPP patients on 
admission ranged from 1.4 to 2.7 (~ean=2.1) mmol/L. After 
recovery from paralysis the concentration of plasma 
potassium in TPP patients ranged from 3.5 to 5.1 
(mean=4. 3) mmol/L. The FT3 concentrations for the two 
groups of thyrotoxic patients were comparable and the 
difference was not statistically significant. 
Table 6.2 shows the changes in (a) plasma glucose, 
(b) plasma insulin and (c) platelet Na-K ATPase activity 
at 0, 1 and 2 hours after an oral glucose load. Plasma 
glucose concentrations at zero time were similar in all 
four groups. Plasma glucose levels at 1 and 2 hours in 
untreated TPP patients were higher than those in healthy 
subjects and t ,hyrotoxic patients (Table 6.2). In treated 
TPP patients the glucose values were similar to those in 
healthy subjects. 
However, there was a high incidence of impaired 
glucose tolerance among the two groups of thyrotoxic 
patients. Based on the W.H.O. (1985) criteria, two 
patients (12%) in the uncomplicated thyrotoxic group had 
"impaired glucose tolerance", whereas four and two 
patients of the TPP group have "impaired glucose 
tolerance" (28%) and "diabetes mellitus" (14%) 






















































































































































































































































































































































































































































































































































































































































































































































































































































































undiagnosed diabetes mellitus and impaired glucose 
tolerance were 3% and 7% respectively in Hong Kong). 
Basal insulin concentrations did not differ between 
thyrotoxic subjects and heaithy controls but tended to be 
higher in untreated TPP patients. The insulin 
concentrations at 1 and 2 hours were significantly higher 
in untreated TPP patients than in either healthy controls 
or thyrotoxic -patients without paralysis (Table 6 ".3). In 
treated TPP patients insulin concentrations were similar 
to those of the healthy controls. 
Basal platelet Na-K ATPase activity was higher in 
untreated "thyrotoxic patients without paralysis and, in 
TPP patients, it was further increased. Oral glucose 
stimulated platelet Na-K ATPase activity in all three 
groups. 
To examine the - changes further, the AUCs were 
calculated for glucose, insulin and platelet Na-K ATPase 
(Table 6.3 (a». The TPP group has a significantly higher 
mean glucose AUC than that of the control group (16.5 vs 
12.4, p<O.01). The same applied to mean insulin AUC (189.6 
vs 98.5, p<O.001). In uncomplicated thyrotoxicosis, the 
resul ts were similar to those of the heal thy controls. 
These results further confirm that there was glucose 
intolerance in TPP patients and this was accompanied by 
higher insulin levels. 
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Ingestion of glucose increased platelet Na-K ATPase 
activity in all groups. Platelet Na-K ATPase activity was 
significantly higher in uncomplicated thyrotoxic patients 
compared to controls and in TPP patients was even higher. 
Mean AUC for platelet Na-:-K ATPase activity in TPP patients 
was significantly higher than that of uncomplicated 
thyrotoxic patients (601 vs 482, p<O.Ol) or healthy 
controls (601 vs 315, p<O.OOl) ~ Analysis of the AUCs for 
male subjects only (Table 6.3 (b» showed similar results. 
In the four treated TPP patients the results were similar 
to those of the healthy controls. 
When the insulin response (AUC) was correlated with 
stimulation of platelet Na-K ATPase activity (AUC) in the 
different groups it was found that in healthy subjects 
there was a significant relationship (r=0.521, p=0.009) 
but not in thyrotoxic or TPP groups. 
Differences between the sexes in the AUCs of glucose, 
insulin and platelet Na-K ATPase activity were not 
statistically significant. 
Results of the four TPP patients given propranolol 
are summarized in Table 6. 4. There is no statistically 
significant difference between the two set of results. 
Propranolol has no demonstrable effect on glucose 



























































































































































































































































































This is the first study which involves simultaneous 
measurement of plasma insulin and tissue sodium pump 
activity in TPP patients. Without exception, all previous 
studies did not study the sodium ,pump activity. It is 
essential to demonstrate a direct relationship between 
insulin (the stimulator) and the sodium pump activity (the 
target of stimulation) before a definite conclusion can be 
made on the r9'le of insulin in ' the pathophysiology of TPP 
(Ruff & Gordon, 1987). This missing link has been 
addressed for the first time in this study. 
The results presented from this study confirm the 
findings of other workers that there is an association 
between thyrotoxicosis and impaired glucose tolerance 
(Kozak & Cooppan, 1985; Ganda OP, 1990). In comparison to 
the local population both groups of thyrotoxic patients 
have a higher incidence of impaired glucose tolerance. 
Despite comparable circulating FT3 concentrations, 
the TPP group had a higher glucose AUC than that of the 
thyrotoxic group. 42% of the TPP patients had either 
impaired glucose tolerance or diabetes mellitus. None of 
the thyrotoxic group patients had diabetes mellitus but 
12% of them have impaired glucose tolerance. 
Impaired glucose tolerance, together with elevated 
plasma insulin are features of an insulin-resistant state 





6.2.4, the mechanism for ' glucose intolerance in 
thyrotoxicosis is not yet clear. Recent studies have 
suggested that there is an underlying hepatic insulin 
resistance which results in increased glucose production 
in the liver and a compensatory . increase in' insulin 
secretion (Ahren, 1986; Cavallo-Perin et al., 1988). 
Glucose intolerance will not occur if the c~mpensatory 
rise in insulin secretion is adequate. In addition, an 
increased sensitivity of the beta-cells to glucose in 
thyrotoxic subjects has also been suggested (O'Meara et 
al. , 1993) . In this study, hyperinsulinaemia was not 
documented in the uncomplicated thyrotoxic group. There 
was hyperinsulinaemia in the TPP group. It appears the 
glucose homeostasis mechanism in TPP patients is more 
sensitive to the adverse effect of an excess in thyroid 
hormones. 
In keeping with previous reports (section 6 . 2 . 5 ) , 
results in this study confirm that hyperinsulinaemia is a 
feature of TPP. A higher insulin level is important in the 
pathophysiology of TPP for two reasons. It will lead to 
greater stimulation of sodium pump activity because its 
effect is dose-related (Bia & DeFronzo, 1981). The sodium 
pump is the driving force behind the transcellular shift 
of potassium ions which triggers the development of 
paralysis. Thyrotoxic patients who have a high stimulated 
sodium pump activity are more likely to develop the 
paralysis. Although the effect of insulin on Em . in 
thyrotoxic patients is not yet clear, there is no doubt 
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that insulin will aggravate the depolarization (decrease 
in Em) in TPP patients (Hofmann & Smith, 1970). A change 
in membrane permeability to ions has been suggested as the 
mechanism behind the ' insulin-induced depolarization ' (Ruff, 
1989; Lehmann-Horn et al." 1994). 
In healthy subjects platelet Na-K ATPase activity was 
increased one hour after an oral glucose load. Increased 
activity of the sodium pump in leucocytes following a 
glucose load has also been reported (Ng & Hockaday, 1987; 
Turaihi et al., 1988). The increase in platelet sodium 
pump activity (22%) observed in this study was comparable 
to that reported in leucocytes (25 - 46%). Although this 
increase in sodium pump activity could result directly 
from glucose, it is more likely to reflect the action of 
insulin (Turaihi et al., 1988). 
Resul ts' also show that the insulin concentrations 
induced by oral glucose are adequate to stimulate platelet 
Na-K ATPase activity. The greater stimulating effect of 
oral glucose load on platelet Na-K ATPase activity in TPP 
patients parallels higher insulin concentrations. 
In chapter 4 it was demonstrated that changes in 
platelet Na-K ATPase activity measured in vitro are 
paralleled by changes in the in vivo sodium pump activity. 
Thus platelet Na-K ATPase activity is likely to reflect 
activity in skeletal muscle because this tissue has large 







Since TPP patients have a higher basal as well as 
stimulated platelet - Na-K ATPase activity than all other 
groups of subjects, it is logical to conclude that TPP 
patients -have a higher basal as well as stimulated sodium 
pump activity in skeletal muscle than those in all other 
groups of subjects. 
The combination of hyperinsulinaemia and a more 
active sodium pump (basal and stimulated) will predispose 
susceptible thyrotoxic patients to hypokalaemic periodic 
paralysis in response to carbohydrate loading. 
On the other hand, these risk factors will disappear 
once the patient becomes euthyroid again. There was no 
demonstrable difference between the healthy controls and 
the treated TPP patients. This provides another piece of 
evidence to support the notion that TPP subjects have an 
underlying defect (or defects) which is unmasked by 
thyrotoxicosis (section 1.2.4"). 
None of the four TPP patients treated with 
propranolol . developed paralysis during the two-week 
period. How propranolol exerts its protective effect· is 
not clear. 
propranolol, at moderate dose, does not seem to have 
a demonstrable effect on FT3, glucose tolerance or 
glucose-in~uced insulin secretion. However, this may be 








TPP patient who required propr'anolol at 480 mg/day before 
attacks of paralysis could be prevented. In contrast all 
the patients reported by Yeung & Tse (1974) were put on 
160 mg/day. A significant change may have been 











7.1 GENERAL DISCUSSION 
Pathogenesis has been defined as the study of the:-
cellular events and reactions or other 
mechanisms ~ccurring in the development of 
disease (Dorland's Illustrated Medical 
Dictionary) . 
- characteristics, causes and effects of disease 
(Mosby's Medical Dictionary). 
- pathological, physiological and biochemical 
mechanisms resulting in the , development of 
disease or morbid processes (Stedman's 
Medical Dictionary). 
The understanding of the pathogenesis of a disease 
process is therefore the cornerstone upon which 
appropriate diagnostic and therapeutic procedures are 
based. In contrast to other types of periodic paralysis 
the pathogenesis of TPP remains largely unknown. The aim 
of this project is to study the role of Na-K ATPase 
activity in the pathogenesisof TPP. 
Medical history has repeatedly , demonstrated that our 
understanding of a disease progresses through stages:-
1. Clinical descriptions. 
2. Identification and elucidation of the mechanism, 
including anatomical, biochemical and pathophysiological 
changes. 
3. Identification of the genetic basis of the 
disease, including changes at the cellular and molecular 
level. 
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Among the periodic paralysis sydromes, much progress 
have been made in recent years in the understanding of the 
pathogenesis of FPP and hyperkalaemic PP. The eighties 
~ere characterized by the elucidation of the pathological 
processes at the cell membrane level using patch clamp 
techniques. Since the beginning of the' nineties, defects 
at the molecular level have been reported. It is now 
realized that mutations of the sodium channel alpha-
subunit gene lead to the development of the hyperkalaemic 
pp (Fontaine et al., 1990; Griggs & Ptacek, 1992). 
Recently it was also reported that FPP may be due to a 
mutation in the calcium channel gene (Jurkat-Rott et al., 
1994). Therefore these pp syndromes are firmly in stage 3 
and moving on to stage 4 where the functional correlation 
between the molecular defect and the phenotypic expression 
will be elucidated. 
In comparison, our understanding of the p'athogenesis 
of TPP lags far behind. Most of th.e p~blications in the 
last 15 -20 years were case reports and reviews. There 
have been very few studies which aim at elucidating the 
pathogenesis of TPP. Much of our present understanding is 
based on the work of Engel (1961), the Shizumi group 
(1966) and that of Yeung et al. (McFadzean & Yeung, 1967, 
Yeung & Tse, 1974; Yeung & Au, 1978). 
In contrast to the hyperkalaemic pp and FPP, the 
physiology and pathophysiology of the muscle membrane have 





report by Hofmann in 1970. Therefore it has not been 
confirmed whether there is any defect in the ion channels 
of muscle membrane in TPP patients. It is not certain also 
how far TPP and other types of pp are related. 
As outlined in section 1.2.4.2, it is difficult to 
conduct studies on TPP because it ' is not a very common 
disease. It is also a transient disturbance which settles 
after effective anti-thyroid therapy and there are 
effective prev~ntive measures (beta-blockers) while the 
patient remains thyrotoxic in the first few weeks of 
treatment. All these factors remove the urgency to 
elucidate the pathogenesis of TPP. For the same reasons, 
it would be difficult to justify obtaining biopsy of 
skeletal muscle for study even though it is the best 
tissue available. 
Nevertheless, it is important to elucidate the 
pathogenesis of TPP. As reviewed in section 1.3, it is not 
known why there is a tendency for Chinese patients with 
Conn's syndrome and Sjogren's syndrome to develop 
hypokalaemic periodic paralysis. Perhaps they share 
certain common denominators with TPP. Furthermore, defects 
in cationic transport are increasingly recognized to play 
an important role in the pathogenesis of essential 
hypertension, diabetes mellitus and hyponatraemia. No 
doubt more will be added to the list and it is likely that 
understanding of the pathogenesis of TPP will contribute 




7.2 ROLE OF SODIUM PUMP IN THE PATHOGENESIS OF TPP 
As summarized in sections 1.5 and 1.6, the hallmark 
of TPP is the transcellular shift of potassium ions which 
precipitates an attack of hypokalaemic paralysis. Sodium 
pumps play a central role in this active transport of 
potassium ions. Therefore it is logical to deduce that 
differences in sodium pump activity may be the reason why 
TPP develops in some but not all thyrotoxic patients. 
However, as indicated in section 4.6.2, studies which used 
the RBC or lymphocyte models have not yielded conclusive 
results perhaps because they are poor substitutes for 
skeletal muscle. Platelets were used in this study because 
they are a better model (section 3.2.4). · 
Sodium pump activity is elevated in thyrotoxicosis. 
There · is much variation in tissue sensitivity to the 
effect of excess thyroid hormones (section 3.2.2). Others 
have reported that there is no difference in thyroid 
hormone results between thyrotoxic patients with and 
rwi thout hypokalaemic paralysis. Therefore TPP patients 
probably represent those who are 'unduly' sensitive and 
respond with an exceptional increase in sodium pump 
activity. The hypothesis of this thesis is that thyrotoxic 
patients who have a high basal or stimulated sodium pump 
activity are more likely to develop hypokalaemic paralysis 
(section 1.8). 
In fact, this project represents the first study of 




able to show that platelet Na-K ATPase is a good tissue 
marker of hyperthyroidism (Ch t 3 ) ap er . Its power of 
discrimination was explored to study the difference 
between thyrotoxic patients with and without hypokalaemic 
paralysis. A greater increase in the basal platelet Na-K 
ATPase activity in TPP patients was demonstrated (Chapter 
4). The finding was confirmed by the rubidium loading 
test. This project represents the first use of this in 
vivo assay of sodium pump activity in the study of thyroid 
patients. 
It is logical to deduce that a high stimulated sodium 
pump activity is just as important in the pathogenesis of 
TPP as a high basal sodium pump activity. The OGTT 
protocol was validated (Chapter 5) and' an improved 
protocol was used to study the difference in the response 
to a glucose load between thyrotoxic patients with and 
without periodic paralysis. The blood glucose profile and 
the stimulated platelet Na-K ATPase activity were elevated 
in the TPP patients. This was associated with a 
compensatory increase in plasma insulin. Insulin is 
important in the pathogenesis because of its ability to 
stimulate the sodium pump activity as well as an ability 
to lower the Em in TPP patients. This project represents 
the first study which simultaneously examines the sodium 
pump and insulin, one of its stimulators. 
These two groups of thyrotoxic patients studied in 
this project have comparable thyroid hormones results even 
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~hough they demonstrate differences in the basal as well 
as the stimulated sodium pump activity. In thyrotoxicosis 
sodium pump activity is increased in many body tissues 
including platelets, white cells, skeletal muscle cells 
and hepatocytes. Results of this study suggest that the 
sodium pump in TPP patients is more sensitive to the 
effect of excess in thyroid hormones. The glucose 
intolerance is probably secondary to an increase in 
hepatic glucose production. It is not known whether "this 
is related to an increase in sodium pump activity in the · 
hepatocytes. 
The mechanism leading to the increase in sodium pump 
activity is not clear. It is not known whether it is a 
result of a direct effect of T3 at the nuclear receptor 
level. It is possible that it is a result of the change in 
passive ion fluxes affecting the expression of the sodium 
pump gene through an unknown mechanism (section ~.5.2). 
Catecholamines are an inciting factor in the 
precipitation of paralysis in TPP patients. Although there 
is no excess "in catecholamine production in thyrotoxic 
subjects (sections 2.4 and 6.2.6), patients with a high 
basal sodium pump activity will be more likely to develop 
paralysis when there is a sudden increase in catecholamine 
secretion. 
Theoretically differences in sodium pump inhibitors 
may contribute to the pathogenesis. However, there is no 
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published data on this aspect. 'In . contrast·, I hqve studied 
the effect of propranolol because there is evidence to 
suggest that propranolol may inhibit the glucose-
stimulated release of endogenous insulin (ie an inhibitor 
on the release of a sodium pump ~timulator) . . However, 
results were not conclusive (section 6.5). 
Why should TPP develop in some but not all thyrotoxic 
patients? This ·,·has been a perennial question for decades. 
I have -attempted to answer this question by focusing on 
the sodi~m pump. Results of this study show that 
differences in sodium pump activity (basal and stimulated) 
is one important factor in the pathogenesis of TPP. 
However, there are still many questions unanswered. 
On the one hand it is well documented that treated 
TPP patients can develop hypokalaemic paralysis if they 
are exposed to thyroxine (section 1.2.4.1). On the other 
hand, patient No. 12 (Table 4. 3) had a history of TPP but 
he did not develop paralysis again when there was a 
relapse of his thyrotoxicosis, confirmed by typical 
thyroid hormones profile and a ~igh platelet Na-K ATPase 
activity. This suggests that' perhaps his threshold had 
changed with time and there may be other factors. Could 
this be due to an improvement in glucose tolerance so that 
the stimulated pump activity and the hyperinsulinaemia had 
improved? This could not be confirmed because an OGTT had 
not been done in the past. The incidence of TPP is 
decreasing dramatically in Japan (section 1.2.4.2) 







intake. ' Perhaps patient No.12 was a typical example. 
However, as · discussed in section 4 . 6 . 3 , it is not 
known why TPP seldom occurs among female thyrotoxic 
subjects despite the sodium pump activity being quite high 
in some of them. This suggests that , differen~es in sodium 
pump activity may not be the complete answer. However, as 
a group, they did not demonstrate glucose intolerance nor 
hyperinsulinaemia, which are features of TPP patients. 
Among the uncomplicated thyrotoxic patients there was no 
statistically significant difference in the response to 
the glucose load between the two sexes. Therefore a 
difference in the concentration of insulin, a 'sodium pump 
stimulator, may be important. It is not known why they are 
less sensitive to the effect of thyroid hormones in this 
aspect . . Among the heal thy controls, there was also no 
significant difference in platelet Na-K ATPase activity 
between the sexes (section 3.5.3). 
It is interesting to note that a preponderance of 
male ' patients is also a feature of FPP, which is an 
autosomal dominant condition. Female patients are 
associated with milder disease and some of them do not 
have overt attacks, or may -have only one attack in a 
lifetime. Partial non-penetrance is a feature of female 
FPP patients. It is recognized that some of these mlldly 
affected female patients would deny the presence of 
symptoms (Schipperheyn et al., 1992). Perhaps f~male TPP 
patients are not diagnosed because of the same reason. 
However, there have been reports of familial TPP patients 









7.3 STRATEGY FOR FURTHER STUDY 
There is a consensus that TPP is an inherited 
disorder. The latent defect is unmasked by thyrotoxicosis 
(section 1.2.4.1). ~he gene or genes responsible for TPP 
have not been identified. Studies which focus on HLA 
analysis, in general, have been uninformative (section 
1.7.1). The molecular pathways for TPP are far from clear. 
No doubt it is important to identify the pathogenesis 
of TPP at the molecular level (stage 3). However, this can 
only be meaningfully attempted when the stage 2 mechanism 
is elucidated. It will help target the gene or genes which 
should be studied closely, eg. sodium pump gene?, sodium 
channel gene? potassium channel gene? T3 receptor gene? 
etc. Furthermore functional correlation (stage 4) is only 
possible when the phenotypic expression (stage 2) is fully 
characterized. Therefore, in the case of TPP, much work 
has yet to be done. We are at the early stage of stage 2. 
It is important to capitalize on modern advances in 
research techniques to study the sodium pump, the membrane 
channels and the genes in TPP patients. 
In recent years, different isoforms of the sodium 
pump have been described (section 1.5.3). The expression 
of these isoforms varies between tissues and they have 
different functional characteristics. The functional 
correlation between these characteristics and the 
pathogenesis of sodium pump related diseases are being 
unravelled. It is not known, whether or not the · isoform 
pattern I of TPP patients is any different from that in 
uncomplicated thyrotoxic patients, and whether this 
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accounts for the observed difference in sodium pump 
activity. 
7.4 CONCLUSION 
TPP is indeed a . fascinating condition which has 
attracted a lot of questions which are difficult to 
answer. Through this project I have produced positive data 
which addresses some of these difficult questions. Further 
studies are required before the pathogenesis of TPP can be 
fully elucidated. In particular, it is important to study 
the biochemical characteristics of the different isoforms 
of the sodium pump , the patho-physiologyof skeletal 
muscle membrane using modern electrophysiological 
techniques and the identification and study of the 
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P5039 THE MONITORING OF LOW MOLECULAR WEIGHT (LMW) HEPARINS 
IN THE CLINICAL, CHEMISTRY LABORATORY 
E voung 
Department 0/ Laboratory Medicine. Henderson General Hospital and Department 0/ 
Pathology, McMaster Uni'lersity, Hamillon, Ontario, Canada. 
Studies have shown that LMW , heparin may be at least as effective as 
unCractionated ' heparin in preventing post-operative thrombosis with perhaps Cewer 
side eCC ects such as bleeding. Almost a dozen LMW heparins have been developed 
and many have undergone clinical trials. Once licensed Cor clinical use, the 
clinical chemistry laboratory may be faced with the task of monitoring these LMW 
heparins. Coagulant assays (such as APTT and Thrombin Time) are largely 
insensitive to these LMW heparins. To meet the anticipated demands of large- .. 
scale monitoring oC patients on LMW heparin therapy, an automated, amidolytic 
assay based on the detection oC anti-Xa activity is essential. For this purpose, 
an assay employing a chromogenic substrate(Spectrozyme FXa, American i: 
Diagnostica), bovine FXa (piagnostica Stago) and antithrombin III from pooled ~~ 
platelet-poor plasma has been developed for the Roche Cob as Bio centrifugal ,,~ lii 
analyzer. The assay is reproducible (intra- and interassay assay CVs of 3.8 and ;11 
6.5% respectively at the level of 0.2 units/mL) and cost-effective. The assay iil 
range is 0.05-0.4 units/mL which is suitable for monitoring the low levels of LM\\' 'j! 
heparins advocated for clinical use. 11 
ill 
ill 
PS040 EFFECT OF STORAGE ON PLASMA POTASSIU~f CONCENTRATION 
A Y W Chan, E Chan and P Chin 
Department of Chemical Pathology, Prince 0/ Wales Hospital. Shatin. Hong Kong. 
It has been shown that plasma potassium concentration (K) will decrease if 
blood is stored at room temperature. This in vitro decrease was suggested to be 
due to an in vivo effect of insulin (Kalsheker & Hales, Eur. J. CHn. Invest. 
(1985) 15:113-120). In order to verify this we studied the effect of in vivo 
insulin secretion on the change in K in vitro. Oral glucose tolerance tests (75 
g) were performed in 10 subjects and blood was collected at 0, 30, 60, 90 and 120 
min. One aliquot of each bloQd sample was spun immediately after collection and 
another aliquot was stored at room temperature for 3 hr before centrifugation and 
analysis. Storage for 3 hr at room temperature caused a drop in K of O.19±O.Oi 
mmol/L. The decreases in K on storage for blood samples taken at 30, 60, 90 and 
120 ' min after oral glucose load (0.21 +0.08, O.l6±0.07, 0.19+0.08 and 0.21 ±O.09 
mmol/L respectively) were not significantly different from that seen Cor the 
sample taken at 0 time. These results suggest that the decrease in plasma K on 
storage is not related to insulin as previously suggested and the possible 











HUMAN PLATELET HA-It ATPAS;E ~CTIVITY IN HYPERTHYROIDISM. 
Shinde R.,· Chan . A.Y.W ., ·Chow C.C. 
"Departments of Chemical Pathology & *Medicine, The Chinese University 
of H9ng Kong, Hong Kong. . 
Diagnosis of hyperthyroidism usually requires measurement of one 
or more thyroid-related hormones ie. thyroxine (total or free), tri-
iodothyronine (total or free) and sensitive thyrotropin. However, each 
has its shortcomings. Various tissue markers have been used but they 
are either non-specific or labour intensive or both. It is well 
documented that red cell and white cell Na-K ATPase are altered in 
hyperthyroidism. However there is considerable overlap \!)etween 
hyperthyroid and euthyroid groups. As far as we know, platelet Na-
K ATPase hasn't been studied in thyroid disorders~ We therefore ' 
examined platelet Na-K ATPase activity in (1) healthy volunteers, (2) 
thyrotoxic patients and (3) thyrotoxic patients in remission. Platelets 
were harvested from Sml blood and treated with saponin before 
measurement of Na-K ATPase activity by the method of Baron & Khan 
(1985). There was no difference in platelet ATPase activity (mean ~ SD) 
between control (167.6 + 33.1, }lmol of Pi/h/g of protein, n=9) and 
thyrotoxic patients in remission (172.4 .:. 60.3, n=21). In thyrotoxic 
patients the activity was significantly increased (386.3 ~ 160.3, n=31, 
p<O.OOl) and there was clear difference in platelet Na-K ATPase 
between subjects with and without hyperthyroidism. It is therefore 
an effective tissue marker of hyperthyroidism. Further" studies are in 
prog:-f.'ss to define its r.lin.ical value. 
Progress in Thyroid Research, Gordon, Gross & Hennemann(eds)C 19918a/kema, Rotterdam./SBN9054100281 
Human platelet Na-K ATPase in hyperthyroidism: A preliminary study 
R.Shinde, A.Y.W.Chan & R.Swaminathan 
D~parrment o/Ch~mical Pathology. The Chinese Univ~r.sity 0/ Hong Kong 
C.S.Cockram 
D~parrm~nt 0/ M~d;cine, The Chinese University 0/ Hong Kong 
INTRODUCTIbN 
Diagnosis of hyperthyroidism usually requires measurement of one or more 
thyroid-related hormones ie. thyroxine (total or free), tri-iodothyronine (total 
or free) and sensitive thyrotropin. However, each of these tests has its 
shortcomings. Various tissue markers have been used in the diagnosis of 
hyperthyroidism but they are either non-specific or labour intensive or both (1). 
It is well documented that red cell and white cell Na-K ATPase are altered in 
hyperthyroidism. However there is considerable overlap between hyperthyroid 
and euthyroid groups (2,3). Recently Turaihi et al. have used platelets as a model 
to study Na-K ATPase (4). Platelet Na-K ATPase has not been studied in thyroid 
disorders and it is a potentially useful tissue marker of hyperthyroidism for 
routine use because the measurement of platelet Na-K ATPase requires a small . 
volume of blood and some of the steps can be automated. In this study we have 
measured platelet Na-K ATPase activity in subjects with and without 
hyperthyroidism and assessed its performance as a diagnostic test. 
METHODS 
Platelet Na-K ATPase activity was measured in the following groups of subjects. 
(i) 34 healthy individuals (17 male and 17 female) (age 18-66 years), none of 
whom had any known illness or were taking any medication. 
(ii) 34 treated thyrotoxic patients (7 male and 22 female) attending the 
thyroid clinic (age 21-69 years) who had been treated for hyperthyroidism 
with antithyroid drugs and at the time of the study were clinically 
euthyroid. . 
(iii) 89 thyrotoxic patients (36 male and 53 female) (age 15-69 years) attending 
the thyroid clinic who had clinical and biochemical evidence of 
hyperthyroidism at the time of the study. 
In all subjects blood s amples were taken in the morning, at least 3-4 h after the 
last meal or after an overnight fast, into trisodium citrate (9 ml of blood to 1 ml 
of citrate) and heparinised tubes. Citrated blood was used for platelet studies 
and plasma from heparinised blood was used for the measurement of thyroid 
hormones and TSH. 
Platelet rich plasma (PRP) was prepared as described by Turaihi et al. (4). The 
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citrated blood was centrifuged at 160 'x g for 15 min at :room temperature. 
Contamination of PRP with erythrocytes and leucocytes was minimal. They 
accounted for < 0.5% of the platelet count. Na-K ~TPase was measured with a 
method based on the rate of release of phosphate by hydrolysis of ATP in the 
presence and absence of ouabain as described by Baron and Khan (5). The PRP 
was centrifuged and the platelet pellet was washed twice with magnesium 
chloride to remov~ any trapped plasma. The platelets were then lysed by 
freezing and thawing followed by the addition of saponin solution (0.05% w/v). 
An aliquot of platelet lysate (0.1 ml) was then incubated with 0.1 ml of incubation 
medium containing the following final concentrations in mmoliL: Na 100, K 15, ATP 
5, Mg 7, EDTA 1, Tris-HCl buffer 50 (pH 7.2 at 3~C) in each of 4 tubes. Ouabain at 
a final concentration of 1 mmol/L was added to two of these tubes. All tubes 
were incubated for 60 min at 3-roC in a shaking water bath and the reaction was 
stopped by the addition of trichloroacetic acid (10% w/v). The' tubes were then 
centrifuged and the phosphate content of the supernatant determined by an 
automated method based on that described by Daly and Ertinghausen (6). The 
precision of the platelet Na-K ATPase, as determined by duplicate analysis was 
8.2% (n=14). 
Plasma TSH was measured by a immunochemiluminometric assay (Ciba Corning, 
USA) with a detection limit of 0.02 mUlL. Plasma FT3 and FT4 were determined by 
commercial immunoassay kits ('Amerlex-M', Amersham Co, USA for FT3 and 
'Gammacoat' two-step assay, Baxter, MA, USA for FT 4). The analytical coefficients 
ATPase activity sTSH Free T 4 Free T 3 350 . . 3 45 45 
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r'. 
of variation of the methods were 6.4%, 4.8% and 7.5% for TSH, FTJ and FT4 
respectively. 
Differences between groups were compared by both the Student t-test and the 
Mann-Whitney U test and a p value ( 0.05 by both tests was considered 
significant. 
RESULTS 
Platelet ATPase and thyroid hormone results are summarised in Fig 1. Platelet 
Na-K ATPase activity was not different between males and females. It was 
significantly higher in thyrotoxic patients (mean.!. SE, llmol Pith/kg protein) (300 
! 13.3) compared to healthy subjects (131 .!. 6.0, P < 0.001) and treated thyrotoxic 
. patients (155 .!. 7.1, P < 0.001). There was also significant difference between 
healthy subjects and treated thyrotoxic patients (p < 0.02). There was a good 
correlation between platelet Na-K ATPase and free T4 (r = 0.696) and free T3 (r = 
0.706). Using cut-off value of 200 the specificity and sensitivity of platelet Na-K 
ATPase in detecting hyperthyroidism were found to be 90.4% and 87.6% 
respectively. The positive predictive value was 92%. 
DISCUSSION 
To the best of our knowledge, this is the first reported study of platelet Na-K 
ATPase in thyroid disease. It is an attractive tissue marker of hyperthyroidism 
because it demonstrates a clear difference between subjects with and without 
hyperthyroidism, and has high specificity, sensitivity and predictive value. It 
may be suitable for routine use because of the simplicity of assay proc~dure and 
the small sample volume required. 
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121 :\EUTROPtlILS U~CERC01~G APOP'TOSIS ARE 
I~GE.ST£O BY MES"NCr"lCELl.S:" RECl,;UTEO MEClI. 
A:-;IS~l fOR ~El.'TROPtJll. Cl.L\R,\~CE FRO~l GlO~1ERUlL 
J. SA YIU lnd Y. RE."4. Ocplnmcnl o( ~!(dicinc. ROYll PosII:J'=1du2te 
MC'dicll xhool. London WI: ONN. 
Ncucrophils (P~l~) medi;.ale tiuue injury in ;lomcruloMpftri~s (G~). 
but mn:h:anism~ by whic:h P~!N lfC clcltcd (rom ,Iomcruh. prom· 
oon; r~lueion r:1lftcr ltun pc:nislcnc:c o( G;-.l. ~ve b(cn obscure. Al 
inO;amc"d lien rnxroptu~cs (Mo) in;nllnUCI scnc3Ccnl P~tNs undc:t· 
COln~ l~"'il in l n=nnc likely to limit the :DXle poccnlllJ of P~tNs 
U.C:ln.lnvc'l. l'JK\): lOo ~(,5)' In G~. JOOOIOUC: P\I~ It'C scen In (he 
mC).Jn~lum (Hi~IOD;un. JlJ!(:i: 12. 6i
'
J). Wc now rej)on Ihll in 
lddlllon 10 Ine Infhmm:1lory \10. thc ;Iomcrullt mcs.ln~l~ cell (:-'1C). 
:a ccn~\le ... hl\:!1 plJvs,J major role In ~Iomcrullt SC':Unn¥ In pcrslslcnl 
(iN. t:in llso in;c1t 'lpoptOUC: P~t~s. 
lIurNn ~'C ... ne prc~rccJ by " 10 6 scrill ~s~;cs of ldherenl . 
JI~lll OUI~wth ,clls in mccJium ... ·uh U)'l hct·U\XU~cd (~"t21 
~I( ~rum (FCS). ~nd MC ph~noe~pc confirmed by sund~ 
~thn~h ,\(tl:r inl~I&..Ift .. ·jlh :Jt\.J,aJ IJ~I:-; r~ jh in \he prncnc:c 
of ur, fCS. P~I~ (dct~tcd by sainin1 (ot myclQ9C1OllUbsc ·MPO) 
~f't'C'=Irnt 10 tuvc bc'en in~ntcd by ~IC monol;~ in ~~ wcll pl:uc:s. 
~~0I."\1mls ... -a COftlirmcd b~ clC1:tron mtCTOSCopy. lnd I.fu~nu(icd 
~ ml\~o.,y o( ~tPn $&:lIned cy10preps o( 1 sin;le<cU SUSpc1tSlOn 
o( ~IC pr~lred h~ Iryp'lnl~1l0n 0(, (leh ... ·cll: J l.j: I.Je:\ 
(~n--SE. ".~:, ot \lC c:ont:1lncd P'I:": :nlC:':C:lon wllh rre~hl~ 
i~lltcd P'I~ Ylclded onlv :"~~.l':i POSllvC \IC (n-ft), The ~ o( 
~IC :,JI.,n\! uo Jl!cO P\I~ was clo\Ctv ~C'lrTCll'cd to ~P\1N ~POOt05IS 
(r.,'')fII. ";:J<tJ.oiXJI. ,...,7) when 'l!:etJ P\I:'1l POoullllons wcrc 
~~:lnled t)v ccnmfut;ll ctum;Ulon InlO (~CtlO"S wllft v:ar'V'n~ 
lpucnn"s (11.1 to 7t).J~). \IC IoIPI:lIC ~I ~~cQ P'I~ wu Cnhlnea2 
tw ,<,nln,: n'~. tJ.l er. 1 ~ md ",,-, fCS prescnl In the inecrxllon 
.ielcJed f'd!tU. I :.J~.J. :7"'~J.b lnu ~.~1.0 C\ .ve ~IC 
~~tl\·clv. In tne "re'cn~c of Ilrc FCS. "reln~uolllon o( \IC ... uh 
LPS Inr fIIh mnUe~'h· cnh:ln~cd l;CcJ P\l~ uPlll.;C: O. 1. IU Jnd 
llX)n\!lml ~LlccJ LPS )' Iclu~u )fd:1.~. -'1.1:J.U. '0.'\:1.u lnd 
""J.l::'~. I ~~ .,·c \IC rc)pc\:\tvcl!i . Prcln,,·ublllnn of \IC. In lhe 
lb~n~c o. FCS. wuh lL·IO le IOnwml for fIIh cntunccd Su)cquc:nl 
inlcrxunn In Ihe pre",,,"":c n( tnr.FCS un :J . J:1.?~,. .ve ~IC. cl 
,,'Onlf"1 of It..1! 1.)('1 t. whllc iCF·, Je IUp.\! inhlhll~cJ ~u~SC\4ucnl 
inlCr:1l.'IUn lIO fII.~J.'J't .vc \ICl. '. 
Thu. the~ \bu in&Ji~:.ale Ift:.al ,he ~n~i:d ,,"cll is C':2~Jble o( re;ul;,ae~-d 
.:tClf"J~C' oi 'Cf1C"Ct:n1 P~I~ undcf;um~ JC)OJttOSIs.. Cump:Jn)lon of 
Ihe nlln .and re~ul;Ulun u( mc!\.iln~l:ll ~clI ~nd inlbmm:uo'! ~t. 
,lar.l~~ ul P:\I~, Llurln~ the ","",IUIIM u,' GN i, nn~· n&:'C\JccJ. 
122 ,\ SPECIFIC ROLE FOR ~rL ,ROPUIL 
A('"v'\n~G PEmDE/I~,E;RlEL:~J~ :< (:"',\PI/Il..~) I~ 
l:U:I:R,\ nVE COLmS·~ 
y It ~IAHID'\. ~t CES~/V. F ~fF[:"'nlRr.E;R·. L 
Kt.:RL\K. I ll:"'CLE"1'·. C J II ,\W~E;Y . 
Oeo:mmenl n; Th~r~J'cutic'\' t.:nl,"cr'llv I r."pie~l. ~"I .. n~h;,am 
NG7 :t.:H. t.:K. ·S",ncJu~ Furchun.'I",l .. ul. A - I~.'i. Vicnn. 
A"'ln:a. 
ISTROOt.:cno~ Rel;,JhC in UI(Cf:Jti\c C1,lili, (h:Jr:2C1Cri~\J 
by ~ di((usc m ucm..;a I inlihf:2lC u( n~ulrllphil" hut thc 
RESCLTS MuaNI ~~ ,aI ~,\'I/1IJC were Npitlcntt, 
..ilher la ICIM uiccmivc CI"il~ (mcdbn 7~J Ir:ansc .7.7 _ 
.5WCl Palm., " • I:) lh:in in :aa~c Cr.,,,,,·s "i.cae OWl 
· I~.o - ..,..9) ",m~ " • Ill. P < IUIC) C1f nonn:aI camruh 
(IIU (~JJ - .' IUI Pl/mc: n • ,. p < I1CJC). C-&lcul:atinl 
!',\'I/IU wa CCncr.a'!r undct4:ct:ablc. bul lhere -cre hilher 
Ic\-cl~ .,1 ;nli - NA'I/IL. .. ;nll"udi~ in :actA'C Ukcr.aI~C CDlicis 
(t.l.9 I~ • .a - !.1"JJl nclmL n • :7) Ih;an in :M:l~. Cmhn", 
dhc~~ ,'.9 I~I - UUI nelm': n • ~I. P c IUIJI). 
in:acti,·c ulccr:a&ftc culilt- ,.a • ., I~ "~1 n • .). 
m~"Clbn.:nD w;,rrhuc:l! &Ji~:&.~ CL' I~.~ - Il.'1 n • ~). 
or nurnW c:aft,ruA~ (IL I p..: - ., .. 11 nl/ml: p C CUIJl. n • 
:7). 
COSCLl:SIOS The !I~(ili( ~~,a;,cilJn nf ~A'I/IU' .ith 
ulccr~Ii\'c colilii bul MC Crnhn'~ &Ji~:N ~"~IS ~ ~cifi( 
role in the ~thc"c~ nf ulccr:ni"e aJlili~ 
1%3 MA-,X-ATPASE AC:IVITY TKnOTOx:e 
PERIODIC PARALYSIS 
A CHAH, R SH:YC~. C C e~ow. c s e:CXRAH and R 
SilAl4I:fAnlAlf 
De~ar::lents 0: C~enu.e~~ P.t~o!oqy and Medie:...n •. 
Th. C~~n.s. UnlverSlt7 ot Konq Konq, Pr:...nc. ot 
Wa!es Koaplt£!. Sna:~,. HT, Kong Xonq 
In order to eX&m~ne v~.th.r sodium pu=p 
aC:ivs.ey plays a par: 1n the pat~oqenesls ot 
thyrOtoxle p.rlochc paralyslS (TPP) pl£telet 
Ma ,K·-A~Pase w.s 2.asured in h.altny subl.cts 
(n-l'). tnyrotox:..c sub lect wltnout paraiys IS 
(n.~5J and T?P patle"tS (n a 12). All TPP 
pat:..ents w.re studled att.r correctlon ot t~.lt 
hypokai.emla and betore treat2.nt Wlth 
antltnyrOld dru"~ ~~ ~-~!~.-~: ~ 




TPP pat lent 
(lNaft • Sat) 
- -
127 ! 9.1 
291 ! 41.0· 
521 ! 102.4··· 
• Slqnlficantly difterent from h •• lthy subl.C::s 
• Slqnlficantly difterent fro. thyrotoxiC 
patients 
'latel.t Ma-,X·-AT'a.e was .lqnlfic~ntly hlq~.r 
1ft tnyrotoxlC: patients wh.n c:o.pared to h.althy 
c:ontrol. (peO.001) and 1ft t.P patlents lt vas 
b19fter thAn 1ft och.r thyrotoxiC: ,atlents (peO.Ol). v. c:onc:lud. that Na-,X -ATPas. 
ac:tlvlty aay be r •• ponsi!:)l. for tn. 
bypokala •• la ••• n 1ft T". 
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In vivo and in vitro sodium pump activity in subjects with 
thyrotoxic periodic paralysis 
A Chan, R Shinde, CC Chow, C S Cockram, R Swaminathan 
Abstract 
Objecriw-To eumiDe wbether sodium pump 
activity plays a part iD the pathogeDesis of thyrotoxic 
periodic paralysis. 
Dai".-Measuremnt of platelet sodium-potassium 
ATPase and iD vivo sodiUm pump activities iD 
healthy subjects ad thyrotODC subjects with and 
without paralysis. 
S.ttin,...,UDiversity bospital iD HODI KODI. 
SlIbj.cu-21 healthy subjects, 23 UDtreated 
thyrotoxic subjects, 13 untreated meD with periodic 
paralysis, seveD treated thyrotoxic subjects, aDd lis 
treated meD with periodic paralysis. 
Main OUICt1f'M rtWCU1Ir.s-P!atelet Na+, K+· 
ATPase activity and plasma rubidium CODceDtratioD 
after oralloadinl. 
R.slIlu-MediaD (rule) platelet Na+, K+-
ATPase activity iD thyrotoxic subjects was 253 (169-
821) ~ol iDorpDic phosphatelhll proteiD-
sipificantiy higher than that1D healthy subjects (134 
(81-ISO) ~ollbll proteiD; p<O·OOI). Na+, K+· 
ATPase activity iD those with periodic paralysis was 
374 (195-1196) ~ollbll proteiD, apiD sipificantiy 
b.i&ber than that iD healthy subj~ (p<O·OOI) ~d 
that iD other thyrotoxic subjects (p<0'01) despite 
similar degrees of hyperthyroidism. Activities iD 
treated thyrotoxic subjects with and without periodic 
paralysis were 148 (110-234) and 131 (86-173) JUDoU 
biC proteiD respectively. Mean (95% coDfideDce 
iaterval) plasma rubidium cODceDtratioD five hours 
after onladministratioD iD thyrotoxic subjects (7·0 
(6-6 to 7·S) JUIIoUl) was sipificantiy lower tIwa iD 
healthy subjects (10·2 (9·5 to 10·9) JUDoUl; p<O·OOl) 
aDd hi&ber than iD those with periodic paralysis (6·0 
(5·7 to 6·3) JUIIoUl; p<O·Ol}. 
Conclauions-Sodium pump activity iD UDtrcated 
subjects with periodic paralysis is higher than iD 
other thyrotoxic subjects, aDd this may be respons-
ible for the hypokalaemia. 
IDtroductiOD 
Hypokalaemic periodic paralysis, in association with 
thyrotoxicosis, occun almost exclusively in orienl31 
men·" and has been reponed to occur in 13·26~ of 
thyrotoxic Chinese men." It is about 70 times more 
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common in men then womcn. l The paralysis usually 
follows ingestion of a carbohydrate meal, heavy exer-
cise, or both.· The paralysis lasts for a shon time and is 
occasionally associated with life threatening complica-
tions such as c:ardix arrest or respiratory failure.' 
Com:ction of hypokalaemia reverses the acute at.W=k 
and subsequeJn treatment with ~ blocken or anti-
thyroid drup effectively preveuafurthcr attacks.· 
Thyrotoxic periodic paralysis ha been suaested to 
be geDCtic:ally determined as its inc:ideuce is strikingly 
high ~ong orieuta1s' and it can be familial.' Funher-
more, a higher prevalence of the haplotype Al, B22 in 
patients with periodic paralysis has been reponed,' 
although this has Dot been confirmed by others.' 
The pathogenesis of periodic paralysis is not fully 
undentood. The associated hypokalaemia is believed 
to be due to a rapid influx of powsium into cells,.· 11 as 
in the familial type. An imPONDt factor in the 
transpon of potassium into cells is the sodium pump 
sodium-potassium ATPase (Na+, K·-ATPase, EC 
3.6.1.3). The sodium pump is known to be affected by 
thyroid status. The number and activity of sodium 
pumps in musclell and white cellsllll• are inCl'e2Sed in 
patients with thyrotoxicosis. In experimental animals 
given triiodothyromneJ' It or in cells cultured in vitro in 
the presence of triiodothyronine17 I. Na + , K'" -ATPase 
activity is stimulated. The increased entry of potas-
sium into cells in patients with periodic paralysis may 
result .from increased Na+, K+ -ATPase activity. In 
this study we tested this hypothesis by measuring the 
platelet Na +, K + ·A TPase activity in vitro together 
with in vivo assessment of sodium pump activity. 
Subjects and methods 
We studied five groups of subjects: healthy subjects 
who had no known illness and denied taking any drugs; 
thyrotoxic subjects who were not receiving treatment 
and who had raised plasma concentrations of free 
triiodothyronine and thyroxine and lowered thyroid 
stimulating honnone concentration at the time of the 
study; thyrotoxic subjects receiving treatment who had 
clinically and biochemically nonnal thyroid function; 
thyrotoxic subjects with periodic paralysis who were 
admitted to hospitai with weakness or paralysis and 
studied within 48 hours of admission after correction of 
plasma potassium concenlr:uion and muscle weakness 
but before staning treatment with ~ blockers or 
antithyroid drugs, or both; and . six subjects who had 
had episodes of periodic paralysis and who were 
receiving treatment and had clinically nonnal thyroid 
function at the time of study. 
All studies were carried out with the full informed 
consent of those concerned and the study was 
approved by the ethics committee of the Chinese 
University of Hong Kong. 
PLATELET NA +, 1C+ -ATPASE ACTIViTY 
The Na +, K + ·A TPase activity in platelets was 
studied in all five groups of subjects: IS healthy men, 
IS unueated thyrotoxic men, seven ueated thyrotoxic 
men, 12 untreated men with periodic paralysis, and six 
treated men with periodic paralysis. Blood sampleS 
were taken from all subjects in the morning, at least 
three hours after the last meal or after an overnight fast. 
The samples were taken into trisodium citrate (9 mJ of 
blood to 1 mJ of citrate) and heparinised tubes. utrated 
blood was used for platelet studies, and plasma from 
heparinised blood was used for the measurement of 
electrolyte, creatinine, thyroid honnone, and thyroid 
stimulating honnone concentrations. 
Platelet rich plasma was prepared as described by 
Turaihi er al. I' The citrated blood was centrifuged at 
160 g for 15 minutes at room temperature. Contami-
~tion of the plasma with erythrocytes and leucocytes 
2 NOVEMBER 1991 
was minimal, accounting for <0·5% of the platelet 
COUDt. Na +, K • -ATPase activity was measured by a 
method based on the rate of release of phosphate by 
hydrolysis of A TP in the presence and absence of 
ouabain.· The platelet rich plasma was centrifuged 
aDd the platelet peIlct was washed twice with magDCSium 
chloride to remove any trapped plasma. The platelets 
were thea lysed by freezing and thawing and thea 
adding saponin solution (0·05% wcighrlvolumc). An 
aliquot of platelet lysate (0·1 ml) was added to each of 
six tubes and incubated with 0·1 ml of incubatioa 
medium containing (final concentratioa) sodium 
100 mmolll, potassium 15 mmolll, ATP 5 mmolll 
magnesium 7 mmolll, EDTA 1 mmolll, TRIS-Hci 
buffer 50 mmolll (pH 7·2 at 3T'C). Ouabain at a final 
concentration of 1 mmolll was added to two of these 
tubes. All tubes were incubated for 60 minutes at 3T'C 
in a shaking water bath and the reaction was stopped by 
adding trichloroacetic acid (10% weighrlvolwne). The 
tubes wen: then centrifuged and the phosphate content 
of the supernatant was determined by an automated 
method based on that described by DaJy and 
Ertinghausen.:1 The precision of the assay, as deter-
mined by duplicate analysis, was 8-20/0 (n= 14). 
IN VIVO SODIUM PUMP ACTIVITY 
In vivo sodium pump activity was measured in six 
healthy subjects (three men and three women aged 
26-43 years), eight unueated thyrotoxic subjects 
(two men and six women aged 17-51 years), and seven 
untreated · subjects with periodic paralysis (all men, 
aged 22 -W years). 
In vivo sodium pump activity was assessed by 
measuring the changes in plasma rubidium concen-
tration after an oral dose of rubidium chloride.zz 
Rubidium chloride (8 mglkg body weight) was dis-
solved in water mixed with orange squash and given in 
eight divided doses at IS minute intervals. Venous 
blood samples were taken before and one and five 
hours after the last dose of rubidium chloride. The 
blood samples were centrifuged and the plasma was 
separated and stored at -200C until analysis. 
The plasma rubidium concentration was measured 
in a graphite furnace atomic absorption spectrophoto-
meter (model AA·1475, Varian Techtron •• \tulgrave, 
Australia) by the standard addition method.:1 Plasma 
samples were diluted with distilled water (one in 20), 
and the peak absorption was measured. In idcntiCll 
samples different amounts of aqueous standards of 
rubidium chloride were added and peak absorption 
was measured again. The peak absorption was plotted 
against the concentration of the added standard and the 
concentration of rubidium in the plasma was deter· 
mined from the intercept on the x axis_ The precision 
(coefficient of variation) of the method at a mean 
plasma rubidium concentration of 5-5 VJDolll was 
5·3%. All samples in the study were analysed in ODe 
batch. 
Plasma concentrations of thyroid stimulating 
honnone were measured by an immunochemilumino-
metric assay (uba Coming, United States) with a 
detection lirnit of 0-02 UIl. Plasma free triiodothyronine 
and thyroxine concentrations were determined 
by commercial immunoassay kits (Amerlcx-M, 
Amersham, United States, for triiodothyromne, and 
Gammacoat two step assay, Baxter, Massachussetts, 
United States, for thyroxine). The analytical co-
efficient of variations of the methods were 6·4%, 
4-8%, and 7-5% for thyroid stimulating hormone, 
triiodothyronine, and thyroxine respectively. 
Differences between groups were compared by 
Student's r test for all parameters except platelet Na + , 
K + -ATPase activity, for which the Mann-Whitney U 
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PlATELET HA + , Jt + -ATPASE ACTIVITY 
Table I shows the • aad plasma COOa:nuabons of 
fia: triiodothyroaioe IDd thyroxine in the unaated 
.,.tic:Da with periodic panlysis. Table II summarises 
the resWa iD the five POUpl of subja:a snadied. 
Plasma coaa:Dtraboas of aiiodothyroaiDc IDd 
tbyroziDc were raised - aod thyroid aimulatiq 
bormoac CODa:Duaboas were SUWi I e et iD all 
UDuatcd thyrocozic subjec:ll with aDd without 
pualysis. McdW1 (9S% ma6dmce iDtenal) plasma 
CODa:DU2boas of free triiodothyroai.ac (19-6 (IS·1 to 
24-1) pmol/l) and free thyroziDe (4S·S (38-4 to S2-6) 
_ pmol/l) iD the unaated subjects with periodic 
paralysis were DOt significantly difi'crmt from those of 
the thyrotoxic subjects without paralysis (t2ble 11). 
Platelet N.+, K+ -ATPase activity iD thyrotoxic sub-
jects (median (range) 2S3 (169-821) JUDOlIbIg protein) 
was signifiontly higher (p<0-00 1) than that iD healthy 
subjects (134 (81-180) J.LIDOllblg protein). In the 12 
subiccts with periodic paralysis the platelet Na + , K + -
ATPase activity (374 (19S-1196) JUDoVblg protein) 
was higher than that in healthy subjects (p<0·001) 
and that in other thyrotoxic subjects (p<0-0 1). In 
treated thyrotoxic subjects mna:ntr.ltioDS of free 
triiodothyrooine and thyroxine and platelet Na + , K + -
ATPase activity were lower tlwl in unueated subjects. 
However, platelet Na + , K + -ATPase activity was still 
significantly higher than that found in healthy controls 
(p<0-01). In subjects with treated periodic paralysis 
the platelet Na + , K + -ATPase activity was not different 
from that ofhCllthy subjects (table 11)_ 
IN VIVO SODIUM PUMP AC11VlTY 
Plasma thyroid stimulating hormone and free 
triiodothyronine and thyroxine concentrations in the 
healthy subjects and thyrotoxic subjects with and 
without paralysis in whom in viv() sodium pump 
activity was measured were similar to those in tables I 
and n. The figure shows the plasma rubidium concen-
trations at one and five hours after the oral dose in the 
lD Yn'O lOdium F~ 
A~ pump ICtIYIry truodolhyroGlDC F .. thyroDDC 
Sub;a:t (}an) IDCUIII'Cd - (pIDOUl)t tpmoIIIn 
I 26 Yes 20·6 
2 49 Yes 16-1 44·0 
-3 22 Yes 16·4 
4 31 Yes 11-0 37-7 
S 20 Yes 12-4 42·S 
6 39 Yes 26·7 
1 40 No 11-1 56·4 
• 31 No 9·0 26-0 9 22 No 31-2 55·3 
10 .39 No 22·9 s.4·4 
11 32 No }4·S SS· 3 
12 39 No 16·4 36·7 
13 26 No 21 ·S 
A1IIUb;ccu baj pAasma thynJid 1limu1aUq barmoDc C'OIKaltnUoaa <0-02 
mUll. 
·pwdct Na •• Ie.. -A TPac aamty ... masurai iD ad bullUbicct 13. 
tRdcrmcc ,....1· W · 2 pmoUl. 
*-Rdcrmcc tuIIC 1 -~21-5 pmoUl. 
~ groups of subj~. The mean (9S% confidence 
mterVal) plasma rubadium COnceDtr.ltioll at five houn 
~ ~yrotozjc subjects (7·0 (6-6 to 7·S) J1DlOlIl) was 
ugntfY:ilDrly lower than that in healthy subjects (10.2 
(9-~ ~ 10-9) I:'ID0I/I, p<O·OOI). In subjects with 
periodic paraJysas the five hour conCCDtr.lUon (6-0 (S.7 
to 6· 3) pmolll) was significantly lower than that in the 
thyrotoxic group (p<0-0 1). ne plasma rubidium 
cona:ntr.ltion at ODe hour also showed a similar picture 
(17·0 (14·9 to ~9-2), 11·4 (10·9 to 11·9), 10·4 (9·7 to 
11· 2) pmolll m healthy, thyrotoxic, and periodic 
panlysis groups, respectively). 
Disc:usaioa 
. Our resW!, ~ow that. Na +, K + .~ TPase activity 
m platelets as incn:ascd ID thyrotoXlC subjects with 
or without periodic paralysis. Increased numben 
of sodium pumps, increased pump activity, and 
increased Na+, K+ -ATPase activity have been shown 
in lymphocytes) and in a mixed leucocyte prepar:nionu 
from thyrotoxic subjects. Increased ouabain binding 
capacity has also been shown in human skeletal muscle 
in hyperthyroidism. IJ The similarity between the 
changes in plateletS and nucle:ued cells such as leuco-
cytes and muscle cells in hyperthyroidism suggests that 
platelet Na" , K + -ATPase activity reflects that occur-
ring in other tissues. The use of platelets is advant-
ageous as the preparation is less tedious and requires a 
smaller volume of blood than is needed with leuco-
cytes. 
In a mixed leucocyte prepar:ation Na" , K" ·A TPase 
activity has been reported to be 22% higher in patients 
with hyperthyroidism. U In our study platelet Na·, 
K . -ATPase activity iD hyperthyroid subjects was 
nearly double that of healthy subjects. Thus platelet 
Na·, KO-ATPase may be a useful tissue marker of 
thyroid SUtus. 
The ideal tissue in which to study periodic paralysis 
is skeletal muscle_ However, muscle biopsy is invasive 
and platelets provide a readily accessible alternative. 
We found that the platelet Na", K+ -ATPase activity 
in untreated subjects with periodic paralysis was 80% 
higher than that in other untreated thyrotoxic subjects 
despite similar degrees of hyperthyroidism. In 
lymphocytes Oh er al were unable to show a significant 
increase in sodium pump mediated rubidium influx in 
patients with periodic paralysis. although they su~· 
gested that ouabain binding sites may be increased. \ 
Other workers have studied erythrocytes to investigate 
periodic paraJysis. 7 :. However, erythrocytes behave 
differently from other cells in thyroid disease'· non and 
are not a suitable cell type to study this condition. 
To verify that platelet Na", K + ·ATPase activity 
measured in vitro reflects the sodium pump activity in 
-vivo, we assessed the in vivo sodium pump activity. 
Rubidium is tr:msported into cells by the sodium 
pump and the transport characteristics of rubidium 
and potasSium are similar. lI The disappearance of 
rubidium from extncellular fluid therefore depends 
largely on the sodium pump activity, and the plasma 
UDU'aCed Traced 
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concentration of rubidium is inversely related to the 
sodium PUQ1P activity. 5keieta! muscle is the largest 
single tissue in the body. Thus it is likely that the 
plasma rubidium concentration minon skeletal 
muscle sodium pump activity. The lower plasma 
concentration of rubidium at onc and five houn after 
ID oral load in untreated thyrotoxic subjects shows that 
the sodium pump activity is iDc:reased. and this 
confirms results from in vitro stUdies in muscle and 
Ieucocytes.I'1I In untreated subjects with periodic 
paralysis the plasma rubidium concentration was 
lower, and thus the activity of the sodium pump higher 
than in thyrotoxic subjects without paralysis. This 
suppons our data from platelets. The observed differ-
ences in plasma rubidium concentration between 
groups could also be due to reduced absorption of 
rubidium or enhanced c:1earancc by the kidney. How-
ever, renal clearance of rubidium is slow and the ba1C 
life is between 20 and SO days.1t Thus it is u.nli.kdy that 
the observed differences are due to renal clearance. 
Rubidium is handled like potassium and it is unJ.ikely 
"" that reduced absorption would have contributed to the 
observed changes. These results therefore indicate that 
higher Na+, K+-ATPase activity is a feature of 
thyrotoxic periodic paraalysis and that this enhanced . 
activity may be responsible for the hypokalaemia seen 
in these patients. 
In treated subjects with periodic paralysis the 
platelet Na", K'" -ATPase activity was similar to that 
found in healthy subjects, showing that the sodium 
pump activity returns to normal with treatment. Thus 
the higher platelet Na", K'" -ATPase activity seen in 
subjects with periodic paralysis is likely to be due (0 
increased sensitivity to thyroid honnones and is 
demonstrable ooly in the presence ofhypenhyroidism. 
We conclude that platelet Na'" , K'" -ATPase activity 
and in vivo sodium pump activity are increased in 
thyrotoxicosis. These findings agree with those in 
other tissues in vitro, although the size of the change is 
greater in platelets than has been reponed in leuco-
c:ytes. In subjects with periodic paralysis both platelet 
activity and in vivo sodium pump activity are increased 
to a greater degree than those in other thyrotoxic 
subjects despite similar increases in thyroid honnone 
concentrations. The difference berween the rwo 
groups disappears wb~n a euthyroid state is restored 
with treatment. 
We thank the volunteers for taking pan in the study, .'tiiss 
Kate Wang for technical help, and .'tiiss Begonia ¥uen for 
typing the manuscript. This study was panly supponed bY:1 
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Effectiveness of Sodium Auoride as a Preservative of Glucose in Blood 
A.Y.W. Chan. R. SwamAnathan, and C. S. Cocktam' 
How effective is sodium fluoride as a preservative of blood 
glucose? We compared changes in glucose concentration in 
fluoride-treated blood specimens with those of heparin-treat-
ed specimens. The former declined rapidly during the first 
hour; thereafter the rate of decrease was slower, and after 4 
h the glucose concentration in the blood samples remained 
stable for up to three days. In contrast, the glucose concen-
tration in the heparin-containing samples declined continu-
ously. During the fir:~t hour, however, the rates of decline in 
the two types of samples were similar. Evidently sodium 
fluoride takes effect slowly but effectively in preserving glu-
cose in blood for at least three days. Its use, however, is 
unnecessary if the concentration of glucose is to be mea-
sured within the first hour after sampling. 
'The glucose concentration in unpreserved blood samples 
decreases rapidly at room temperature, largely because of 
glycolysis (1-3). Various procedures can be used to preserve 
glucose in blood. but each has its own shortcomings (1, 4). 
Nevertheless. the usual practice is to use chemical preserva-
tives such as sodium fluoride (NaF) or sodium iodoacetate. 
NaF, the most widely used (5), is reportedly the best 
available preservative for glucose in blood (6). Nonetheless, 
opinions about its effectiveness differ. Some report that in 
blood samples treated with various amounts of fluoride, 
glucose concentrations remain stable at room temperature 
for up to 10 days (7-10); others report continued declines in 
blood glucose concentrations despite the presence of fluoride 
(2, 11. 12). These discrepanciesr:laY have resulted from the 
poor methods of glucose analysis used in the earlier studies 
(2, 13), 
Others have questioned the need for antiglycolytics for 
routine glucose analysis (14). For example, heparinized 
plasma gives identical values to fluoride-treated pl~~a if 
the heparinized plasma is separated from the cells WIthin 30 
to 60 min (4, 15>. 
Recently, Sanders and Deadman (16), using a fairly 
precise glucose analyzer, reported that NaF was able to 
preserve glucose in whole blood for 48 h. 'Their findings were 
promptly disputed (1 n. 
In view of the controversy and the inevitable delay in 
separation of plasma, we have studied in greater detail the 
changes in glucose concentration with time in blood samples 
with and without added NaF. 
Materials and Methods 
Blood was sampled from diabetic and non-diabetic sub-
jects into 1-mL screw-capped tubes (Sarstedt Ltd., Beau-
mont Ley, Leicester, U.K.) containing either NaF (product 
no. 41.1394.005) or heparin (product no. 41.1393.005t 
In all samples, glucose concentrations were detennined by 
a glucose oxidase method, in a Model 23AM glucose analyz-
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er (Yellow Springs Instrument Co., Yellow Springs, OHJ. 
Within-batch and between-batch CV s were < 1 %. All the 
analyses were performed by one operator. 
Venous blood from 19 adults was dispensed into fluoride-
containing tubes. Concentrations of glucose in whole blood 
were measured immediately and after 1, 2, 4, 24, 48, and 72 
, h. The specimens were thoroughly mixed by inversion 
immediately before each measurement. Blood samples from 
another 10 adults were each aliquoted into seven fluoride 
tubes. One aliquot from each subject was centrifuged imme-
diately and the others 1, 2, 4, 24, 48, and 72 h later. 
Immediately after centrifugation, we removed the plasma 
for measurement of glucose concentration. 
In another study. we obtained blood samples from 16 
adults and aliquoted these into pairs of tubes, one tube 
containing heparin and the other NaF. Whole-blood glucose 
was detennined immediately, then at 15-min intervals for 2 
h. and then after a further 2 h and 20 h. Blood samples from 
another 10 adults were each aliquoted into nine pairs of 
tubes, one set containirig heparin and the other set N aF. 
One pair of tubes was centrifuged immediately and succes-
sive pairs at 15-min intervals over the next 2 h before 
measurement of glucose in the plasma. 
All the specimens were kept at room temperature during 
these studies. 
Results and Discussion 
The stability of blood glucose in fluoride-containing tubes 
at room temperature for three days is shown in Table 1. 'The 
concentration of glucose declined with time. the main de-
crease occurring during the first hour. Thereafter the rate of 
decrease was slower, and after 4 h the blood glucose concen-
tration was stable. The pattern is similar to that reported by 
Side bottom et al. (4) and Nakashima et al. (12), although 
these authors examined the changes only during the first 
few hours. Our results show that. despite the initial drop, 
NaF can maintain blood glucose concentrations near their 
initial values for up to three days. 
'The changes in blood glucose concentration with and 
without NaF are shown and compared in Table 2 and Figure 
1. 'The pattern for whole blood was similar to that for 
plasma. During the first hour, the decrease of glucose in the 
Table 1. Changes In Glucose Concentration with TIme 










M •• n (~ SEM) glueo .. concentration, mmolll 
Whol. blood (n =- 19) Pluma (n • 10) 
7.58 :: 1.15- 9.19: 1.084» 
7.23 :: 1.14 8.83 :: 1.08 
7.12 :: 1.14 8.75:: 1.08 
7.06 :: 1.15 8.66 :: 1.07 
7.06 :: 1.15 8.65 : 1.06 
7.12 : 1.12 8.61 : 1.04 
7.11 ': 1.12 8.62: 1.05 
·Values ranged from 3.7 to 22.6 mmoVL at time O. 
ItValues ranged from 6.0 to 17.5 mmoVL at time O. 
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Table 2. Changea In Blood GIUCOM ConcentratIon Compered In Sample. Collected Into Fluortde-Contalnlng (F) 
and Heparln-Contalnlng (H) Tuba 
'nine ...... __ blood (n • 11) Plum. (n • 10) 
Ulllc .... , H , H 
..... (s. SEll) g.UCOM cDhCiubiltlon, mmo&II. 
o 8.59 ~ 1.21 
(3.7-22.8)· 
8.50 ~ 1.21 
e.41 ~ 1.21 
8.33 ~ 1.21 
8.30 ~ 1.21 
8.24 ~ 1.21 
8.21 ~ 1.21 
6.20 ~ 1.20 
8.18 ~ 1.20 
8.12 ~ 1.20 
8.11 ~ 1.20 
6.84 ~ 1.22 8.88 ~ 1.29 8.88 ~ 1.29 (3.7-22.7) (4.9-15.4) (4.9-15.4J 
8.75 = 1.28 
8.68 ~ 1.28 
8.62 = 1.28 
8.54 = 1.27 
8.48 :!: 1.26 
8.41 ~ 1.26 
8.39:!: 1.26 







8.56 ~ 1.22 8.71 ~ 1.29 
8.48 ~ 1.23 8.62 = 1.28 
8.39 ~ 1.23 8.58 = 1.28 
8.32 ~ 1.23 8.50 ~ 1.27 
6.20 ~ 1.23 8.51 ~ 1.28 





5.98 = 1.22 8.48 = 1.26 
5.85 ~ 1.20 8.48 = 1.27 
5.00 ~ 1.19 
1.86 ~ 1.02 
(0.0-14.7) 
• Range of values given In parentheseS. 
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Fig. 1. Representative changes in mean whole-blood glucose concentration with time in whole-blood (le", or plasma (righ~ samples kept in fluoride-
containing (I=) or heparin-containing (HI tubes . 
Data on indMduaI Samples are available from Ihe auIhors or Ihe ediIDnaI office of !his journal 
f1uoride-containing tubes paralleled that of the heparin-
containing tubes. After 1 h, the rate of decrease in the 
heparin-treated samples was much greater than in the 
fluoride-treated samp~es. 
We therefore conclude that NaF is slow but efrective in 
preserving blood glucose, having no e1I'ect in the first hour 
but slowing glycolysis considerably by the second hour, and 
more or less completely inhibiting it by the fourth hour. It is 
e1fective in preserving blood glucose for at least three days; 
however, for specimens assayed within 1 h after collection, 
NaF is not necessary. 
• 
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Effect of delay in separating plasma for glucose measurement 
upon the interpretation of oral glucose tolerance tests -
A Y W Chan*, C S Cockramt and R Swaminathan* 
From the Departments oJ·Chemical Pathology and t ~'rledicine, Chinese University of Hong Kong, Princt 
of Wales Hospital. Shatin, H",ng Kong 
Additional key phrases: b/ooJ glucose loss: 
, glycolysis with NaF,· misinterpretation of OGTT 
Blood specimens for glucose detennination 
should be processed immediately. However. 
some delay is usually unavoidable. Therefore it is 
usual to employ a preservative such as sodium 
ftuoride (NaF), to inhibit glycolysis. 
NaF is reportedly the best chemical preser-
vative.1 However. it has been shown that the 
blood glucose concentration dec1ines on average 
by approximately 0·5 mmol/L over a _ 2-4 h 
period. with the main decrease occurring during 
the first hour.:: Such decline may lead to errors in 
diagnosis. 
We have examined the effect of delayed 
measurement of glucose on the interpretation of 
. oral glucose tolerance tests (OGTTs). 
One hundred consecutive OGTIs (using a 75 g 
glucose dose) were studied. Blood samples were 
collected in commercial ftuoride tubes (Product 
No. 41.1,394.005 from Sarstedt Ltd. Beaumont 
Ley. Leicester. UK). Our nonnal practice is to 
TABLE 1. Giucose tolerance 
send all specimens (0. I and 2 h) in on~ batch to 
the laboratory. In our experience. it may take up 
to 4 h for the specimen to re:lch the laboratory 
vi:l the routine tr:lnsport service of the hospit:ll. 
Therefore the time interv:ll between collection of 
the blood sample and separation of plasma varies 
from 0 to 4 h for the '2 h specimen' and 2-6 for 
the '0 h specimen'. In ord~r to examine the effect 
of this delay an aliquot of all blood samples was 
centrifuged immediately and the plasma 
separated for glucose analysis. A second aliquot 
was sent to the tabor:ltory, :lccording to our 
normal practice. 
Thus. for each patient two se~s of OGTI 
results were obtained: OGTI result A from 
samples processed immediately and OGTI result 
B from samples measured routinely. These were 
then classified according to the revised World 
Health Organization' and the AmeriQn 
National Diabetes Data Group (NDDG)" 
criteri:l into normal. diabetes melIitus. impaired-
glucose rolerance and non-diagnostic. 
Blood glucose concentration (mmol, L) Classificatlon 
P:uient WHO NODG 
No. 0 l·h :h criteria cnteria 
A 5-6 11·1 ;·1 N NO 
B 5·0 10·3 6·4 ~ N 
2 A 6·2 11· 3 9·4 IGT IGT 
B 5·5 10·7 8·6 IGT NO 
3 A 7·3 12-0 10·0 lOT IGT 
B 6-5 10·6 8·3 IGT NO 
4 A S·7 10'5 7·8 IGT NO 
B 4·7 9· t 7·6 N N 
S A S·3 10·0 7·8 lOT lOT 
B 4·6 9·2 7·1 N ~ 
6 A 6·~ 13·7 8·S lOT lOT 
B 5·4 13·2 7-6 N NO 
7 A S·S 13·3 8·7 IGT IGT 
B 4·5 11·4 ; ·6 N- ~O 
N. nonnal; lOT. impaired glucose: tolC:r3nce; !'D. non-diagnostic. 
Correspondence: Or A Y W Chan. 
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Plasma glucose concentration wasme35ured 
by'a glucose oxidase: method using the 'Encore' 
centrirugal analyser (Baker Instruments Co. 
Allentown. USA) with a between-batch coeffic-
ient or variation not exceedinl 3· 7~ •• 
Ninety-three patients had concordant clas- · 
sifications irrespective or whether OOTI results 
A or B were used. In these 93 patients the me:ln 
(± SEM) difference in glucose concentration 
between the two sets or results were O' 7 ( ± 0.03). 
0·6 (± 0'05). O· 5 (± 0'06) mmol/L at O. I and 2 h. 
respectively. Seven patients by the NDDG 
criteria and rour patients by the WHO ·criteria 
had discordant classifications between results A 
and B (Table 1). The mean differences in blood 
glucose concentr:1tion in these seven patients 
were 0·8 (± 0·06). 0·9 (± 0'14) and 0·9 
(± 0·17)mmol/L at O. 1 and 2 h. respectively. 
Our results show that delay in processing 
blood specimens ror glucose determination in 
normal practice may le3d to misc1assific:ltion in 
up to 7% of OGTTs. In this series. no patient 
with diabetes mellitus was misclassified as im-
paired glucose tolerance. However. since com-
pleting the study. we have discovered two su~h 
patients. . 
We therefore conclude that marginal oon 
results should be interpreted with c:lution and the 
test repe:1ted. panicularly ir there was delay in 
sepal'3ting plasma rrom the cells. Delayed 
sepal'3tion is one cause of the lack of 
reproducibility or OGns and this is of par-
ticular importance in the context oi 
epidemiologiQl studies where single tests are 
often used. 
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TECHNICAL NOTE 
Handling of Blood Specimens for, Glucose A.nalysis 
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Summan: There is no consensus concentration of sodium tluor-
ide (Naf) required for preserving glucose in blood specimens. 
We e:t61mined the effectiveness of different concentr:ltions of 
NaF. Glucose concentl'3tion in blood SOlmples decreased with 
time. despile the presence of 61 high cOnCenlr:llion of NaF (12 
gl1). The decrease in glucose concentr:llion was less with in-
CfC61sing amounts of NaF but could not be totally abolished. 
The clinic:ll implications of these pre-analytic611 errors is dis-
cussed. 
Introduction 
Idolly me61Surement of glucose concentr:ltion in .blood speci-
mens should be perfonT\ed immediately after sampling. How-
ever. usually. some delay is unavoidable. It is well documented 
that. despite the addition of sodium fluoride (NaF). glucose 
concentrations in blood specimens decline significantly and 
rapidly (I - 3). This decrease may be cliniclly significant (4). 
We have recently shown that it may lead to the misc:lassific:ation 
of 7~/. of routine or611 glucose toler:lnce test results (5). 
Despite the widespre61d use of NaF. there is as yet no consensus 
concerning the ide611 concentr:ltion of NaF. Recommended con-
c:cntr:llions of NaF include 2 (6), 2.S (7), 4.3 (8). 6 (9. 10) and 
10 (11) 8/1 blood. 
We have recently shown that NaF is effective but slow in 
preserving glucose in blood specimens. At low concentr:ltion. 
NaF has no effect ~uring the first hour and it takes 4 h before 
the decline in glucose stops (3). 
We have therefore studied the effectiveness of NaF 3t different 
concentr3tions. in the hope that at higher concentrations NaF 
m3Y act much faster and therefore minimiscthe d«line in 
glucose concentration in blood specimens. 
J. Clin. Chcm. Clin. Bioc:hcm. V ul. ~~. 19'J0 No. 3 
~Iateri:d and ~Ielhods 
All blood glucose conc:cnlr:ltions were determined by 3 glucose 
oxidase method in a YSI Model 23 AM glucose analyser (Yel-
low Springs Instrument Co .• Yellow Springs. OH). Within-
batch 3nd between-batch CVs were < 1 %. All the analyses 
were performed by one operator. 
Heparinised venous blood samples were taken from six adults 
3nd dispensed into a set of sc:rew-Clpped tubes (Sarstedt Ltd .• 
Bc:aumont Le:y. Ll!icester. U. K.) containing NaF at a concen-
tr61tion of 0'). 1 :). :J). 6J ) 3nd t :1) g,' 1. The specimens were kept 
at room temper:lture and glucose concentrations were measured 
immedi3tely. then 3t t 5-min intervals for 1 hours for each tube. 
The specimens were thoroughly mixed by inversion immediately 
before och measurement. 
Results and Discussion 
The blood \!Iucose concentration decreased with time in 311 the: 
tubes. The decrease was less with increasin~ amounts of N3F. 
but it could nOI be tOt311v abolished. At I ~O min the decre61SC 
in tubes containing 6 g of N3F per litre was less than that seen 
in tubes containing 1 g. I (P < O.OS by paired .t' test). Also. the 
decrease at 12 Sll was less th3n that at 6 git (P < 0.01 by paired 
"t' test) (tab. 1). 
The measured glucose values thus depend on the concentr:ltion 
of N3F in the specimen and the delay between uking the blood 
specimen 3nd 3nalysis or sep3r3tion. These sources of variation 
m3Y significantly 3ffect the interpretation of results. It is par-
I) Product No. 41.1393.005 
!) Product No. ~ 1.139~.OOS 
') Prepared by adding different amounts of NaF to 3 plain 
tube (Product No. 71.694.00S). 
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Tab. I. Dec:reasc in blood glucose concentration (mmol/l) with 
time (mean ± SO) at different NaF concentr:ltions 
(n - 6) 
NaF TIme (mini 
{JJ1l 0 30 60 90 120 
0 8.11 0.25 0.48 0.65 0.86 
±1.76 ±0.01 ±O.l:! ±O.:!:! ±0.22 
8.18 0.23 0.42 0.53 0.51 
± 1.79 ±0.17 ±0.01 ±O.IS ±O.IS 
2 8.18 0.11 0.31 0.47 0.53 
± 1.81 ±0.10 ±0.10 ±0.l7 ±0.11 
6 8.18 0.13 0.11 0.38 0.45 
::: 1.79 ::0.07 ±0.07 ;:0.11 ;:0.07 
12 8.23 ·' 0.07 0.13 0.30 0.32 
:: 1.81 ±0.10 ::0.10 ::0.11 ::0.12 
Note: Values in the colut11ns (30 min or greater) show the 
difference from the zero-time mean. 
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Technic:a1 note 
ticularly important in newborn babies in whom the rate of 
alycolysis in erythrocytes is much higher (12. 13) as well as in 
some adults who are "Slronl &1ycolysers" (13). These soun:es 
of errors may also lead to ovcrdiagnosil of hypopycacmia. Our 
results show that it is important to define the concenlr3tion of 
NaF and the duration of the delay before Ilucosc measuremenL 
The recent controvmies (4. 14. 15) about the effectiveness of 
NaF as a preservative of glucose in blood specimens might 
'have been due to the use of different concentrations of NaF in 
these studies. Smrde,~ & Deadman (14) used 10 I NaF per litre 
blood. whereas other authors did not specify the concentration 
of NaF used (4. IS). 
The use of NaF at a concentration of 1 8/1 blood or less should 
be discouraged since it is slow in action and has no demon-
strable effect in the lirst hour or so. At high concentrations. 
however. NaF causes haemolysis (16). Th(reforc the use of 6 g/l 
blood. as recommended by the World Health Organization (10) 
and the ~ational Diabetes Data Group (9). seems an appro-
priate compromise. On the other hand. a search of catalogues 
showed that the majority of commercially available specimen 
tubes use NaF at a much lower concentrations. This is a cause 
for consid(rable concern and hopefully a consensus will be 
rcached .on this matter in the near future. 
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D-Mannose as a Preservative of Glucose in Blood Samples 
A. Y. W. Chant C. S. Ho, T. Y. K. Chan, and R. SwaminathanJ 
We studied the changes in blood glucose concentration in 
blood samples collected in heparinized specimen tubes 
containing no other preservative. or containing NaF, 
o-mannose. or a combination of NaF and o-mannose. 
Blood concentration in samples taken into NaF decreased 
by 0.40 mmollL in the first 2 h; thereafter, there was no 
change. In samples collected into mannose there was a 
small but significant decrease in blood glucose concen-
tration with time. When samples containing man nose 
were analyzed immediately after collection, the concen-
tration of glucose was higher than in later analyses, 
probably because of an exchange of intracellular glucose 
for extracellular mannose. When a combination of NaF 
and mannose was used. the blood glucose concentration 
was relallvely stable but slightly higher than nonpreserved 
samples for the next 24 h. However, samples containing 
mannose were unsuitable for electrolyte analysis. We 
conclude that a combination of o-mannose and NaF may 
be a better preservative for blood glucose than either 
compound alone. 
Additional Keyphraaes: sample hantJling enzymatic methOds 
• e/tlCtrO/ytes 
Sodium fluoride (N aF), the most widely .used anti-
glycolytic agent for preserving glucose (1), has been 
reported to be the best available preservative (2). Nev-
ertheless. even in the presence of NaF, glucose concen-
tration decreases by 5-15% within the first 2--4 h after 
sample collection (3). D-~rannose has recently been 
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suggested to be a useful anti-glycolytic agent to pre-
serve glucose in blood samples (4-0) and reportedly acts 
faster than NaF (5). However, D-mannose is known to 
interfere with several methods for glucose analysis (7), 
causing positive interference in the glucose oxidase 
method and negative interference in the hexokinase 
method (8). Although Nakashima et a1. (4) found that 
the rate of decrease in blood glucose in mannose-con-
taining tubes was less than that in the presence ofNaF, 
at 5 h after collection the blood glu~ose concentration 
was still decreasing. Because another reported advan-
tage of D-mannose is that samples containing mannose 
can be used for electrolyte determination. we studied 
the changes in plasma glucose and electroiytes in blood 
samples collecte<i in tubes containing NaF, mannose. or 
a combination of ~ aF and mannose. 
Materials and Methods 
A known amount of NaF and (or) D-mannose <Sigma 
Chemical Co., St. Louis, ~!O) dissolved in water was 
added to I·mL screw-capped plain tubes and dried in an 
oven at 70 °C. 
To study the effectiveness of D-mannose as a preser· 
vative for glucose. we obtained heparinized blood sam-
ples from 16 adults and aliquoted each sample into 
seven sets of tubes containing no other preservative (P); 
D-mannose, 3 glL (M); N aF, 6 glL (F); or a mixture of 
NaF (6 g/L) and D-mannose (3 gIL) (C). The contents of 
each tube were gently mi"ted. One set was centrifuged 
immediately and the remaining sets were left at room 
temperature (25 °C) and centrifuged after 2, 4, 6, 8, 12. 
and 24 h. The plasma was collected and stored at -70 °C 
for glucose analysis. 
To study the short·term effect of D·mannose. we ob-
tained heparinized blood samples from 17 adults and 
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Tabl. 1. Chang .. ln Plum. Gluco .. ConcentnnJon (mmollL. Mean ~ SEM) with nme, by PreservatJve Used 
.,.,.. type (Md preMI •• ttwe, 
n-, .. , (noM' ,(fW) . 11 ( .... w .... t C ,Hall + IMMOM, 
0 ~ -0.02 = 0.07 +0.31 = 0.040 +O~: 0.()4" 
2 -0.82 = 0.07" -0.41 = 0.04- -0.25 : 0.04· +0.14 : O.OS· 
4 
-1.19 = O.O~ -0.47 = 0.05" -0.51 = 0.04° +0.14 : O.OS· 
8 -1.54 = 0.,,0 -O.SO = 0.040 -0.59 = 0.05° +0.18 = 0.07-
8 -1.97 = 0.12" -0.48 = 0.05° -0.78 = 0.04° +0.17 : 0.05° 
12 -2.51 = 0.14° -0.44 = 0.05° -0.94 = O.08D +0.27 : 0.05· 
24 -3.81 = 0.18" -0.39 = 0.06· -1.44 = 0.08D +0.33 : 0.05° 
• The blood gIucoM value in IN P IUCe8 at time ZIIO vaned from 4.9 10 10.1 mmoIIL 
... SIgnIftclnUy different from P ~be It time zero. • P <0.01. • P <0.05. 
aliquoted these into seven pairs of F and M tubes (see 
above). One pair-was centrifuged immediately (within 2 
min) and the remaining pairs were centrifuged after 
storage at room temperature for 15. 30. 45, 60, 90, and 
120 min. The plasma was separated and stored for 
glucose analysis. 
The effect of O-mannose on the plasma sodium and 
electrolyte potassium concentrations was studied in 
heparinized blood samples obtained from 31 adults. 
Blood samples were aliquoted into seven pairs of P and 
~I tubes. After gently mixing the samples, we centri-
fuged one pair immediately and the remaining pairs 
after storage at room temperature for 2, 4. 6, 8, 12, and 
24 h. The plasma was stored at -70 OC until analysis for 
potassium and sodium concentrations. 
Plasma glua>8e concentration was determined by a 
hexokinase method with the Dimension clinical chemistry 
system (Du Pont Co., Wilmington, DE). The between-
batch CV was 1.2%. o-Mannose at 3 gtL in blood does not 
interfere with the assay of glucose by !.his method (8), 
Plasma potassium and sodium concentr:ltions were de-
termined by Bame photomea-y with the IL-943 flame 
photometer (Instrumentation Laboratory, Inc .• Le..~gton. 
MA), which has a between-batch CV of 1.5%. All speci-
mens from an individual subject were analyzed in the 
same batch. The value for the P tubes at time zero was 
taken as the baseline and all results were determined as 
the mean difference (=SE1fl from this value. Differences 
between groups were compared by Student's paired t-test.. 
Results 
Changes in plasma glucose concentration in the var-
ious types of tubes are summarized in Table 1. The 
glucose concentration in the unpreserved samples (P 
tubes) decreased rapidly, the rate of decrease in blood 
glucose being about 0.3 mmollL per hour during the first 
12 h. Blood glucose concentration in the F tubes de-
creased by about 0.4 mmollL during the first 2 h, after 
which the rate of decline was negligible. confirming our 
previous results (9). The blood glucose concentration in 
O-mannose-containing tubes (11 and C) at time zero was 
about 0.3 mmollL higher than that in P or F tubes. In 
the ~1 tubes the plasma glucose concentration decreased 
continuously with time; the rate of decrease was -0.25 
mmouL per hour for the first 2 hand -0.05 mmollL per 
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hour thereafter. In the presence of NaF and O-mannose 
(tube C), the blood glucose concentration decreased bv 
0.11 mmollL per hour during the first 2 h; thereafte;, 
there was very little decrease for 24 h (Table 1). 
Changes in glucose concentration in M and F tubes 
during the first 2 h are shown in Table 2. The rate of 
decrease in glucose concentration in the F tubes was 
greatest during the first 15 min. In the M tubes the 
glucose concentration at time zero was 0.3 mmollL 
greater than in the corresponding F tubes and this 
increased furt."ler (to 0.60 mmollL higher) at 15 min. 
There was a gradual decrease in the blood glucose 
concentration after the first 15 min. 
Changes in plasma potassium and sodium concentra-
tions in P and M tubes are summarized in Table 3. In 
the P tubes, the plasma potassium concentration de-
creased slowly with time. being 0.23 mmollL lower at 12 
h than at time zero. It then increased by 0.2 mmollL 
over the next 12 h. In contrast. the plasma potassium 
concentration increased progressively in the M tubes. 
some samples being visibly hemoiyzed towards the end 
of the experiment. By 12 h the plasma potassium con-
centration was 0.6 mmollL higher than at time zero. The 
changes in plasma sodium concentratIOns were rela-
tively small; however. results in the P tubes were 
consistently higher than those in the ~ tubes. 
Discussion 
Ideally. blood specimens for glucose estimation should 
be processed without delay. Very often t however. this is 
Table 2. Changes In Plasma Glucose Concentration In 
Blood Samples Stored at Room Temperature tor 2 h 
Cttference. mmo~ from P tube va'", It Um. 
:.to (mean : SEM) 
TIme. mtn Fa y-
0 0 +0.29 : O.osc 
15 
-0.15 = 0.02° +0.S1 = 0.13C1 
30 -0.25 : 0.04c +0.34 = O.ose 
45 
-0.34 = 0.07c +0.13 = O.03c 
60 
-0.39 = o.oac +0.04: 0.04 
90 -0.40 = O.OSCI -0.25 : 0.06e 
120 
-0.50 = 0.05e -0.27 : 0.0r: 
• easa. glucose c:cncentraaon 8.37 : 1.2(nn;1 .£.3-21.0) mmoUL 
• Basal glucose concemrahOn 8.68 : 1.~(raroc;e ~.~21 .21 mmo4l1-
c SiqnlflC3ntty Clrfeter.t !rem !tie value ar :Jme :ero In (n. Fl ruce: P <0.01. 
I 
--





+0.05 = 0.21· o 
~ 
"1Utae 
-1.9 = 0.28· 
2 
-0.13 = 0.0200 +0.11 = 0.021· +0.9 = 0.28· 
+1.3 = 0.25-
+1.1 = 0.3~ 
+0.7 = 0.38 
+1.2 : 0.31° 
+2.4 = 0.28° 
-0.8 = 0.<60 
4 
-1.13 = 0.029- +0.23=0.~ 
-0.8: OoW 
8 ~1.15 = 0.040- +0.38 = 0.041· 
-0.8: 0.31 
8 -1.18 : 0.()47- +0.47 = 0.047-




-0.23 = 0.056- +0.81 = 0.060· 
24 
-0.05 = 0.0J3 +0.62 = 0.079° 
• Cifference from IN vaJue at dme zero in the P tube . 
... 5ign1ficanUy differenc from Ume zero: • P <0.05. • P <0.01. 
impracticable (lO) and it is not uncommon to receive 
samples 18 h after collection. Therefore, an ideal preser,,: 
vative should be able to presserve samples for at least 24 
h. As our results show, mannose is not an ideal preser-
vative because the blood glucose concentration de. 
creased continuously with time in the samples contain-
ing mannose <Table 1). The mechanism accounting for 
the incomplete action of ~mannose is not clear. Man-
nose is metabolized to fructose 6-phosphate (11) so that 
the concentration of mannose in the tubes decreases 
progressively. The lower concentration of O-mannose 
may not be adequate to prevent giycolysis (4), 
At time zero, the glucose concentrations in the man-
nose-eontaining tubes (M and C) were about 0.3 mmollL 
higher than in the P and F tubes (Tables 1 and 2). This 
is not likely to be due to interference with the glucose 
assay by O-mannose because, as we have shown (8), at 3' 
gIL the O-mannose does not int-erfere with the glucose 
assay used in this experiment. The high glucose concen-
tration in the mannose-<:ontainin~ tubes is likely to be 
due to rapid exchange of intracellular glucose for extra-
cellular mannose across the erythrocyte memorane (12). 
Glucose and O-mannose are tr.msported across the 
erjthrocyte cell membrane by the same transporter, and 
the hetero-exchange between intracellular glucose and 
enernal O-mannose is very rapid (12-14). The apparent 
increase during the first 15 min of storage in an M tube 
(Table 2) is probably also due to this transcellular 
e."(change. Thus the use of O":mannose can lead to over-
estimation of plasma glucose. However, measurement of 
whole-blood glucose may not be a.ff~..ed by this trans-
cellular exchange. 
In the C tubes (combination ofmannose and NaF),the 
glucose concentration was relatively stable (Table 1), 
although the concentration was higher than in P tubes 
at time zero. If whole-blood glucose is not affected by 
mannose, then a combination of O-mannose and NaF . 
may be the best preservative for estimation of whole. 
blood glucose. 
The plasma potassium concentration in heparinized 
blood samples decreased (Table 3) probably beQuse of 
the entry of potassium ions into the cells (15), On the 
oth~r hand. the plasma potassium increased in blood 
samples containing O-mannose. This increase was small 
(0.11 mmoUL) in the first 2 h and was probably due to 
the leakage of potassium as 3 result of inhibition of 
glycolysis. The rate of change in potassium could be 
slowed if the samples were stored at lower temperature; 
this may explain the observation of Nakashima et a1. 
(4). The small change in plasma sodium concentration 
in the presence of mannose (Table 3) is probably not 
clinically significant. 
We conclude that D-mannose alone is not reliable for 
glucose assay and that a combination of O-mannose and 
NaF may be a better preservative for determination of 
blood glucose. 
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Assessment of' Glucose 
Tolerance Test Criteria for 
Diagnosis of Diabetes'in 
Chinese Subieds 
Cuvt s. Cooat"-'C. nOt 
JOSEPH T.F. uu. PHD 
ALBEln' y.w. CHAN. ~aAnt 
OBJICTM - To examine and compare WHO diagnostic criteria for diabetes 
mellirus. 
RUIARCH DISIGN AND METHCD - The relaticr.ship be~een FPG and 2-h 
glucose are e.:omined in 680 OGTIs \Vit.~ a quadratic regr~on mo~el ar.d RO~ 
lIlalysLS. Simultaneous me!lSUre:nentS of HbA1 and fruc:osanune are alSO comp~c 
w'lth multiple linear regression. 
RUULTS- Two hundred eighte~subjectS 02%) had 2-h glucose ~11.1 mM. of 
which only 86 had FPG ~7.8 ~\t Only 2 subjeCtS had FPG >7.8 mM and 2-h 
glucose <7.8 mM. Of subjectS with 2-h glucose <7.8 mM en a 332). only 9 had 
FPG >6.0 mM. From the quadratic model. the predicted FPG corresponding to 2-h 
glucose ::11 11.1 mM was 5.7 m.\i, whereas the predicted 2-h glucose correspondil'1g 
to FPG = i. 8 mM was 15.1 m..\{. RC C analysis showed thac. \Vith 2- h glucose ~ 11.1 
mM lS indicang diabe~es. In FPG of 5.6 m.\{ gave 1Il intersect for scr.s1cvuy ar.d 
spe:::.licity of 8i%. HbA1 and fruc:csarrune correlated more closely wuh 2-n giuccse 
and 3l'Cl under the OGIT CUIVe than with FPG. 
CONCJ.USIOHS- Given that a 2-h glucose CUtott of 11.1 mM c3.n be justified 
from other Studies, our resultS suggest that the FPG CUtot! of 7.8 m~ whe:l used for 
scree:ung purposes should be reduced. At a suggested Value of 7.0 mM •. spccificity 
remains 98.5%, where3S sensitivity incre3SCS to 57%. 
O GTr remains the definitive stan-dard for diagnosing diabetes melli-rus, despite concerns regarding cri-
teria. reproducibility, sensitivity, and 
specifiCity (1-6). WHO aiteria (7) rec-
ommend that FPG ~7.8 mM or a 2-h 
value ~ 11.1 mM be used Cor the diag-
nosis oC diabetes, where:lS a 2-h glucose 
••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
FlOW mE OO'AJm,(!HTS 0' MmlC.'4! Al"D CKDClCAL PAntOlOCY, UGN!s! UNlVDSnY 0' HONG 
KoNG. SHAnN. HONG Ko~. 
AcCRlss cC~PONDC'c! ~D W'1U:lT RfQVlSTS TO OR. C!..M S. Cooaw.c. RzADEll IN MEDIc.'4!. 
~!IIc! Of WAJ.,D HosPfTAL. SHAn.~. NT. HONG KoNG. 
Rlc:MD fOil P\JIUCAnON 16 MAy 1991 AND Acanm IN RfV1Sm FORM J ~tAJo( 1992. . 
WHO, WOILD Hw.nt ORGANlZAT.CN: FPG. PASTlNG PUSWA GlUCOS!; OGIT. ORAL GU:COSI 
TOL.!lWIC! 1"ES'r, ROe. aEC!.1VD OPDAn.~G o,'KV!S. 
988 
, 
< 7.8 m.\{ at 2 h distingubhcs nonr.a1ity 
from impaued glucose tolerance. Our 
impression is ~t many patients with 
2-h glucose indiotive oC d.i.abc:tcs have 
FPG < 7.8 mM, where:lS the reverse is 
rarely trUe. This agrees with Finch et al. 
(8) in that the FPG CUCO[ oC 7.8 mM 
unduestim3tes diabetes prcva.1cnu. with 
Taylor and Zimmet (9) in that the sensi-
tivity oC FPG is not high and its predic-
tive value is lowest in popuLations with a 
low diabetes prevalence. and with Harrts 
et al. (la) in that only 26% oC subjects 
meeting \\1110 critcria for diabetes have 
FPG ~7.8 mM. 
To c.."q)lore furthcr the reLation-
shio betvlee.'1 F?G ar.d 2-h glucose. we 
analy::ed the resuitS ef 680 OGTIs c:.:-
ricd out over l J-yr ~enod. 
RlSlARCH DISIGN AND 
MITHOC5- Six hundred eighty 
OGIT s were c.."C1IIlined. All patients were 
Chinese. The incllctions for OGTI in-
cluded routine clinical indications 
(n = 126), postpartum screening 
en = 113), screening of subjects with l 
poS1ci~ faITuly history (n = 321). :lr.C 
screenmg of elderiy paCCrlts as part Ot m 
eplderruoiogld survcy (n = 228). 
Four hundred t\~·e.!'1cy-(ight pa-
tients were women (me:m age i8 yr), me 
252 were me."1 (mean age 49 yd. The 
age-range was 14-92 yr. The me:m 1ge 
in the elderly subjects (>60 yr old) w:lS 
71 yr lnd that oC the younger subjec:s 
was 37 yr. All received 75 g glucose 
monohydr:lte aftcr an overnight f.as~ a 
normal diet for 3 days before test, and 
abstention from smoking for 2" h. None 
of the women were pregnant when 
tested. All OGITs were commenced be-
tween 0900 and 0930 at the Pr.nce oC 
Wales Hospital. Hong Kong. in an ambi-
ent tempc..rarurc oC - 22·C. Blood w:J.S 
drawn by venipuncture from an antecu-
biu! vei.."1 lt 0 mm (fasting) and 1 and 2 
h after glucose loading. Samples from 
C3Ch' patic.."1t were batched and sent to-
ge '~,er for glucose esti.m3tion at the com-
pletion of the test. Blood was collected 
into fluoride tubes (final concn 1 mg/ 
,- . 
.A ..... •• ..... ' .. ~~ ... tl.,,"'t ... ~ •.• _ ... ~ • • \..r ... __ 11. " . ..... ~ -'* . ' ...... ~ .. .... f'" ". • • - ~ '" ·'···~ ' ''·f '' -''''''''''''''. '' .I''''''''''''· . ~Jo ... -r ......... U..,.. 
mD. Plasma glucose W3S measured by a 
glucose oxidase method with the E.~re 
ccnaiIugal an.a1yzer (Baker lnsaument. 
AllcntoWn. P A). with a ' between-batch 
coefficient of variation :s3.7%. Simulta-
neous mC3.SUrement of HbA1 and &uc-
tosamine was carried out with methods 
desaibcd previously (11). 
Statistical analysis was c:uricd out 
with multiple regression models oC qua-
dratic form. according to the equation 
y sa a + hx + ~, to compare the rela-
tionships between FPG and 1-h and 2-h 
glucose values. A quadratic model Qeast-
squan:s me;hod) was found to best ac-
commodate the nonlinC3rlty oC the data 
whe.~ compared with other models Oog-
log. semilog. e..~nencial. and higher-
order regression models). Relationships 
between HbA1, fruc::osarrur.e. and giu-
cose values were studied by multiple lin-
C3I' regression analysis. 
The area under the OGIT curve 
was estimated approximately with the 
• following fonnula. 
Arr:2 - FPG + 2-h gluccsc/2 + l-h glucosel2 
The se..~nvlcy md spec" ... 'ki::y for the pre-
dic=on of diabe~es (taken :J.S 2- h giucese 
~ 11.1 m.\t) by FPG, HbA1• and truc-
tosamme were studied by the ROC 
met..~oci. 
RlSUL TS - The reLaoonship betvleen 
FPG and 2- h glucose is shown in Fig. 1. 
The re13tionship is nonline:u-: the rise in 
2-h glucose per unit · rise in FPG being 
relatively smaller at higher FPG. The re-
lationship between FPG and 1-h glucose 
was similar (data not shown). 
The mean FPG corresponding to 
a 2-h glucose oC 11.1 mM predicte~ by 
the model was 5.7 mM (95% confidence 
inteIV:ll !5.5-5.8 m..\{). The 2-h glucose 
corresponding to an FPG of 7.8 m.\{ was 
15.2 mM 04.8-15.6 mM). Two hun. 
dred eighteen (32%) p3tients had a 2-h 
glucose ~ 11.1 mM. However. only 86 oC 
these had FPG :2:7.8 mM. Of the 332 
subjec:s with nonnal glucose tolerance 
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figure l-~ rcUuionship ~ FPG and 
2- It gl~ for all OGrrs. Solid line. bes: fit to 
data dmvai from quadracu: rcgrcSW" PniXUL 
Tnt quadractC equano" swnm~ng cnt mocid 
was FPG :11 4.4i67 - (0.0491 x 2-h glu-
cost:) + (0.0142 X 2·" gl~). 
>6.0 mM, and in only 1 was the value 
>7.8 mM. 
HbA 1 (n = 651) and fruc-
tosamine (n = 669) correlated more 
closely with 2- h glucose er = 0.66 ma 
r = 0.68. respec:lv-ely: P < 0.001) than 
with FPG (r = 0.+7 and r = 0.50, re-
spectively: P < 0.001) and correlated 
most closely with OGIT are:l er = O. i8 
and r = 0.69. respectMly. P < 0.0001). 
. \Vith ROC analysis. an FPG of 
5.6 mM giv-es an optimal 86% sensitivity 
and 87% specifidty when 2-h glucose 
~ 11.1 mM is taken to iIldic1te diabetes. 
At an- FPG oC 7.8 mM. specifidty was 
99% and sensitivity 40%. ROC analysis 
oC HbA1 and &uctosamine. with the same 
criteria Cor diabetes. showed that an 
HbA1 value oC 8.3% yielded an intmea 
for sensitivity and spc~.ficity of 84)% and 
a &Uctosamine v:Uue of 2.1 mM gave a 
spcci.6city and sensitivity of 77%. The 
upper limit oC the laboratory nomul 
range is 8.5% for HbA1 and 2.2 m..\{ for 
fructosamine. 
CONClUSIONS - The results show 
duc. applyi.~g \\!HO criter..a. more than 
twice the number of subjec:s m classi-
fied as having diabeteS on the basis oC 
2-h glucose compared to !=PG. !he ob-
servation that 99.5% of patients with 
FPG :2:7.8 mM also have 2-h glucose 
~ 11.1 mM agrees with pmiOU5 reportS 
(5,9.12). Thus. spccificity is high but 
sensitivity is poor for FPG. This is further 
supported by the observation tr..3t only 
2.7% oC the normal subjects had FPG 
~6.0 mM. 
The FPG (5.6 mM) giving opti-
mal sensitivity and specificity wtth ROC 
analysis was similar to the predicted 
value of FPG (5.7 mM) derived from the 
quacir::uiC model as corresponding to 3 
2- h glucose of 11.1 m..'vt. However, this 
would be too low in the dinic:U SC!ting i.~ 
which spedfidt'/ is more irnpor.mt :"~:J.:: 
se:-.siovlty. 
The effect of immediate seParJ-
tion oC plasma has been p~tiously re-
ported in a subset of these patients (11). 
Tne nonline:1rlty of the data and the re-
lationship between FPG and 2-h glucose 
values were not aEected by immediate 
separation. However, absolute values 
we:-e 0.5-0.6 m~ higher in imrnediate~y 
seF3r::uec s:unpie.s. ar.d my r~on er 
di3gnostic cnter.a should :illow fer &.:.s 
becllSe the eiec: is grocer in f.:lsc.ng 
samples (12). 
Our study confir.r.s dut eithe: 
the 2-h glucose cutoff 3t 11.1 mM is teo 
sensitive or that the FPG cutoff of i .8 
m..\1 is too insensitive. Finch et al. (8) 
suggested that. for screening purposes. 
the FPG should be cut to i.O m.'vt. Our 
dau lend strong support to this sugges-
tion. The altemaove possibility, that t.~e: 
2-h glucose cutoff is coo low, c:mnoc be: 
justified becUSt! 11.1 m..\{ divices those 
at risk oC microvascular dist!3Se from 
those not at risk (13-15). Also, the bet-
ter correlation of HbA1 and fructosarnir.e 
with 2-h glucose suggestS wc 2- h glu-
cose relates more closely to e<ee.sslve 
protein glycosyUtion. The senslrivtcy md 
spcci.ficity inte.~c:s for HbA1 and fruc· 
cosamine. with ROC arul)'SlS. ~re also 
better than in a more recent report (i5 
and 55%. respectively) in which snuller 
989 
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Gluusc tDlcTancc rau in Cilincsc suhjccu 
numbers were studied (16). However. 
we share the generally held view that 
both are inappropnate as diagnosnc: 
tcsts. 
We c:onclude that WHO c:riteria 
produce discrepant results in Chinese, as 
in other ethnic: groups. Our analysis sug-
gests that. for screening purposes. the 
FPG above. which diabetes is suspected. 
should be reduced. A value of 7.0 mM 
yielded. in our Study. a spedficity of 
98.5% and a sensitivity of 57%. Based on 
a local diabetes prevalence nue of 4.5% 
(unpublished data). we estimate that 
3.9% of subjects would require retesting 
with a FPG cutoff of 7.0 mM compared 
to 2.1% with 7.8 mM. 
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HYPERINSULIN SECRETION IN THYROTOXIC 
PERIODIC' PARALYSIS (TPP) PATIENTS 
ChaD A,Y.w .. 'Shinde R., ·~how C.C., Swcminathon R. 
Departments of Chemlcol Pathology and -Medicine, The Chinese 
University of Hong Kong, Hong Kong 
The basic defect in TPP is not known. An attack of paralysis is associated with 
hypokalaemia secondary to transcellular shift in potassium, a process where the 
sodium pump is thought to play a central role. !be number and the activity of 
sodium pump in muscle and other tissues increase in hyperthyroidism and insulin 
is a known stimulant of the sodium pump. Nevertheless the role of insulin is not 
certain in TPP. We therefore performed standard 75 gm OGTTs.on euthyroid (Eu), 
unneated thyrotoxic (Tx) and TPP patients (after correction of hypokalaemia). 
Plasma glucose and insulin levelsat 0,1 and 2 h were measured and the 'area under 




1.2.9 + 4.5 P < 0.05 
94.6 ± 55.9 P <0.01 
TPP (n=6) 
16.8 + 4.7 
202.3 + 85.8 P < 0.01 
TX (n=25) 
13.8- + 2.0 
96.6 ± 21.2 
Our results showed that there was no difference between Eu and Tx patients. 
However TPP patients had a significantly greater increase in glucose and insulin 
AUC. The increase in insulin AUC was even greater than Tx patients. We conclude 
that TPP patients, on stimulation, secrete more insulin. This might explain their 
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15 THt:: RE1.A TIO~SHIP BETWEE.~ INSUl.IN RESISTANCE. I UIASTOI.IC 0l.000 PR ESSI:RE. URI!'IARY Al.OUMIN CONCr-:STRATJON ASO fmRI!'~OLYTJC ACTIVITY IN PATI~vrS WITH TYPE 2 DIABETES ~U·:l.l.ITUS 
COCCI 1 SCL. McCOK~"'CK L. CIIAP~AN C. RICE P J. 
GRAST I'J 
Unlven,,,, Ucpannscn" o( ~'c:d,cJn.:. The: Ccneral In/lrmary. 
Leeds. l.:K 
J lyperinsulini1Cmla and insulin resistancc UR) have been 
shown to 1Jc rIsk (actors (or coronary artery disease. IR 
and type 2 diabetes melUtus (OM) are UIOCllced With 
deprcSled (ibrinolytlC actlv,ty due to elevated pla,minolen 
acUvator Inhibitor (PAI-l). Increased PAl-I and 
microalbumlnuria are Independent risk (actors (or the 
developmen" o( Ischaemic heart disease and microalbwninuria 
predicts prolressiO(\ to chronic renal failure which Is 
associated WIth the development of hypertension. To 
InvestiCate the relationship between IR. vascular rbk. ractors 
and blood pressure (BP) at dla,nosis. urtnary albwnin 
concentralJon, dlastolic BP, IR and Indices o( rlbrlnolysb 
(pre and post uerClse) were studied in 15 newly dlalnoaed 
type 2 OM patients with normal creaunlnes. Urine was 
collected as a 1st voided momlnl sample over 3 consecutive 
days, and IR assessed by the (asun, lnsullnl,luc:ose ratio. 
The plasma insulin/glucose ratio correlated with urinary 
albumin conCenU3t10n, r.0.7I, p.0.OO4: basal t1s.sue 
plasminogen activator Inhibitor activity (tPAI) and antilen 
(PA1:Ag), raO.88. p •• O.OOI. ~nd r.0.74. p.O.002 respectively: 
post e.lerClse tPAI. r aO.S6, p •• O.OOI: and post e:cerClse 
PAl:Ag, raO.S6, peO.OOI; and WIth tPA:Ag. r.0.76, p.a.002. 
Plasma insulin correlated WIth urinary albumin concenuation. 
r.0.S6. p.O.OJ9: basal tPAl, r.0.85, p.O.OOI; post e.xerClM 
tPAI. r.0.78, p.0.004: basal PAI:AC. r.0.73. p.0.OO3; post 
exerCIse PAI:Ag, r.0.8, p.O.OOI; and basal tPA:AI. r.0.76. 
p.0.OO2. Oiastolic BP showed no relatlOft$hlP to 
mlcroalbumlnUrll, IR or fibrInolytic actlvlty. These results 
indicate that in newly diagnosed type 2 O~(. plasma lft$utin 
and IR are already related to the decree o( 
microalbuminurll and to levels 01 PAI-l activity and 
antlcen. There wU no correlation with diastoJic BP to 
sUllest that IR a((ecu BP over a lonler term. 
16 AN IMPROVEC ALC%AN BLUE 
QUANTlT" TIVE CETERY.NA TlON 
GLYCCSA~NOGLYC"NS 





AcaCSemlC Untt of ClaC,'es aM Encsocrtnol09Y, W"IIt1nQlo~ 
Hosplla., ~lCnwa, ROoICS. I.onaon N19 5NF 
Glyc:oastnlnoqlyCanS (GAGl are a etass 01 comet,. PO~accl'\ancslS 
ana ar, pt,,.,,. in !lSSU,s InG et- SUt1ac:ts usuall., ,n cova .. nt 
as~llOn Wltn a pro"," moat" 10 10"" ptOleGQrycans. .AI)no~1 
levelS Of GAG in s,""m ancs UlIfte have lM,n '100"'"' in I varatty 
01 '-'man I2I,.U" ana usa,s lOt GAG "'IT I"'reto,. be ,.leva". 
10 1ft undersaanGan..; 01 In. ~ Of ""SI OaAasll. GAG 
assays -nen "" on preQQII1l1Oft wtln 'IINr ClllOftIC ellet9.".s Of 
callOn1C ay" ~y b. SUOIId to d.ff.r.ne. Oy ~t"'IIy-cnan;1d 
molta.lll' in t)lOlOc)cal ~ICIS. W. have SftICS1ICS "" inI.ff,,.ne. of 
IftIOne abm.n 1ft th •• aca.n ~. assay ana l'IalUattG In. use 01 
OCI~ ICIG as I CSfOlOllIftIHf. W. Iouna SJQftllcartI n:r.ases ... 
1Sl~'1G GAG conc,,,.'atlOns an" adaltlOn 01 Ilbunwl 11 
conc:e",rlliOns '1nQtn9 ItOm 02·10 QI1 (pose",. NS: 1 .• ,ZC .... 
pcO.OOO1J. The" WIS slQftllleant COrrtWIOft t)ftwHn IN aGded 
.tI)u,.,.. conc:'NrallOft ancs 1ft. inctease in COlOnmetnc ISum_lIOn 01 
GAG concencralon (r.0.978. peO 0021. GAG llCOVefY In" 
~a,tOn of ItIunWt .. Ih oCsanoc acid was in IN ranQ. 9. 8. 
10''''.. No sqndicanc eMerene.s t)y p,,,,", H.SI b.tw •• n GAG 
S"nd.1I'QS t)elOl, ana antI IrUlmeN .aen octanoc ICId was 
ocse""ed (P.O.651. In 70 samotes Of unnes ItOm CiaOttc !)alieNS. 
a Sl9ftl'tca,.. CSatt'ftf'C' an GAG cone''''''tlO''' was s.en 1)etO,. 
(melft: 52.7 (SO 28. 1) ~ anG an" (m. an: C3.9 (SO 24 JJ "9'1 
prot"' or~.altO" Wtln ocunoc ICICI (peO.COO',. tfte aM.,.nc .... 
concentrarlOns con"atInQ .tln U'IIW'Y 10111 CIOt,1ft (r.O.lS. p.O.OOJI 
Ind alt)um.n 1,.0 .• '. p.O 0006f cone,m"lIons. These '.SulI 
1U9I;.SI Inal at\lOmC orall"', ''''''''f, .ltn GAG ", .. noes wncn r." 
on C)ltcOI3l"'9 .It" ClllOnc relQ''''. ana l"-at CIOIOI..,.lIlOn .. ft 
OCIlno.c lOG can OOv-at. sue" ant." "encl. 
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'LATttET IA-.X-4T' ••• ACTl'tTT 1. 'ATICITS VIT. 
T"T.OTOXIC 'EIIODIC . • A.AtTSlS (t,,). 
ATV CMA'·, I 'RINDr.-, CC CROV-- I.d • SVA~t.ATRA~ 
D.p.re •• nc •• f ·Ch •• leal '.e~.IOI' Ind 
·-".4leia., Chi •••• a.' •• r.icy of .o.c lo.~, 10. lo.~ •• 4 D.,.re ••• , of Clinic.l lioCh •• l.er, C 
U"DS. ~u,· •• 0.,i'a1, tondon. . ' 
'.r.ly.l. 'n T.' i. pr.eiplt.e.d by ~l~~ 
e.rbo~ydr.t •••• 1. I. or'.r Co •••• In. vh,lh.r 
1 ••• 11. ,la, •• rol., v. ,.rfor •• d a .ea.4.r' 7S 
I or.l Cluco •• Col.ranc. ee.e o. 2S h •• lch, 
.ubJ.et. (8). IS uncr •• ,ed th,roco.le p.el,.c. 
(TX) 1.4 , T" p.cl.nc. (.tc.r eorr'etlon of 
~ypokal ••• i.). .1 •••• clueo •• , 'ft.ul1_ .~~ 
pl.t.l.c N'-,t-4T' •• , •• r ••••• ur •• at 0, 1 .ad % 
h .fe.r the ,lueo •• 10.' .n4 the .r •• G.~,r ,h. 
cur •• Vir, eal~ul.c.4. Th, re.ulc. ( ••••• 04 
SD) .r •• ho.n la ch. tabl •• 
Ar •• und.r the cur •• 
Cluco •• 1, ... lin 'laulu 
M'-,l-AT' ••• 
" 
1%.9('.'9) 95(55.9) 319(07) 
TX 13.80.02) 96.601.%) 482(109) 
TP' 16.8(t •• 73) 101.H8S.8) 601(99) 
4r •• und.r the curv. tor 11ueo •• , in.ulin ."~ 
pl.t.l.t ~.-.I.ATP ••• v.r •• ilnitic.ncly ~i~h.r 
in TP' co.p.r.' co TX or K ,fOUP.. V. h ••• 
pr,viou.l, .~ovn th.c In .ivo .odiu. ,u.p 
accivicy i. iner, ••• d ia TP' ,.ti,nc. (IMJ 'n 
pr ••• ). Th. pr •• ,n' r ••• lt •• how th.c T" 
p.ci,nc. h.v. ,luco •• incol.r.nc.. Th. re.ulcl"~ 
hi,h.r ia.utia COI.ch.r with the hilh .odiu~ PUM~ 
.cti.icy •• , •• pl.ia Ch. pr.cipitacin, .ff,ec ot 
• hi,h c.rbohydrac •••• 1 ia TPP • . 
1 a RES?ONSE TO VENOUS OCCLUSION IN NON·I~SUlIN 
DEPENDENT DIABETICS AND ITS REl.ATIONSHIP TO 
BLOOD C~UCOSE 
M MClAREN, PE :ENNINCS. JJF 8ElCH 
Unlversuy Deputment of MeClClne. Nlnewells Hospu.1 ,ncs 
Mechc:~l SChool. Duncsee. DD 1 'Sy 
We h.ve previously shown th.1t the endotnela.l response to 
the Stimulus of venous occ:1U510n IS Imp.Aared In Insultn 
depenaenl CI.ACellCS wltn mlcrov.scul.r comphcauons. In th.s 
"uey we n.ve InVeSlI&.teCS the response to vc no us occlUSion 
In non-Insulan depcnaene dl.Cetlc.s. We SluCICC 27 d'.At)cucs 
.11 of whom n<la developed dl.betes .her tl'\e I&e ol ,.0 yeus 
Ind ".C n'vcr /)een treated with lnsulan. All naCS been on 
est.tblucC ~lpnonylure. tl'\erapy lor .t leue two ye.rs wltn 
or WUhout 1C2luncuve .met1ormln tnerapy. The Ise 0' the 
p.uenu r.nCecs trom It' -71 years Wl U\ a me.n .,e 0& "., 
ye.rs. All p.uencs were subJected to 10 minutes venous 
occlUSion .nd blood samples were t.ken prIor to) anCS 
ImmediAtely pose occlUSion. We measured pluma levelS of 
tassue pI.smlnO&en acuvator (t-PA) .nCS plaSlftlnOsen 
.c"v.tor annlbuor (PAl) and 'Ion Wallebrand lactor anusen 
(vWF). 8100d &Iucose levels were .Iso meuured ptlor to 
venous occluSIon. t-PA levels rose lrom a mean level of I.ll 
./. 0."2 IU/ml Prior to venous occlusaon to ,." -/- 1.37 
lU/ml alter occlUSion (p<O.OO U. PAl levels leU Irom I mun 
pte level of 17.ll _I. I.U AU/ml to 1).7 .,- 1.76 AU/ml post 
occ:luSlon (p<O.O". PJ.sma levels of vWF rose lrom 1" ./-
17.'~ to 20' ./- 23.1 pan occlUSion (".0.121). In lout of 
tne 27 p.Uents tePA levels dad not rase Ifter venous 
occ:luslon and PAl levels dlCS noe 1.11. 8100CS &hlCose levels 
Sl\owed a slcnahcane Invene correl.uon wuh pon occlUSIon 
le.,els of • pOSlUve correl.tuon In ,-PA and PAl p.O.O)) and 
p.O.OlO respectively, altftou&n there wu no conela"on wuh 
pre occlUSIon levels. These results suc&ese tnlt tnere as I 
relauonsnlp between blooCS ,'ucose level and enCotneh~1 cell 
response to Stimulus .nCS may p.nly upl~ln ehe "'Cher 
IncIdence of vue"l., compllcauons In poorly controUed 
da.Deucs. 
• 
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Hyperinsulinaemia and Na +, K + -ATPase activity in 
thyrotoxic periodic paralysis. . 
A. Chan-, R. Shlnde-, c. c. Chowt, c. S. Cockramt and 
R. Swamlnathan·~ 
Departments of ·Chemical Pathology and tMedicine, 
Prince of Wales Hospital, Shatin, Hong Kong, and 
Wepartment of Clinical Biochemistry, Guy's Hospital, 
London, UK 
(Received 14 October 1993; returned for revision 17 December 
1993: finally revised 25 January 1994; accepted 18 February 
1994) 
Summary 
OBJECTIVE Thyrotoxic periodic paralysis (TPP) usually 
follows a heavy carbohydrate meal and this may be 
explained by hyperinsullnaemia stimulating Na +, K-+-
ATPase activity. To clarify this the effect of glucose load 
on serum Insulin concentration and platelet Na· K + -
ATPas. activity In thyrotoxic periodic paralysis (TP~) was 
examined. 
DESIGN In aUsubJects a standard 75-g glucose tolerance 
test was done and blood samples were taken at 0, 1 and 2 
hours. 
SUBJECTS Twenty-five healthy controls (8 M and 17 F), 17 
uncomplicated thyrotoxic patients (7 M and 10 F), 15 TPP 
patients who presented with paralysis and 4 TPP patients 
after treatment with antithyroid drugs. 
MEASUREMENTS Plasma glucose was measured by the 
glucose oxidase method, serum Insulin by radioimmu-
noassay and platelet Na + , K + -ATPase by the release of 
phosphate from ATP. 
RESULTS TPP patients showed glucose intolerance 
(area under the curve (AUC) 16-5 ± 4-4 (mean ± SO) In 
TPP compared to 12-9 ± 4-5 In controls (P < 0'01» and 
hyperlnsul.:1aemla (AUC 189-6 ± 100-6 vs 98-5 ± 53·4 , 
P < 0'001). In uncomplicated thyrotoxicosis the resuUs 
were similar to that In healthy controls. Platelet Na + , 
K + -ATPase were Significantly higher In thyrotoxic 
patients compared to controls and In TPP patients were 
even higher. Ingestion of glucose Increased platelet Na + 
+ • 
K -ATPase In all groups. AUC for platelet Na +, K + -
ATPase In TPP patients were significantly higher than In 
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uncomplicated thyrotoxicosis (801 ± 99'3 vs 482 ± 109'4, 
P < 0'01) or healthy controls (320 ± 107'3). In the 4 TPP 
pallents studied after antithyroid tr.atment · the results 
w.re similar to h.althy controls. 
CONCLUSION Patlen .. with thyrotoxic periodic paralysis 
have hyperlnsuUnaemla and this Is accompanied by 
higher Na + , K + -A TPas. activity. 
Thyrotoxic periodic paralysis (TPP) is a common complica-
tion of thyrotoxicosis in Chinese (McFadzean & Yeung, 
1967; Yeo et al .• 1988) and it is 70 times more common in 
men than in women (McFadzean & Yeung, 1967; Yeung & 
Lam. 1987). Typically the attack follows a heavy carbohy-
drate meal or heavy exercise (Yeo et al.. 1988). Occasionally 
respiratory muscles may be involved causing respiratory 
distress. The muscle weakness is usually accompanied by 
hypokalaemia and complete recovery occurs within 36-72 
hours. The exact pathogenesis ofTPP is not clear (Oh et al.. 
1990) although Na +, K"'·A TPase activity, an important 
regulator of potassium homeostasis. has been implicated 
(Yeo et al.. 1988). We have previously shown that platelet 
Na'" • K ... -ATPase activity and in-vivo rubidium uptake are 
higher in untreated TPP patients than in other thyrotoxic 
patients without paralysis (Chan et al .• 1991). Important 
factors regulating the sodium pump are insulin and 
adrenaline (Clausen. 1986). The relation between TPP and 
heavy carbohydrate meals may be explained by hyperinsu-
linaemia leading to stimulation of Na.... K • -ATPase 
activity and hence hypokalaemia. Furthennore. high 
serum insulin concentrations have been reported in some 
patients at the time of paralysis (Shishibu et al .• 1972; Hay & 
McDougall. 197 5). Recently. Lee et al. (1991) reported that 
glucose and insulin response to oral glucose are higher in 
TPP patients than in patients with uncomplicated thyrotox-
icosis. We have studied the effect of glucose load on insulin 
concentrations and platelet Na"', K ... -ATPase in TPP 
patients after an acute attack and have compared it in 
patients with uncomplicated thyrotoxicosis. 
Materials and methods 
Twenty-five healthy controls (8 M and 17 F. 21-59 years), 
17 uncomplicated thyrotoxic patients (7 M and 10 F. 18-45 
years), 15 TPP patients before treatment (all M. 22-39 
years) and 4 TPP patients after antithyroid treatment were 
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studied. All IS TPP patients were studied after they had 
recovered from the acute paralytic episode but before 
treatment with anti-thyroid drugs. All TPP patients had 
been admitted with paralysis and had hypokalaemia. They 
were given potassium supplements and recovered from the 
paralysis spontaneously. In all patients thyrotoxicosis was 
confinned biochemically with suppressed TSH and clearly 
elevated concentrations offree-T3 (FT3) and free-T4 (FT4). 
None of the healthy controls were on any medication or 
known to have diabetes or thyroid disease. Infonned 
consent was obtained from all subjects and the study was 
approved by the Ethical Committee of the Chinese 
University of Hong Kong. 
In all patients and healthy subjects a standard 75-g 
glucose tolerance test was done. Blood samples were taken 
into fluoride, heparin and citrate tubes for measurement of 
glucose, potassium and insulin and platelet Na.... K ~ -
ATPase respectively at 0, 1 and 2 hours. 
Plasma glucose was measured by a glucose oxidase 
method (Beckman. California. USA). Blood samples for 
glucose (fluoride tube) were spun immediately and the 
plasma stored until analysis as we have previously found 
that delay in the separation of plasma can cause a significant 
decrease in blood glucose (Chan et al., 1989). Blood samples 
for insulin were centrifuged and plasma stored at -70°C 
until analysis. Insulin was measured by a radioimmunoassay 
using a commercial kit from Phannacia (Sweden). Platelet 
Na .... K - -ATPase activity was measured as described 
previously (Chan et ai .. 1991). Briefly, citrated blood was 
centrifuged at 160 I: for 15 minutes at room temperature and 
platelet rich plasma (PRP) was prepared as described by 
Turaihi et ai (1989). Contamination of PRP with erythro-
cytes and leucocytes were checked and found to be minimal 
« 0'5%). PRP was centrifuged and the platelet pellet was 
washed twice with ice cold magnesium chloride to remove 
trapped plasma. Na·, K'" -ATPase activity was measured 
by the rate of release of phosphate from A TP in the presence 
or absence of ouabain. Platelets were lysed ~y freezing and 
thawing followed by the addition of saponin solution 
(0'050/0 w/v). An aliquot of pl~telet lysate (0'1 ml) was 
then incubated with 0'1 ml of incubation medium containing 
(final concentrations mmol/I): Na lOO. K 15, A TP 5, Mg 7, 
EDTA 1, Tris-HCI buffer 50 (pH 7·2 at 37°C) in each of four 
tubes. Ouabain at a final concentration of 5 mmol/I was 
added to two of the tubes. All tubes were incubated for 60 
minutes at 37°C in a shaking water bath and the reaction 
was stopped by the addition of trichloroacetic acetic acid 
(100/0 w/v) and centrifuged. The phosphate content of the 
supernatant was measured by an automated method and 
protein content of the platelet lysate was measured by a 
method based on that of Lowry et ai. (1951). Na", K"'-
\ , 
. . 
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A TPase activity was given by the difference in rate of release 
of phosphate in the presence or absence of ouabain. The 
precision of the method was 8·20/0 (n = 14). 
Plasma concentration of TSH was measured by an 
immunochemiluminometric assay (Ciba Coming, USA) 
with a detection limit of 0·02 mUll. Plasma free thyroid 
honnone concentrations were detennined by commercial 
kits (Amerlex-M. Amersham. USA for free triiodothyronine 
and Gammacoat two-step assay, Buter. Massachussetts. 
USA for thyroxine). 
Differences between basal values between groups were 
compared by the Mann-Whitney U-test. A P-value less 
than 0·05 was considered significant. 
Area under the curve was calculated by the trapezoid 
method and changes in plasma glucose, insulin and platelet 
Na + , K + -ATPase during OGTI were compared by two-
factor analysis of variance (ANOV A) for repeated measure-
ments using a commercial software package. 
Results are expressed as mean ± SO. 
R.sults 
Table 1 shows the age and plasma concentration of FT3 and 
potassium in the different groups of patients. Plasma 
potassium concentration in TPP patients on admission 
ranged from 1·4 to 2·7 (2·1 ± 0'5) mmol/l. After recovery 
from paralysis the concentration of plasma potassium in 
TPP patients ranged from 3·5 to 5·1 (4·3 ± 0·5) mmoLI. 
Table) shows the changes in (a) plasma glucose. (b) plasma 
insulin and (c) platelet Na - . K - -ATPase at O. 1 and 2 hours 
after oral glucose load. Plasma glucose concentration at 
Table 1 Characteristics of patient groups 
Plasma 
potassium 
Age IT3 (pmolfl) (mmoJ:l) 
Sex (years) (3'3-8'2)- (3 '5-5')-
Healthy controls 17F 11-50 6·1 ::0·1 4·1 ::0-4 
8M 21-56 (4'9-1'0) (3·5-5'0) 
Thyrotoxic: patients 10 F 18-45 28·5:: 11·1 4·0 ± 0·3 
without paralysis 1M 24-43 (8·9-40'0) (3'6-4'6) 
Untrealed TPP ISM 21-49 22·3 ± 8·9 4·3 ± O'St 
patients (10·1-39'9) (3'5-5'1) 
Treated TPP 4M 24-32 5·9 ± 0·1 4·3 ± 0·8 
patients (5'2-6'8) (3 '5-5'1) 
Results are given as range for age and as mean z SO and range for 
IT3 and plasma pOlassium. 
- Reference ranges. 
t Plasma potassium c:oncentration after these patients have 
recovered from paralysis but before treatment of thyrotoxicosis. 
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Tabl. Z Changes in (a) plasma glucose concentration. (b) insulin 








(a) Plasma glucose concentration (mmol/l) 
o 4·8 % 0·6 4·9 % 0·6 4·8 % 0·6 
I 7·6 % 3·2 8·7 ± 1,5- 10·4 % 3·I-t: 
2 5·8 % 2·5 5·4: 1·6 7·3 ± 2·9 




6·0 % 1·9 
4·7: 1·4 
o 9·5%4·2 10·2: 3·2 13·3 ± 4·00 6·8 ± 1·7 
1 73·8 ± 47,5-
2 39·9 % 29,0-
72·8 % 18,3- 131·8 ± 7S'3-t: 57·5 ± 21·6 
37·5 ± 18·2 96·9 ± 73'S-t: 21·3 ± 14·6 
(c) Platelet Na·.K"'·A TPasc: activity (I'mol pi/g protein) 
o 142 ± 43·8 217: 61·9t 275 ± 63·5t 
1 173 ± 69,9- 255 % 59· 2-t 323 ± s8'I-t: 
. 2 151 ± 57·6 237 ± 54'S-t 280 ± 9O·2t 
Results are mean ± SO. 
• Significantly different from value at 0 time for the corresponding 
group. 
t Significantly different from healthy subjects for that time. 
t Significantly different from thyrotoxic patients for that time. 
zero time was similar in all four groups. Plasma glucose 
levels at I and 2 hours in untreated TPP patients were higher 
than those in healthy subjects and thyrotoxic patients (Table 
2). In treated (euthyroid) TPP patients the glucose values 
were similar to those in healthy subjects. Basal insulin 
concentrations did not differ between thyrotoxic patients 
and healthy controls but tended to be higher in untreated 
TPP patients. The insulin concentrations at 1 and 2 hours 
were significantly higher in untreated TPP patients than in 
either healthy controls or thyrotoxic patients without 
paralysis (Table 2). In treated TPP patients insulin 
concentrations were similar to those in healthy controls. 
Basal platelet Na • , K • ·A TPase was higher in untreated 
thyrotoxic patients without paralysis and. in TPP patients. it 
was further increased. Oral glucose stimulated" platelet Na +. --
K ... ·A TPase in all three groups. 
To examine the changes further, the areas under the curve 
were calculated for glucose. insulin and platelet Na'" , K'" -
ATPase (Table 3). These results further confinn that there 
was glucose intolerance in TPP patients and this was 
accompanied by higher insulin levels. Platelet Na +, K + -
ATPase was significantly higher during the OGTT in TPP 
patients than in either healthy controls or other thyrotoxic 
patients. Analysis of the area under the curves for male 
subjects only (Table 3b) showed similar results. 
When the insulin response (area under the curve) was 
correlated with stimulation of platelet Na'" , K ... -ATPase in 
• 
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Tabl.3 Alea under the curve for glucose. insulin and platelc:l Na·. 
K'" ·A TPasc in the three groups in (a) all subjects. and Cb) in maJc:s 
only 
Glucose: Insulin Na • .K • ·A TP:Lse 
(a) All subjects 
Healthy 12·9 == 4·5 98'S % 53·4 320 ± 107·3 
subjects 
Thyrotoxic 13·8 ± 2·0 96·6 % 19·3 482 ± 109,4-
patients 
TPP patients 16·5 ± 4'4-t 189·6 % l00'6-t 601 ± 99'2-t 
Treated TPP 
patients 
(b) Males only 
10·5 % 2·5 
Healthy I 1·6 ± 3·4 
subjects (n = 8) 
Thyrotoxic 14·1 ± 1·4 
patients (n = 7) 
TPP 16·5 ± 4,4-
patients (n = 15) 
Results are mean::: SO. 
71 ·5 ± 29·4 
102 ± 80·0 
86·0 == 21·4 
• Significantly different from healthy group. 
t Significantly different from thyrotoxic group. 
289 ± 140·5 
516 ± 47,3-
the different groups, it was found that in healthy subjects 
there was a significant relationship (r = O' 521, P = 0'009) 
but not in thyrotoxic (r = -0'328, P = 0·22) or TPP 
(r = -0·07) groups. 
Discussion 
The association of.TPP with carbohydrate intake suggests 
that insulin may play a role in the pathogenesis of TPP. 
. ·Previous studies in individual patients have shown hyper· 
insulinaemia (Shishibu el al.. 1972; Hay & McDougall. 
1975) or normal insulin levels (Yeung & Tse. 1974). In a 
recent study, Lee el al. (1991) showed significant hyper· 
. insulinaemia during an oral glucose tolerance test. Our 
results confinn and extend these findings. 
Changes in platelet Na ... , K .. ·A TPase activity measured 
in vilro are paralleled by changes in in-vivo sodium pump 
activity (Chan el al., 1991). Thus in-vivo sodium pump 
activity is likely to reflect activity in skeletal muscle because 
"this tissue has large amounts of Na ... , K ... -ATPase (Clausen 
& Everts, 1989). We therefore suggest that the changes 
observed in platelet Na"', K ... -ATPase are likely to be 
reftected in other tissues including skeletal muscle. 
In healthy subjects. platelet Na"', K + -ATPase were 
increased one hour after an oral glucose load. Increased 
activity of sodium pump in leucocytes following a glucose 
load has also been reported (Turaihi el al.. 1988). The 
increase in sodium pump activity in platelets (220/0) 
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observed in this study was smaller than that reported in 
leucocytes (460/0). Although this increase in Na", K"· 
ATPase activity/Na pump activity could result directly frC?m 
glucose it is more likely to reflect the action of insulin 
(Turaihi et al., 1988). 
We have previously shown that Na"', K ... -ATPase 
activity measured in vitro and in vivo is higher in TPP 
patients (Chan et al., 1991). Stimulation of Na"', K"· 
ATPase activity by thyroid hormones is well documented 
(Ismail-Beigi, 1988; Shinde et al .• 1991; Arumanayagam & 
Swaminathan._,1992). Our previous study showed that, in 
spite of similarly elevated thyroid hormone concentrations, 
Na ... , K .. -ATPase activity was higher in patients with TPP 
compared to other thyrotoxic subjects (Chan et al., 1991). 
Our present study confirms this and in addition shows that 
the insulin concentrations induced by oral glucose are 
adequate to stimulate Na"', K'" -ATPase activity. The 
greater stimulatory effect of oral glucose load on 
Na'" ,K ... -ATPase activity in TPP patients parallels higher 
insulin concentrations. The mechanism of action of insulin 
on Na ... , K ~ -ATPase has been discussed by Clausen (1986). 
The fact that basal Na"', K ... -ATPase is higher in TPP 
patients and that this is accompanied by hyperinsulinaemia 
may explain the propensity for hypokalaemia following a 
high carbohydrate meal in TPP patients. The reason why 
basal Na"', K ... -ATPase activity is higher in TPP patients 
than in thyrotoxic patients without paralysis is not clear. We 
have shown that when TPP patients are treated the Na'" • 
K .. -ATPase activity in platelets is similar to that in healthy 
controls (Chan et al .• 1991). Thus TPP patients are likely to 
be more sensitive than other subjects to thyroid hormone. 
Whether this is because of differences in the isoforms of the 
Na"', K .. -ATPase in susceptible subjects awaits further 
studies. 
We conclude that patients with thyrotoxic ' periodic 
paralysis have increased basal Na"', K'" -ATPase activity 
and increased insulin concentrations in response to oral 
glucose and that this is accompanied by greater stimulation 
of Na"'. K'" -ATPase activity. The combination of these 
factors predisposes them to hypokalaemic periodic paralysis 
in response to carbohydrate loading. 
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Summary 
Chinese herbal medicines (CHM) are com-
monly used in Hong Kong. To determine the 
importance of adverse reactions to CHM as 
a cause of medical admissions in Hong Kong, 
all 1701 patients admitted to two general 
medical wards at the Prince of Wales Hospital 
over an eight-month period were prospectively 
studied. In only three patients (0.2~,~) was the 
admission attributed to the adverse effects of 
CHM. These were life-threatening in two cases 
('dazao' -induced angio-neurotic oedema and 
liquorice-induced hypokalaemic periodic par-
alysis). Despite this low it:lcidence of adverse 
reactions, in cO,mmunities where CHM are 
commonly used, it is important that there is a 
continuing effort to collect new information on 
the safety of these compounds. 
Introduction 
The harmful effects of some Chinese herbal 
medicines (CHM) have become a c~use for con-
cern among the general public and 'the medical 
profession in Hong Kong following an inci-
dent in 1989 in which two people lapsed into 
coma following ingestion of a Chinese herbal 
broth containing podophyllin (Ng et al. 1991). 
Recently, we reported a case of life-threatening 
ventricular tachycardia associated with the use 
of'caowu', the root of various Aconitum species 
(Tomlinson et al. 1991). In order to assess 
the magnitude of this problem, a prospective 
C~r~espondence: Or Thomas Y. K. Chan, Department of 
Chmc:11 ~h:1rmacology, The Chinese University of Hong 
~ongJ Prmce of Wales Hospital, Shatin, NT, Hong Kong. 
+Presen.t address: Or Albert Y. W. Chan, Pathology Insti-
tute, Pnncess Margaret Hospital, Kowloon, Hong Kong. 
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study of the involvement of CHM in medical 
admissions to a general teaching hospital in 
Hong Kong was undertaken. This paper pres-
ents our findings and highlights the potentially 
life-threatening adverse effects of CHM. 
~la terials and methods 
The Prince of Wales Hospital is a 1400-bed 
general teaching hospital situated in the Ne\v 
Territories in Hong Kong. It served a popu-
lation of over one million in 1990. As part of a 
prospective study on hospital admissions due to 
adverse reaction to drugs (Chan et al. 1992), 
consecutive patients admitted over an eight-
month period in 1990 to two of the eight general 
medical wards at the Prince of Wales Hospital 
were screened for adverse reactions to CHM 
causing their admission. 
A diagnosis of ad verse reaction to CHM was 
based on the following criteria: (a) there was a 
reasonable temporal relationship between the 
. administration of CHM and the occurrence of 
the reaction; (b) the reaction could not be 
reasonably explained by the patient's under-
lying' clinical condition. 
Results 
A total of 1701 patients were studied during 
the eight-month period. An adverse reaction 
to CH~l was judged to be the major cause of 
admission in only three (0.21l (») patients. These 
three cases are summarized below. 
CASEI • 
A 41-year-old otherwise healthy man was well 
until he drank a soup containing 10 different 
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herbs prescribed by a herbalist for the swell-
ing associated with his fractured left radius. 
One hour later, he -felt dizzy and weak. This 
was accompanied by generalized tighmess and 
numbness. He also had four bouts of diar- . 
rhoea. On admission, his blood pressure was · 
90/60 mmHgwithapulserateof60beatsmin -~ . . 
He was hyperventilating. Physical examination 
was otherwise unrevealing. His plasma electro-
lytes and calcium level were within normal 
limits. His blood pressure rapidly returned to 
normal (110/70 mmHg) and he was completely 
well about 10 hours later. The herbalist refused 
to disclose the contents of his prescription. 
CASE 2 
A 14-year-old girl without any history of allergy 
presented with urticaria, puffy eyelids and diffi-
culty in breathing, 2 hours after eating a pancake . 
and drinking a soup made from 'dazao' (Fructus 
ziziphi jujubae), which is often consumed as 
food or as a medicine. The amount ingested was 
estimated to be 45 g. On admission, her blood 
pressure was 130/90 mmHg with a pulse rate 
of 84 beats min -I. She had puffy eyelids and 
a generalized urticarial rash. Her chest was 
clear. The clinical diagnosis was angio-neurotic 
oedema caused by 'dazao', which subsided over 
the next 24 hours after intravenous ~tihistamine 
administration and a course of corticosteroids. 
CASE 3 
A 41-year-old man presented with a history of 
progressive weakness of all four limbs during 
the day of admission. He was a known case of 
essential hypertension and NIDD~1~ The only 
medication he had received was nifedipine SR. 
One year ago, he presented with the first attack 
of hypokalaemic periodic paralysis but no pre-
cipitating factor was identified. Investigations 
including thyroid function tests were all nor-
mal. On examination, his limb power was grade 
2-3/5. He had bilateral lid lag and lid retraction. 
His heart rate was 84 beats min - 1. Plasma 
potassium level on admission was 1.3 mmoll- I 
and sensitive TSH < 0.02 mIU 1-1. Following 
intravenous and oral potassium supplements, 
his power and serum .potassium level gradually 
returned to normal in the next 48 hours. On 
direct questioning, he admitted drinking 3 to 5 
doses of herbal tea for several days before each 
attack. The actual prescription was traced and 
was found to contain liquorice (G/ycyrrihzia 
glabra), which can induce severe hypokalaemia 
(Penn 1986). His present attack was thought to 
be precipitated by the potassium-losing effect 
of liquorice in a patient with an underlying 
predisposition to hypokalaemic paralysis due 
to thyrotoxicosis. He was later discharged on 
nifedipine SR and carbimazole. 
Discussion 
In Hong Kong, CHM are widely used by the 
Chinese community (Chan & Davies 1987; 
Tomlinson et al. 1991). It is thus remark-
able that only 0.2~~ of our general medical 
admissions 'were due to adverse reactions to 
CHM. In comparison, adverse reactions to 
'Western' drugs were responsible for 4.4(~~ of 
these admissions (Chan et al. 1992). The pres-
ent study, however, has demonstrated that the 
adverse effects of CHM were potentially fatal, 
as illustrated by cases 2 and 3 . . 
When a case of adverse reaction to CHM is 
suspected, the difficulty in establishing the 
diagnosis is well recognized (Chan & Davies 
1987; Sung 1987). Each preparation (herbs or 
compound medicines) typically is made up of 
a number of ingredients which in turn consist 
of many different chemicals. Very often, the 
nature and actions of these ingredients and their 
constituents are largely unknown. Moreover, 
as in case 1, if the actual prescription cannot 
be traced, chemical analysis of each ingredient 
is not possible. On the other hand, the success 
in making the diagnosis to some extent will 
also depend on the clinician's suspicion. As in 
case 3, the diagnosis can be missed as would 
have been the case if a detailed history had not 
been taken during his second admission. 
In communities where CHM are commonly 
used, it is important that there is a continuing 
effort to collect new information on the safety of 
these compounds. In Hong Kong, we are build-
ing a data-base on CHM with the information 
coming from spontaneous reporting, hospital 
surveys, reviews of local and international liter-
ature, and the work of our colleagues at the 
Chinese Nledicinal ~laterial Research Centre. 
-~""'" . . .. ~ . . : .:..~ '. . '. \ ,~ 
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Changes in erythrocyte zinc in a case of transient thyrotoxicosis 
- A Y W Chan, Y T Mak, C C Shek and R Swaminathan 
From the Department 0/ Chemical Pathology, The Chinese University 0/ Hong Kong, 
Prince 0/ Wales Hospital, Shatin, Hong Kong 
Additional key phrases: thyroid hormones,· tissue 
marker of thyroid hormones 
Thyroid dysfunction is usually investigated by 
measurement of a combination of serum thyroid 
hormones such as thyroxine (T4), tri-iodothyronine 
(T3) or their free hormones, and thyroid 
stimulating hormone (using a sensitive immuno-
metric assay: sTSH). However, each of these 
measurements has its shortcomings and there are 
occasions when it is important to assess the tissue 
effects of thyroid hormones.! It has been shown 
that erythrocyte zinc (EZn) is subnormal in 
thyrotoxicosis.2•3 However, changes in EZn lag 
behind those of thyroid hormones because of 
the relatively long half-life of erythrocytes.2•3 
Therefore, patients who are recovering from 
thyrotoxicosis may show relatively normal serum 
thyroid hormones and a subnormal EZn which 
will increase over the following weeks. 
The usefulness of this characteristic was 
recently shown in the differential diagnosis of 
hyperthyroidism in pregnancy. EZn is reduced in 
patients with established thyrotoxicosis but normal 
in those suffering from transient hyperthyroidism 
of hyperemesis gravidarum.4 •5 In addition, it was 
shown recently6.7 that EZn remains relatively 
undisturbed in subacute (painful) thyroiditis 
where the hyperthyroid phase develops acutely 
and usually lasts for 2 to 6 weeks.8 However, -it 
might be expected that the EZn will be reduced 
in situations where the hyperthyroid phase is more 
prolonged. For instance, the hyperthyroid phase 
can last up to 12 months in subacute thyroiditis.8 
The diagnosis of transient thyrotoxicosis can 
be difficult especially when the patients are seen 
some weeks after the onset of symptoms. It is 
likely that some of these patients will have normal 
serum thyroid hormone levels by the time they 
are seen, a situation where conventional thyroid 
function tests are of limited value and the correct 
diagnosis may be -missed. Therefore, a tissue 
marker like EZn which reflects the thyroid status 
Correspondence: Or A Y W Chan. 
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over the preceding months may be useful. This 
is demonstrated in the following case. 
CASE REPORT 
A 45-year-old housewife, who had been treated 
elsewhere for Graves' disease 7 years previously, 
presented with a 10 month history of amenorrhea. 
In additIon, she had tremor, palpitations and 
weight loss over the preceding 2 months. She had 
no neck pain. Her serum FT" and FT 3 measured 
3 weeks previously were high. Her thyroid gland 
was slightly enlarged and clinically she appeared 
marginally thyrotoxic. Physicial examination was 
otherwise unremarkable. She was treated with 
propranolol. However, she did not take the 
propranolol because her symptoms improved 
spontaneously during the next 3 months and her 
weight increased. 
Serial changes in body weight and thyroid 
hormone status are shown in Table 1. The patient 
had elevated thyroid hormones which declined 
spontaneously associated with a suppressed sTSH 
which, subsequently, increased. EZn measured at 
12 weeks after presentation, when the serum T" 
was normal, was reduced (99 JLmollL of cells). 
While the serum T 4 remained within normal 
limits and the serum TSH returned to normal, the 
EZn increased spontaneously over the following 
weeks. These results suggested that the patient 
had an episode of transient thyrotoxicosis. 
DISCUSSION 
Subnormal EZn concentrations have only been 
reported in thyrotoxicosis and in sickle cell 
anaemia.9 Our patient did not have sickle cell 
anaemia. Patients who recover from thyro-
toxicosis, typically show a rise in EZn.2•J In 
thyrotoxic patients treated with anti-thyroid 
drugs, normalization of EZn on average lags 
behind the normalization of thyroid hormones by 
3 months. Our patient had low EZn on presenta-
tion which progressively increased over the 
following months. 
, ....... 
. Erythrocyte zinc in transient thyrotoxicosis S2S 
TABLE 1. Changes in body weight, serum thyroid hormones and EZn with time 
T4 TSH- EZn 
Wt (nmol/L) (mIU/L) ~oUL RBC) (FT4 FT) 
Date (kg) (46-140) (0' 3-4'0) 155-237) (pmol/L) (pmoI/L) 
6 Jan 
27 Jan 48'S 
22 Feb 49 
18 Apr SO 




















(2· 28-S· 32) 
t Assay performed at another laboratory. 
Laboratory reference ranges are shown in brackets. 
Interpretation of serial changes in EZn requires 
knowledge of its critical difference. to We have 
found that EZn has a critical difference of about 
100/0 which implies that a serial result should be 
at least 1 DOJo different from the previous result 
to indicate that a significant change has occurred. 
The changes in our patient were spontaneous and 
highly significant and strongly support the 
diagnosis of recovery from recent thyrotoxicosis. 
We therefore conclude that EZn may be a 
useful addition to current thyroid function tests . 
in the investigation of transient thyrotoxicosis, 
especially when there is delay in presentation. 
Serial changes in EZn may be the only clue to the 
diagnosis when serum ~hyroid hormone levels 
have returned to normal. EZn is unique in this 
respect becauuse it is the only known retrospective 
marker of previous hyperthyroidism. 
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Free Triiodothyronine in Sera of Acutely III General Medical Patients: a Prcgnostic 
Indicator? 
. . . • J 
Y. T. Mak.· E. L. P. Cban,' A.Chan,' J. Woo.2 and R. SwallW13thaD 
We measured free triiodothyronine (Fi 3), thyrotropin 
(TSH), and C-reactive protein (CAP) in sera of 39 acutely 
ill medical patients who died within three months of 
admission and 39 age- and sex-matched control patients 
selected at random from a total of 294 acute medicaJ 
admissions. Serum FT 3 in nonsurvivors (1.91 ~ 1.51 
pmoUL) was significantly lower than that in survivors (3.01 
~ 1.3 pmoUL. P <0.01) and the CAP in nonsurvivo~ 
(54.6 ~ 59.2 mgtL) was significantly higher than .n 
survivors (43.6 ~ 59.5 mgtL P <0.05). There was no 
difference in plasma TSH between the two groups. The 
estimated odds ratio relating death to a plasma FT 3 value 
< 1.0 pmoUL on admission was 17 (highly significant: P 
<0.001). We conclude that plasma FT3 may be a useful 
prognostic indicator in acutely ill patients. . 
Additional Keyphrases: thyrotrc()in . C·reactive protein • 
oaas rauo for ()redictmg monallty 
Alterations in serum concentrations of thyroid hor-
mones are common in euthyroid patients suifering from 
various nonthyroidal medical and surgical diseases 
(nonthyroidal illness; NTD (l)." The most common abnor-
mality is a decrease in circulating 3,5.3' -triiodothyro-
nine (T 3) and an , increase in 3,3',5' -triiodothyronme 
(rT 3) concentrations in serum. caused by altered periph~ 
era! metabolism of thyroxin (T.) (1), Serum concentra-
tions of T 4 and thyrotropin t TSID may be initially 
normal. However, in critically ill patients. serum T 4 
concentrations are low (1), at least partly because of'the 
presence of a thyroid-hormone-binding inhibitor (2), 
The degree of'decrease in T. is related to the severity of 
illness. and several studies have shown that mortality is 
high in patients with abnormal concentrations of serum 
T. (3,4). Serum concentrations ofTSH may also be low 
in many severely ill patients (5). With second-genera-
tion TSH assays (detection limit. 0.5 milli-int. unitIL), 
the serum contents were reported to be undetectable (5). 
However, with a third-generation assay (detection 1imi~ 
0.003 milli-int. unitIL), serum concentrations oCTSH in 
NTI patients were reportedly low but detectable, in 
Departments oC ' Chemical Pathology and 2 ~eclicine. Prince oC 
Wales Hospital. The Chinese University of Hong Kong. Shatin. 
N.T .• Hong Kong. 
~ Department oC Clinical Biochemistry. 5th Floor. Guy', Tower. 
United Medical and Dental Schools. Guy's Hoapit3l Medical 
School. London Bridge. London SEl 9RT, U.K. (address for corre-
spondence). 
• Nonstandard abbreviations: NTI. nonthyroidal illness. T 3. tn-
iodothyronine; FT,. free T ,; rT " "revena" T:I (3,3' ,5' ·triiodothyro. 
nine'; TSH. thyroid.lltimulating hormone (thyrotropin); T •• thy-
roxin: and CRP. C·reactive protein. 
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contrut to thyrotoxic patients. in whom TSH was un-
detectable (6). 
Recent studies have confirmed low serum concentra-
tions ofT3 and T" in heart failure (7), 'fulmiMnt hepa-
titis (8), and patients with advanced AIDS (9). Serum T 3 
and (or) Ty'rT3 ratios were found to be oC prognostic 
significance in these studies (7-9). However, in moat 
studies total T 3 was measured. and the studies were 
restricted to specific disease groups. 
In this preliminary report, we examined serum con-
centrations of free T 3 (FT:S> and TSH in a group oC 
acutely ill general medical patients who died and com-
pared these values with the corresponding concentra-
. tions in a group of age- and sex-matched control pa-
tients. 
Materials and Methods 
. All patients admitted to t.he general medical wards 
over a one-month period were included in a study for 
assessment of nutritional status of acutely ill medical 
patients. The clinical and nutritional status of these 
patients are described elsewhere (10). All patients were 
seen by a nurse interviewer, and 20 mL of venous blood 
was collected for various biochemical and hematological 
tests. An aliquot of serum was stored at -70 °C for 
subsequent analysis. 
The outcomes of these patients were followed for three 
months. During this period. 39 patients died. For each of 
these nonsurvivors. we selected without conscious bias 
an age- and sex-matched control from the rest of the 255 
patients. The stored sera from the group of 39 nonsur· 
vivors and their 39 age- and sex-matched control pa-
tients were analy-zed for FTJ , TSH. and C-reactive 
protein (CRP). CRP was chosen as a nonspecific acute-
phase reactive protein. 
Serum TSH was assayed by a chemiluminometric 
assay (Ciba-Coming, Diagnostics Corp., Medfield. MA 
02052) having a detection limit oCO.02 milli-int. unitsIL 
and an interassay coefficient of variation (Cv) oC 6.2%. 
Serum FT3 was also measured with a radioimmunoas-
say (Amerlex IT 3; Amersham Corp., Arlington Heights. 
IL). This assay is analog-based and reportedly is unaf-
fected by the concentration of albumin in the serum 
sample (11). The detection limit of this assay is 0.3 
pmol/L and the interassay CV was 4.0%. Serum CRP 
was assayed by nephlometry, with reagents from Beck-
man Co. (Brea. CA 92621). All samples (from patients 
and controls) were assayed in one batch. 
, Wilcoxon signed~rank sum test and McNemar's test 
for paired proportions were used for statistical analyses 
oC matched da~. . 
-' 
RHuIta and Dlacualon 
OCthe 294 patienta we studied during thia period. 60'11 
of them were --60 years old. The meaD age of the 39 
patientl who died within the three montba wa 72.9 
years <SD 11.6, range 43-96 years); 2S were men and 14 
were women. The mean length of survival after admis-
sion wa 10.5 = 12.8 days <median six days, range 1-61 
days). Table lahows the serum concentrations of TSH, 
FT" and CRP iD both groups ofsubjec:t&-the survivors 
and the nonsurvivot'S". There was no significant diff'er-
ence in serum TSH between the two groups. Serum FT, 
was significantly lower and CRP was significantly 
higher in nonsurvivors (P <0.01 and <0.05, respec-
tively, by WiIcoxon's test). Nine patients (23%) had 
undetec:table (<0.3 pmoUL) FT 3, and 11 others had 
values <1.0 pmollL. In the control group, only three 
patients had values <1.0 pmoUL and two (5.1 %) of these 
were undetec:table. These difi"erences were highly signif-
icant by McNemars test for paired proportions (P 
<0.001). The number of patients with serum TSH less 
than the reference range ' «0.03 milIi-int. unitsI'L) in 
the two groups was similar (six in each group). 
The mortality rate in those admitted to the general 
medical wards was 13.3% and the majority of those who 
died were elderly people. This study confirms that FT 3 is 
decreased in NTI patients (1). Subnormal concentra- ~ 
tions of T 3 and T" were found in 68% and 43%, respec-
tively, of the medical intenSive.are patients (4). Our 
results show that, in an unselected group of medical 
patients, subnormal FT 3 concentrations were seen in 
61.5% of survivors and in 76.9% of the nonsurvivors. 
Recent reports have focused the prognostic value ofT 3 
in acute illness. Fried et al. (9) showed that in patients 
with AIDS and concurrent Pneurrux:ystis carinii pneu-
Table 1. Serum TSH, FT 3. and CRP In the N.onsurvivors 
and In the Age- and Sex-Matched Survivors 
lab. Mean : So (and ,.~) 
rwfennce 
ran~ 5urvtvors Nonaurvtvora 
TSH. milll-int. 
unitslL 0.3-4.0 1.06 !: 0.93 1.21 !: 0.94 
«0.02-3.38) «0.02-4.14) 
. FT,. pmolll 3.3-8.2 3.01 !: 1.33 ' 1.91!: 1.51· 
«0.3-5.9) «0.3-4.9) 
CRP. mgtL <10 43.6: 59.5 54.6 = 59.2° 
«0.8-262) «0.8-265) 
• P <0.01: • P <O.O~ ':Jy W1lcoxon signed-rank sum test groucs. 
• 
monia, a low serum total T3 value was aaaoc:iated with 
poor prognosis and a T, value of <0.70 ,..mollL wu the 
best prognostic indicator of acute mortality. In trauma 
. patients, low FT, wu aasoc:iated with higher mortality 
. U2). Hamilton et al. (7) reported a low FT, index in 
advanced heart failure and considered that the ratio of 
FT 3 index to rT 3 was the best predictor of poor prognosiJ. 
Similar findinp have been described in patients with 
fulminant hepatitis (8). In the patients we studied. the 
estimated odds ratio relating a FT3 value <1.0 pmollL to 
death, based on matched pairs, was equal to 17, which 
emphasizes the importance of FT 3 as a prognostic indi-
cator. 
We conclude that, in acutely ill medical patients, 
serum TSH and FT 3 are decreased and a very low FT 3 
value is associated with a poor prognosis. 
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Interference of o-Mannose in 
Glucose Measurements by Glucose 
Oxidase and Hexokinase Methods 
To the Editor: 
Nakashima et a1. ,( 1) showed that 
D-mannose at 3 g/L i 16.7 mmoLLJ is 
an effective preservative for blood glu-
cose. It does not interfere with glucose 
measurements by glucose oxidase and 
hexokinase enzymatic methods and 
does not interfere with other routine 
measurements. However, an earlier 
report (2) demonstrated that the same 
concentration of D-mannose interferes 
with enzymatic glucose methods. 
In our laboratory, we often receive 
sampie tubes of blood for glucose mea-
surement that contain as little as one-
third of the required volume. This in-
creases the concentration of oreserva-
tive in the plasma samples. Therefore. 
in studying the use of D-mannose as a 
preservative for blood glucose. we in-
vestigated the interference of D-man-
nose at higher concentrations than 
those recommended. We found that 
D-mannose cauSes positive interfer-
ence in the. glucose oxidase method 
and negative interference in the hex-
okinase method. 
To a pooled plasma sample contain-
ing 5 mmol of glucose per liter we 
added various concentrations of 
D-mannose (Sigma Chemical Co., St. 
Louis. MO>. ranging from 0 to 100 
mmollL. [This source of 0-mannose 
had been recommended by N aka-
shima .et a1. (1).1 The glucose contam-
ination of the D-mannose was < 0.1 % 
as determined by gas chromatography 
(personal communication with Sigma 
Technicl Service). We then measured 
the plasma glucose, using both enzy-
matic methods. For the glucose oxi-
--
due method. we used the YSI Model 
23 A.\t glucole analyzer <Yellow 
Springs Instrument Co., Yellow 
Springs. OH), and the Cobas-Fara cen-
trifugal analyzer (F. HoaTmann-La 
Roche. Basle. Switzerland) with glu-
cose oxidaselTrinder reagent (Diag-
nostic Chemical Ltd .• Prince Edward 
Island. Canada). For'the hexokinase 
method. we used the Dimension Clin-
ical Chemistry System (DuPont, 
Wilmington. DE> and the Cobas-Fara 
analyzer with Roche hexokinase re-
agent. Between-day CVs for glucose 
measurement with these analyzers 
were <2%. 
The gl ucose oxidase method showed 
positive interference in assays with 
both analyzers (Figure 1). We esti-
mated that 1 mmol of D-mannose was 
measured as 0.01-0.02 mmol of appar-
ent glucose by these analyzers. Dif-
ferent preparations of the enzyme 
could account for the difference in 
magnitude of the interference. We furo: 
ther tested this difference with a Beck-
man ASt1"a-8 chemistry analyzer 
(Beckman Instruments. Brea. CA) and 
obtained similar findings. Glucose ox-
idase is not specific for glucose (3) but 
our results showed that it has a 100-
fold higher affinity for glucose than for 
D-mannose. Nevertheless. when the 
D-mannose concentration in plasma is 
increased to three times the recom-
mended concentration (i.e., to 50 
mmol/L). D-mannose alone would con-
tribute 1 mmoL'L to the apparent glu-
cose concentration. 
The hexokinase method on the Co-
bas-Fara analyzer showed negative 
interference at D-mannose concentra-
tIons > 20 mmoliL; the Dimension was 
affected only by D-mannose concentra-
tions > 75 mmol!L (Figure 1l. \Vhen 
another pooled plasma sample con-
taining glucose at 10 mmoliL was sup-
plemented with D-mannose at 50 
mmoL L. the Cobas-Fara analyzer 
gave an apparent glucose concentra-
tion ~OCC lower than the expected 
value; the Dimension was unaffected. 
D-Mannose is known to be a competi-
th·e inhibitor of hexokinase (3). The 
:1 ~--ii :J. ~~~'''''-.: ~~ ~ 
1 1-.--.-.----o ~ ~ ~ ~ I~ 
Fig. 1. Acparent glucose concentration 
(mmollL) in a pooled plasma sample with 
vanous O·mannose concentrations added 
• 
Dimension reagent contained eight-
rold more hexokinase activity than the 
Roche reagent, which may explain the 
increaaed tolerance 0{ the Dimension 
method to D-mannoae interference. 
We conclude that iCD-mannoee it to 
be URd as a preservative" (or blood 
glucose specimens, it ia important (or 
each laboratory to investigate D-man-
nose interference in the particular 
glucose methods used, especially at 
J>mannose concentrations higher 
than those recommended. 
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More on Pregnancy Tests 
To the Editor: 
We have the following comments to 
the article "Three highly sensitive 
'bedside' serum and urine tests for 
pregnancy compared" by Christensen 
et a1. (Clin Chem 1990;36:1686-8). 
Two urine samples were negative 
when tested with the NovoClone" 
HCG kit (Novo Nordisk AlS), despite 
the fact that the serum specimens 
collected at the same time contained a 
high concentration of choriogonado-
tropin (HCG). In one of these urine 
samples, we demonstrated the pres-
ence of a sediment interfering with 
the peroxidase-generated colored 
product on the membrane. This prob-
lem has been eliminated because we 
have modified the kit, and now have a 
prefilter mounted on each test device. 
Can serum HCG results be catep 
rized as "raIse negative" (Christensen 
et al.'s Table 2) when the quantitative 
measurements referred to were below 
the detection limit of the kits (range 
10-23 into unitsiL)? The urine results 
were referred to the respective serum 
results without correction for diuresis 
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